Therapeutic agent for Parkinson&#39;s disease

ABSTRACT

Methods for the treatment of Parkinson&#39;s disease comprising administering to a patient an agent which contains, as an active ingredient, a xanthine derivative or a pharmaceutically acceptable salt thereof. The xanthine derivative is represented by the formula: ##STR1## wherein R 1 , R 2  and R 3  are independently hydrogen, lower alkyl, lower alkenyl, or lower alkynyl; and R 4  is cycloalkyl, --(CH 2 ) n  --R 5 , wherein R 5  represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group; and n is an integer of 0 to 4, or ##STR2## wherein Y 1  and Y 2  represent independently hydrogen, halogen, or lower alkyl; and Z is substituted or unsubstituted aryl, ##STR3## wherein R 6  is hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, or amino; and m is an integer of 1 to 4, or a substituted or unsubstituted heterocyclic group; and X 1  and X 2  are independently O or S.

CROSS REFERENCE TO RELATED APPLICATION

This application is a division of application Ser. No. 08/133,510, filed on Oct. 17, 1993 (now U.S. Pat. No. 5,484,920), which is a continuation-in-part of application Ser. No. 08/042,535, filed on Apr. 5, 1993 (abandoned).

BACKGROUND OF THE INVENTION

The present invention relates to a therapeutic agent for Parkinson's disease containing a xanthine derivative or a salt thereof as an active ingredient. ##STR4##

It is known that adenosine antagonistic action is found in compounds represented by Formula (A) in which R^(1c) and R^(2c) represent propyl, R^(3c) represents hydrogen, and R^(4c) represents substituted or unsubstituted phenyl, aromatic heterocyclic group, cycloalkyl, styryl, or phenylethyl [J. Med. Chem., 34, 1431 (1991)]. Further, Japanese Published Unexamined Patent Application No. 26516/72 discloses, as brain stimulants, compounds represented by Formula (B) in which R^(1d) and R^(2d) independently represent methyl or ethyl, R^(3d) represents methyl, Y^(1d) and Y^(2d) represent hydrogen, and Z^(d) represents phenyl or 3,4,5-trimethoxyphenyl. WO92/06976 discloses, as adenosine A₂ receptor antagonists, compounds represented by Formula (B) in which R^(1d) and R^(2d) independently represent hydrogen, propyl, butyl, or allyl, R^(3d) represents hydrogen or lower alkyl, Y^(1d) and Y^(2d) independently represent hydrogen or methyl, and Z^(d) represents phenyl, pyridyl, imidazolyl, furyl, or thienyl unsubstituted or substituted by 1 to 3 substituents such as lower alkyl, hydroxy, lower alkoxy, halogen, amino, and nitro. Furthermore, other compounds represented by Formula (B) are known. One is 8-styryl caffeine which is a compound of Formula (B) in which R^(1d), R^(2d), and R^(3d) represent methyl, Y^(1d) and Y^(2d) represent hydrogen, and Z^(d) represents phenyl [Chem. Ber. 119, 1525 (1986)]. Another is a compound of Formula (B) in which R^(1d), R^(2d), and R^(3d) represent methyl, Y^(1d) and Y^(2d) represent hydrogen, and Z^(d) represents pyridyl, quinolyl, or methoxy-substituted or unsubstituted benzothiazolyl [Chem. Abst. 60, 1741h (1964)]. However, there is no description with regard to the pharmacologic action of any of these compounds.

SUMMARY OF THE INVENTION

An object of the present invention is to provide an excellent therapeutic agent for Parkinson's disease having a xanthine skeleton and having a potent and selective adenosine A₂ receptor antagonistic activity.

The present invention relates to a therapeutic agent for Parkinson's disease containing as an active ingredient a xanthine derivative or a pharmaceutically acceptable salt of the xanthine derivative, the xanthine derivative being represented by the following Formula (I): ##STR5## in which R¹, R², and R³ represent independently hydrogen, lower alkyl, lower alkenyl, or lower alkynyl; R⁴ represents cycloalkyl, --(CH₂)_(n) --R⁵ (in which R⁵ represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group; and n is an integer of 0 to 4), or ##STR6## (in which Y¹ and Y² represent independently hydrogen, halogen, or lower alkyl; and Z represents substituted or unsubstituted aryl, ##STR7## (in which R⁶ represents hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, or amino; and m represents an integer of 1 to 3), or a substituted or unsubstituted heterocyclic group);

and X¹ and X² represent independently O or S.

The present invention also provides a xanthine derivative represented by the following Formula (I-A): ##STR8## in which R^(1a) and R^(2a) represent independently methyl or ethyl; R^(3a) represents hydrogen or lower alkyl;

and Z^(a) represents ##STR9## (in which at least one of R⁷, R⁸, and R⁹ represents lower alkyl or lower alkoxy and the others represent hydrogen; R¹⁰ represents hydrogen or lower alkyl) or ##STR10## (in which R⁶ and m have the same meanings as defined above), or a phamaceutically acceptable salt thereof.

The present invention also provides a xanthine derivative represented by the following Formula (I-B): ##STR11## in which R^(1b) and R^(2b) represent independently hydrogen, propyl, butyl, lower alkenyl, or lower alkynyl;

Z^(b) represents substituted or unsubstituted naphthyl, or ##STR12## (in which R⁶ and m have the same meanings as defined above); and R³, Y¹ and Y² have the same meanings as defined above, or a pharmaceutically acceptable salt thereof.

The present invention further provides a method of treating Parkinson's disease comprising administration of an effective amount of a xanthine derivative.

DETAILED DESCRIPTION OF THE INVENTION

In the definitions of the groups in Formula (I), Formula (I-A), and Formula (I-B), the lower alkyl and the lower alkyl moiety of the lower alkoxy mean a straight-chain or branched alkyl group having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, neopentyl, and hexyl. The lower alkenyl means a straight-chain or branched alkenyl group having 2 to 6 carbon atoms, such as vinyl, allyl, methacryl, crotyl, 3-butenyl, 2-pentenyl, 4-pentenyl, 2-hexenyl, 5-hexenyl. The lower alkynyl means a straight-chain or branched alkenyl group having 2 to 6 carbon atoms, such as ethynyl, propargyl, 2-butynyl, 3-butynyl, 2-pentynyl, 4-pentynyl, 2-hexynyl, 5-hexynyl, 4-methyl-2-pentynyl. The aryl means phenyl or naphthyl. The cycloalkyl means a cycloalkyl group having 3 to 8 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Examples of the heterocyclic group are furyl, thienyl, pyrrolyl, pyranyl, thiopyranyl, pyridyl, thiazolyl, imidazolyl, pyrimidyl, triazinyl, indolyl, quinolyl, purinyl, and benzothiazolyl. The halogen includes fluorine, chlorine, bromine, and iodine.

The substituted aryl and the substituted heterocyclic ring each has 1 to 4 independently-selected substituents. Examples of the substituents are lower alkyl, hydroxy, substituted or unsubstituted lower alkoxy, halogen, nitro, amino, lower alkylamino, di(lower alkyl)amino, trifluoromethyl, trifluoromethoxy, benzyloxy, phenyl, and phenoxy. The lower alkyl and the alkyl moiety of the lower alkoxy, lower alkylamino, and di(lower alkyl)amino have the same meaning as the lower alkyl defined above. The halogen has the same meaning as the halogen defined above. Examples of the substituent of the substituted lower alkoxy are hydroxy, lower alkoxy, halogen, amino, azide, carboxy, and lower alkoxycarbonyl. The lower alkyl moiety of the lower alkoxy and lower alkoxycarbonyl has the same meaning as the lower alkyl defined above, and the halogen has the same meaning as the halogen defined above.

The above-mentioned pharmaceutically acceptable salts of Compounds (I), Compounds (I-A), and Compounds (I-B) include pharmaceutically acceptable acid addition salts, metal salts, ammonium salts, organic amine addition salts, and amino acid addition salts.

Examples of the pharmaceutically acceptable acid addition salts are inorganic acid addition salts such as hydrochloride, sulfate, and phosphate, and organic acid addition salts such as acetate, maleate, fumarate, tartrate, and citrate. Examples of the pharmaceutically acceptable metal salts are alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as magnesium salt and calcium salt, aluminium salt, and zinc salt. Examples of the pharmaceutically acceptable ammonium salts are ammonium salt and tetramethyl ammonium salt. Examples of the pharmaceutically acceptable organic amine addition salts are salts with morpholine and piperidine. Examples of the pharmaceutically acceptable amino acid addition salts are salts with lysine, glycine, and phenylalanine.

The processes for producing Compounds (I) are described below. Compounds (I) can also be produced according to the methods described in, for example, U.S. Pat. No. 3,641,010; J. Med. Chem., 34, 1431 (1991); Chem. Ber., 119, 1525 (1986); and Chem. Abst., 60, 1741h (1964).

Process 1

Compound (I-a) [Compound (I) in which R³ is hydrogen] can be prepared by the following reaction steps: ##STR13##

(In the formulae, R¹, R², R⁴, X¹, and X² have the same meanings as defined above.)

(STEP 1)

A uracil derivative (II) obtained by a known method [for example, Japanese Published Unexamined Patent Application No. 42383/84; J. Med. Chem., 32, 1873 (1989)] is allowed to react with either a carboxylic acid (III) or a reactive derivative thereof to give Compound (IV). Examples of the reactive derivative of the carboxylic acid (III) are acid halides such as acid chloride and acid bromide, active esters such as p-nitrophenyl ester and N-oxysuccinimide, commercially available acid anhydrides, acid anhydrides produced by using carbodiimides such as 3-(3-dimethylaminopropyl)-1-ethylcarbodiimide, diisopropyl carbodiimide, and dicyclohexyl carbodiimide, and mixed acid anhydrides with monoethyl carbonate or monoisobutyl carbonate. If the carboxylic acid (III) is used, the reaction is completed in 10 minutes to 5 hours at 50° to 200° C. without using a solvent.

If a reactive derivative of the carboxylic acid (III) is used, the reaction can be carried out according to a conventional method employed in peptide chemistry. That is, Compound (II) and a derivative of the carboxylic acid (III) are allowed to react in a solvent, preferably in the presence of an additive or a base, to give Compound (IV). Examples of the solvent are halogenated hydrocarbons such as methylene chloride, chloroform, and ethylene dichloride, ethers such as dioxane and tetrahydrofuran, dimethylformamide, dimethylsulfoxide, and water if necessary. An example of the additive is 1-hydroxybenzotriazole. Examples of the base are pyridine, triethylamine, 4-dimethylaminopyridine, and N-methylmorpholine. The reaction is completed in 0.5 to 24 hours at -80° to 50° C. The reactive derivative may be formed in the reaction system and then used without being isolated.

(STEP 2)

Compound (I-a) can be obtained by reaction of Compound (IV) carried out in any of the following manners: in the presence of a base (Method A); by treatment with a dehydrating agent (Method B); or by heating (Method C). In Method A, the reaction is carried out in a solvent in the presence of a base such as an alkali metal hydroxide (e.g. sodium hydroxide and potassium hydroxide). As the solvent, water, lower alcohols such as methanol and ethanol, ethers such as dioxane and tetrahydrofuran, dimethylformamide, dimethylsulfoxide, and the like may be used alone or in combination. The reaction is completed in 10 minutes to 6 hours at 0° to 180° C.

In Method B, the reaction is carried out in an inert solvent or in the absence of a solvent using a dehydrating agent such as a thionyl halide (e.g. thionyl chloride) and a phosphorus oxyhalide (e.g. phosphorus oxychloride). Examples of the inert solvent are halogenated hydrocarbons such as methylene chloride, chloroform and ethylene dichloride, dimethylformamide, and dimethylsulfoxide. The reaction is completed in 0.5 to 12 hours at 0° to 180° C.

In Method C, the reaction is carried out in a polar solvent such as dimethylformamide, dimethylsulfoxide, and Dowtherm A (Dow Chemicals). The reaction is completed in 10 minutes to 5 hours at 50° to 200° C.

(STEP 3)

Compound (II) is allowed to react with an aldehyde (V) to give a Schiff's base (VI). As a reaction solvent, mixtures of acetic acid and a lower alcohol such as methanol and ethanol may be used. The reaction is completed in 0.5 to 12 hours at -20° to 100° C.

(STEP 4)

Compound (VI) is oxidatively cyclized in an inert solvent in the presence of an oxidizing agent to form Compound (I-a). Examples of the oxidizing agent are oxygen, ferric chloride, cerium (IV) ammonium nitrate, and diethylazodicarboxylate. Examples of the inert solvent are lower alcohols such as methanol and ethanol, halogenated hydrocarbons such as methylene chloride and chloroform, and aromatic hydrocarbons such as toluene, xylene, and nitrobenzene. The reaction is completed in 10 minutes to 12 hours at 0° to 180° C.

Process 2

Compound (I-b) [Compound (I) in which R³ is a group other than hydrogen] can be prepared by the following reaction step.

Compound (I-b) is obtained from Compound (I-a) prepared by Process 1. ##STR14##

(In the formulae, R^(3e) represents a group other than hydrogen in the definition of R³ ; and R¹, R², R⁴, X¹, and X² have the same meanings as defined above.)

Compound (I-b) can be obtained by reaction of Compound (I-a) with an alkylating agent, in the presence of a base if necessary. Examples of the alkylating agent are alkyl halides such as methyl iodide, ethyl iodide, and allyl bromide, dialkyl sulfates such as dimethyl sulfate, sulfonic esters such as allyl p-tolenesulfonate and methyl trifluoromethanesulfonate, and diazoalkanes such as diazomethane. Examples of the base are alkali metal carbonates such as sodium carbonate and potassium carbonate, alkali metal hydrides such as sodium hydride, and alkali metal alkoxides such as sodium methoxide and sodium ethoxide. As a reaction solvent, aromatic hydrocarbons such as toluene and xylene, ketones such as acetone and methyl ethyl ketone, dimethylformamide, dimethylsulfoxide, or the like may be used. The reaction is completed in 0.5 to 24 hours at 0° to 180° C.

Process 3

Compound (I-d) [Compound (I) in which Z is phenyl having hydroxy as substituent(s)] can be alternatively prepared by the following reaction step. ##STR15##

(In the formulae, R¹¹ represents substituted or unsubstituted lower alkyl; p and q are integers of 1 to 4 and p≧q; and R¹, R², R³, X¹, X², Y¹, and Y² have the same meanings as defined above.)

The substituted or unsubstituted lower alkyl in the definition of R¹¹ has the same meaning as defined above.

Compound (I-d) can be obtained by react ion of Compound (I-c) [Compound (I) in which Z is phenyl having lower alkoxy as substituent(s)] obtained by Process 1 or Process 2 with a dealkylating agent. Examples of the suitable dealkylating agent are boron tribromide and the complex thereof with dimethyl disulfide, boron trichloride, iodotrimethylsilane, sodium ethanethiolate, sodium benzenethiolate, and hydrobromic acid. A reaction solvent is selected from aromatic hydrocarbons such as toluene and xylene, halogenated hydrocarbons such as methylene chloride, chloroform, and ethylene dichloride, dimethylformamide, acetic acid, etc. depending upon the kind of the dealkylating agent used. The reaction is completed in 10 minutes to 120 hours at -30° to 140° C.

Process 4

Compound (I-e) [Compound (I) in which Z is phenyl having lower alkoxy as substituent(s)] can be alternatively prepared by the following reaction step. ##STR16##

(In the formulae, R¹² represents substituted or unsubstituted lower alkyl; r is an integer of 1 to 4 and q≧r; and R¹, R², R³, R¹¹, X¹, X², Y¹, Y², p, and q have the same meanings as defined above.)

The substituted or unsubstituted lower alkyl in the definition of R¹² has the same meaning as defined above.

Compound (I-e) can be obtained from Compound (I-d) according to the method of Process 2.

Process 5

Compound (I-h) [Compound (I) in which Z is phenyl having amino-substituted lower alkoxy as the substituent] can be alternatively prepared by the following reaction step. ##STR17##

(In the formulae, Q represents lower alkylene; Hal represents chlorine, bromine, or iodine; and R¹, R², R³, X¹, X², Y¹, and Y² have the same meanings as defined above.)

The lower alkylene in the definition of Q means a straight-chain or branched alkylene group having 1 to 6 carbon atoms, such as methylene, ethylene, propylene, 1-methylethylene, butylene, 1-methylpropylene, 2-methylpropylene, pentylene, and hexylene.

(STEP 1)

Compound (I-g) can be obtained by reaction of Compound (I-f) [Compound (I) in which Z is phenyl having chlorine, bromine, or iodine-substituted lower alkoxy as the substituent] obtained by Process 4 with 5 to 10 equivalents of sodium azide. As a reaction solvent, an inert solvent such as dimethylformamide may be used. The reaction is completed in 1 to 10 hours at 50° to 80° C.

(STEP 2)

Compound (I-h) can be obtained by treatment of Compound (I-g) in an inert solvent such as tetrahydrofuran and dioxane in the presence of 2 to 5 equivalents of a reducing agent such as triphenylphosphine, followed by addition of an excess of water and further treatment for 1 to 10 hours at 50° C. to the boiling point of the solvent used.

Process 6

Compound (I-j) [Compound (I) in which Z is phenyl having carboxy-substituted lower alkoxy as the substituent] can be alternatively prepared by the following reaction step. ##STR18##

(In the formulae, R¹³ represents lower alkyl; and R¹, R², R³, Q, X¹, X², Y¹, and Y² have the same meanings as defined above.)

The lower alkyl in the definition of R¹³ has the same meaning as defined above.

Compound (I-j) can be obtained by hydrolysis of Compound (I-i) [Compound (I) in which Z is phenyl having lower alkoxycarbonyl-substituted lower alkoxy as the substituent] obtained by Process 4 in the presence of an alkali metal hydroxide such as sodium hydroxide and lithium hydroxide. As a reaction solvent, a mixture of water and an ether such as dioxane and tetrahydrofuran, or a mixture of water and an alcohol such as methanol and ethanol may be used. The reaction is completed in 10 minutes to 12 hours at room temperature to the boiling point of the solvent used.

Process 7

Compound (I-m) [Compound (I) in which Z is phenyl having hydroxy as the substituent(s)] can be alternatively prepared by the following reaction step. ##STR19##

(In the formulae, t is an integer of 1 to 4; and R¹, R², R³, X¹, X², Y¹, and Y² have the same meanings as defined above.)

Compound (I-m) can be obtained by treatment of Compound (I-k) [Compound (I) in which Z is phenyl having methoxymethoxy as the substituent(s)] obtained by Process 1, Process 2, or Process 4 in the presence of hydrogen chloride gas, an aqueous solution of hydrochloric acid, or the like. As a reaction solvent, ethers such as dioxane and tetrahydrofuran, alcohols such as methanol and ethanol, or the like may be used. The reaction is completed in 1 to 20 hours at room temperature to the boiling point of the solvent used.

Process 8

Compound (I-o) [Compound (I) in which X² is S] can be alternatively prepared by the following reaction step. ##STR20##

(In the formulae, R¹, R², R³, R⁴, and X¹ have the same meanings as defined above.)

Compound (I-o) can be obtained by reaction of Compound (I-n) [Compound (I) in which X² is O] obtained by Process 1 to Process 7 with a thionating agent. Examples of the thionating agent are phosphorus pentachloride and Leawsson's reagent. As a reaction solvent, pyridine, dimethylformamide, dioxane, tetrahydrofuran, or the like, preferably pyridine, may be used. The reaction is completed in 10 minutes to 36 hours at 50° to 180° C.

The desired compounds in the processes described above can be isolated and purified by purification methods conventionally used in organic synthetic chemistry, for example, filtration, extraction, washing, drying, concentration, recrystallization, and various kinds of chromatography.

In the case where a salt of Compound (I) is desired and it is produced in the form of the desired salt, it can be subjected to purification as such. In the case where Compound (I) is produced in the free state and its salt is desired, Compound (I) is dissolved or suspended in a suitable solvent, followed by addition of an acid or a base to form a salt.

Some of Compounds (I) can exist in the form of geometrical isomers such as an (E)-isomer and a (Z)-isomer, and the present invention covers all possible isomers including the above-mentioned ones and mixtures thereof. In the case where separation between an (E)-isomer and a (Z)-isomer is desired, they can be isolated and purified by fractionation methods, for example, fractional crystallization, fractional precipitation, and fractional dissolution.

Compounds (I) and pharmaceutically acceptable salts thereof may be in the form of adducts with water or various solvents, which can also be used as the therapeutic agent of the present invention.

Examples of Compounds (I) are shown in Table 1.

                                      TABLE 1-1                                    __________________________________________________________________________      ##STR21##                                                                     Compound                                                                             R.sup.1   R.sup.2   Z           R.sup.3                                  __________________________________________________________________________     1     (CH.sub.2).sub.2 CH.sub.3                                                                (CH.sub.2).sub.2 CH.sub.3                                                                 ##STR22##  CH.sub.3                                 2     CH.sub.3  CH.sub.3                                                                                  ##STR23##  "                                        3     (CH.sub.2).sub.2 CH.sub.3                                                                (CH.sub.2).sub.2 CH.sub.3                                                                 ##STR24##  "                                        4     CH.sub.2 CH.sub.3                                                                        CH.sub.2 CH.sub.3                                                                         ##STR25##  "                                        5     (CH.sub.2).sub.2 CH.sub.3                                                                (CH.sub.2).sub.2 CH.sub.3                                                                "           "                                        6     "         "                                                                                         ##STR26##  "                                        7     CH.sub.2 CHCH.sub.2                                                                      CH.sub.2 CHCH.sub.2                                                                       ##STR27##  "                                        8     (CH.sub.2).sub.3 CH.sub.3                                                                (CH.sub.2).sub.3 CH.sub.3                                                                "           "                                        9     (CH.sub.2).sub.2 CH.sub.3                                                                (CH.sub.2).sub.2 CH.sub.3                                                                "           H                                        10    CH.sub.3  CH.sub.3  "           "                                        11    CH.sub.2 CHCH.sub.2                                                                      CH.sub.2 CHCH.sub.2                                                                      "           "                                        12    (CH.sub.2).sub.2 CH.sub.3                                                                (CH.sub.2).sub.2 CH.sub.3                                                                 ##STR28##  "                                        13    "         "         "           CH.sub.3                                 14    "         "                                                                                         ##STR29##  H                                        15    "         "         "           CH.sub.3                                 __________________________________________________________________________

                                      TABLE 1-2                                    __________________________________________________________________________     Compound                                                                              R.sup.1                                                                               R.sup.2                                                                               Z            R.sup.3                                      __________________________________________________________________________     16     (CH.sub.2).sub.2 CH.sub.3                                                             (CH.sub.2).sub.2 CH.sub.3                                                              ##STR30##   H                                            17     "      "      "            CH.sub.3                                     18     "      "                                                                                      ##STR31##   H                                            19     "      "      "            CH.sub.3                                     20     "      "                                                                                      ##STR32##   H                                            21     "      "      "            CH.sub.3                                     22     "      "                                                                                      ##STR33##   H                                            23     "      "      "            CH.sub.3                                     24     "      "                                                                                      ##STR34##   H                                            25     "      "      "            CH.sub.3                                     26     "      "                                                                                      ##STR35##   H                                            27     "      "      "            CH.sub.3                                     28     "      "                                                                                      ##STR36##   H                                            29     "      "      "            CH.sub.3                                     30     "      "                                                                                      ##STR37##   H                                            31     "      "      "            CH.sub.3                                     __________________________________________________________________________

                                      TABLE 1-3                                    __________________________________________________________________________     Compound                                                                              R.sup.1                                                                               R.sup.2                                                                               Z           R.sup.3                                       __________________________________________________________________________     32     (CH.sub.2).sub.2 CH.sub.3                                                             (CH.sub.2).sub.2 CH.sub.3                                                              ##STR38##  H                                             33     "      "      "           CH.sub.3                                      34     "      "                                                                                      ##STR39##  H                                             35     "      "      "           CH.sub.3                                      36     "      "                                                                                      ##STR40##  H                                             37     "      "      "           CH.sub.3                                      38     "      "                                                                                      ##STR41##  H                                             39     "      "      "           CH.sub.3                                      40     "      "                                                                                      ##STR42##  H                                             41     "      "      "           CH.sub.3                                      42     "      "                                                                                      ##STR43##  H                                             43     "      "      "           CH.sub.3                                      44     "      "                                                                                      ##STR44##  H                                             45     "      "      "           CH.sub.3                                       46*   "      "                                                                                      ##STR45##  "                                             __________________________________________________________________________      *: An about 6:4 mixture with Compound 1                                  

                                      TABLE 1-4                                    __________________________________________________________________________     Compound                                                                             R.sup.1                                                                               R.sup.2                                                                               Z             R.sup.3                                      __________________________________________________________________________     47    (CH.sub.2).sub.2 CH.sub.3                                                             (CH.sub.2).sub.2 CH.sub.3                                                              ##STR46##    H                                            48    "      "      "             CH.sub.3                                     49    "      "                                                                                      ##STR47##    H                                            50    "      "      "             CH.sub.3                                     51    "      "                                                                                      ##STR48##    H                                            52    "      "      "             CH.sub.3                                     53    "      "                                                                                      ##STR49##    "                                            54    "      "                                                                                      ##STR50##    "                                            55    "      "                                                                                      ##STR51##    H                                            56    "      "      "             CH.sub.3                                     57    "      "                                                                                      ##STR52##    H                                            58    "      "      "             CH.sub.3                                     59    "      "                                                                                      ##STR53##    H                                            60    "      "      "             CH.sub.3                                     61    "      "                                                                                      ##STR54##    H                                            62    "      "      "             CH.sub.3                                     63    "      "                                                                                      ##STR55##    "                                            __________________________________________________________________________

                                      TABLE 1-5                                    __________________________________________________________________________     Compound                                                                              R.sup.1                                                                               R.sup.2                                                                               Z           R.sup.3                                       __________________________________________________________________________     64     CH.sub.2 CH.sub.3                                                                     CH.sub.2 CH.sub.3                                                                      ##STR56##  H                                             65     "      "      "           CH.sub.3                                      66     "      "                                                                                      ##STR57##  H                                             67     "      "      "           CH.sub.3                                      68     "      "                                                                                      ##STR58##  H                                             69     "      "      "           CH.sub.3                                      70     "      "                                                                                      ##STR59##  H                                             71     "      "      "           CH.sub.3                                      72     "      "                                                                                      ##STR60##  H                                             73     "      "      "           CH.sub.3                                      74     "      "                                                                                      ##STR61##  H                                             75     "      "      "           CH.sub.3                                      76     "      "                                                                                      ##STR62##  H                                             77     "      "      "           CH.sub.3                                      __________________________________________________________________________

                                      TABLE 1-6                                    __________________________________________________________________________     Compound                                                                              R.sup.1                                                                               R.sup.2                                                                               Z           R.sup.3                                       __________________________________________________________________________     78     CH.sub.2 CH.sub.3                                                                     CH.sub.2 CH.sub.3                                                                      ##STR63##  H                                             79     "      "      "           CH.sub.3                                      80     "      "                                                                                      ##STR64##  H                                             81     "      "      "           CH.sub.3                                      82     CH.sub.3                                                                              CH.sub.3                                                                               ##STR65##  H                                             83     "      "      "           CH.sub.3                                      84     "      "                                                                                      ##STR66##  H                                             85     "      "      "           CH.sub.3                                      86     "      "                                                                                      ##STR67##  H                                             87     "      "      "           CH.sub.3                                      88     "      "                                                                                      ##STR68##  H                                             89     "      "      "           CH.sub.3                                      90     "      "                                                                                      ##STR69##  H                                             91     "      "      "           CH.sub.3                                      92     "      "                                                                                      ##STR70##  H                                             93     "      "      "           CH.sub.3                                      94     "      "                                                                                      ##STR71##  H                                             95     "      "      "           CH.sub.3                                      __________________________________________________________________________

                                      TABLE 1-7                                    __________________________________________________________________________     Compound                                                                             R.sup.1                                                                               R.sup.2                                                                               Z             R.sup.3                                      __________________________________________________________________________      96   CH.sub.2 CH.sub.3                                                                     CH.sub.2 CH.sub.3                                                                      ##STR72##    H                                             97   "      "      "             CH.sub.3                                      98   "      "                                                                                      ##STR73##    H                                             99   "      "      "             CH.sub.3                                     100   "      "                                                                                      ##STR74##    H                                            101   "      "      "             CH.sub.3                                     102   "      "                                                                                      ##STR75##    H                                            103   "      "      "             CH.sub.3                                     104   "      "                                                                                      ##STR76##    H                                            105   "      "      "             CH.sub.3                                     106   "      "                                                                                      ##STR77##    H                                            107   "      "      "             CH.sub.3                                     108   "      "                                                                                      ##STR78##    H                                            109   "      "      "             CH.sub.3                                     110   "      "                                                                                      ##STR79##    H                                            111   "      "      "             CH.sub.3                                     112   "      "                                                                                      ##STR80##    H                                            113   "      "      "             CH.sub.3                                     114   CH.sub.3                                                                              CH.sub.3                                                                              "             H                                            115   "      "      "             CH.sub.3                                     116   CH.sub.2 CH.sub.3                                                                     CH.sub.2 CH.sub.3                                                                      ##STR81##    H                                            117   "      "      "             CH.sub.3                                     __________________________________________________________________________

                                      TABLE 1-8                                    __________________________________________________________________________     Compound                                                                              R.sup.1 R.sup.2                                                                               Z          R.sup.3                                       __________________________________________________________________________     118    CH.sub.2 CH.sub.3                                                                      CH.sub.2 CH.sub.3                                                                      ##STR82## H                                             119    "       "      "          CH.sub.3                                      120    CH.sub.3                                                                               CH.sub.3                                                                              "          H                                             121    "       "      "          CH.sub.3                                      122    CH.sub.2 CH.sub.3                                                                      CH.sub.2 CH.sub.3                                                                      ##STR83## H                                             123    "       "      "          CH.sub.3                                      124    "       "                                                                                      ##STR84## H                                             125    "       "      "          CH.sub.3                                      126    "       "                                                                                      ##STR85## H                                             127    "       "      "          CH.sub.3                                      128    "       "                                                                                      ##STR86## H                                             129    "       "      "          CH.sub.3                                      130    "       "                                                                                      ##STR87## H                                             131    "       "      "          CH.sub.3                                      132    "       "                                                                                      ##STR88## H                                             133    "       "      "          CH.sub.3                                      __________________________________________________________________________

                                      TABLE 1-9                                    __________________________________________________________________________     Compound                                                                             R.sup.1                                                                               R.sup.2                                                                               Z             R.sup.3                                      __________________________________________________________________________     134   CH.sub.2 CH.sub.3                                                                     CH.sub.2 CH.sub.3                                                                      ##STR89##    H                                            135   "      "      "             CH.sub.3                                     136   "      "                                                                                      ##STR90##    H                                            137   "      "      "             CH.sub.3                                     138   "      "                                                                                      ##STR91##    H                                            139   "      "      "             CH.sub.3                                     140   "      "                                                                                      ##STR92##    H                                            141   "      "      "             CH.sub.3                                     142   "      "                                                                                      ##STR93##    H                                            143   "      "      "             CH.sub.3                                     144   "      "                                                                                      ##STR94##    H                                            145   "      "      "             CH.sub.3                                     146   "      "                                                                                      ##STR95##    H                                            147   "      "      "             CH.sub.3                                     148   "      "                                                                                      ##STR96##    H                                            149   "      "      "             CH.sub.3                                     150   "      "                                                                                      ##STR97##    H                                            151   "      "      "             CH.sub.3                                     __________________________________________________________________________

                                      TABLE 1-10                                   __________________________________________________________________________     Compound                                                                             R.sup.1                                                                               R.sup.2                                                                               Z             R.sup.3                                      __________________________________________________________________________     152   CH.sub.2 CH.sub.3                                                                     CH.sub.2 CH.sub.3                                                                      ##STR98##    H                                            153   "      "      "             CH.sub.3                                     154   "      "                                                                                      ##STR99##    H                                            155   "      "      "             CH.sub.3                                     156   "      "                                                                                      ##STR100##   H                                            157   "      "      "             CH.sub.3                                     158   "      "                                                                                      ##STR101##   H                                            159   "      "      "             CH.sub.3                                     160   "      "                                                                                      ##STR102##   H                                            161   "      "      "             CH.sub.3                                     162   "      "                                                                                      ##STR103##   H                                            163   "      "                                                                                      ##STR104##   "                                            164   "      "      "             CH.sub.3                                     165   "      "                                                                                      ##STR105##   H                                            166   "      "      "             CH.sub.3                                     167   "      "                                                                                      ##STR106##   H                                            168   "      "      "             CH.sub.3                                     __________________________________________________________________________

                                      TABLE 1-11                                   __________________________________________________________________________     Compound                                                                             R.sup.1                                                                               R.sup.2                                                                               Z              R.sup.3                                     __________________________________________________________________________     169   CH.sub.2 CH.sub.3                                                                     CH.sub.2 CH.sub.3                                                                      ##STR107##    H                                           170   "      "      "              CH.sub.3                                    171   "      "                                                                                      ##STR108##    H                                           172   "      "      "              CH.sub.3                                    173   "      "                                                                                      ##STR109##    "                                           174   "      "                                                                                      ##STR110##    "                                           175   "      "                                                                                      ##STR111##    "                                           176   "      "                                                                                      ##STR112##    "                                           177   "      "                                                                                      ##STR113##    "                                           178   "      "                                                                                      ##STR114##    "                                           179   "      "                                                                                      ##STR115##    "                                           180   "      "                                                                                      ##STR116##    "                                           181   "      "                                                                                      ##STR117##    "                                           182   "      "                                                                                      ##STR118##    H                                           183   "      "      "              CH.sub.3                                    184   "      "                                                                                      ##STR119##    H                                           185   "      "                                                                                      ##STR120##    CH.sub.3                                    __________________________________________________________________________

                                      TABLE 1-12                                   __________________________________________________________________________     Compound                                                                             R.sup.1   R.sup.2   Z             R.sup.3                                __________________________________________________________________________     186   (CH.sub.2).sub.2 CH.sub.3                                                                (CH.sub.2).sub.2 CH.sub.3                                                                 ##STR121##   CH.sub.3                               187   "         "                                                                                         ##STR122##   C.sub.2 H.sub.5                        188   "         "         "             CH.sub.2 CCH                           189   "         "                                                                                         ##STR123##   CH.sub.3                               190   CH.sub.2 CHCH.sub.2                                                                      CH.sub.2 CHCH.sub.2                                                                       ##STR124##   H                                      191   "         "         "             CH.sub.3                                192* (CH.sub.2).sub.2 CH.sub.3                                                                (CH.sub.2).sub.2 CH.sub.3                                                                "             H                                       193* "         "         "             CH.sub.3                               194   "         "                                                                                         ##STR125##   H                                      195   "         "         "             CH.sub.3                               196   "         "                                                                                         ##STR126##   H                                      197   "         "         "             CH.sub.3                               __________________________________________________________________________      *: 2 -                                                                   

The pharmacological activities of Compounds (I) are shown below by experimental examples.

Experimental Example 1 Acute Toxicity Test

Test compounds were orally administered to groups of dd-strain male mice weighing 20±1 g, each group consisting of three mice. Seven days after the administration, minimum lethal dose (MLD) of each compound was determined by observing the mortality.

The results are shown in Table 2.

                  TABLE 2-1                                                        ______________________________________                                         Compound                                                                               MLD (mg/kg)   Compound  MLD (mg/kg)                                    ______________________________________                                         1       >300          33        >300                                           2       >300          34        >100                                           3       >300          35        >100                                           4       >300          36        >100                                           5       >300          37        >300                                           6       >300          38        >100                                           7       >300          39        >300                                           8       >300          40        >100                                           9       >300          41        >100                                           10      >300          42        >100                                           11      >300          43        >100                                           12      >300          44        >300                                           13      >300          45        >300                                           14      >100          46        >300                                           15      >300          47        >100                                           16      >300          48        >300                                           17      >300          49        >100                                           18      >300          50        >300                                           19      >300          51        >100                                           20      >300          52        >300                                           21      >300          53        >100                                           22      >300          54        >100                                           23      >300          55        >100                                           24      >100          56        >100                                           25      >300          57        >300                                           26      >100          58        >300                                           27      >100          59        >300                                           28      >100          60        >100                                           29      >300          61        >100                                           30      >100          62        >300                                           31      >300          63        >100                                           32      >100                                                                   ______________________________________                                    

                  TABLE 2-2                                                        ______________________________________                                         Compound                                                                               MLD (mg/kg)   Compound  MLD (mg/kg)                                    ______________________________________                                         64      >300          94        >100                                           65      >300          95        >100                                           66      >300          96        >300                                           67      >300          97        >300                                           68      >100          98        >100                                           69      >300          99        >300                                           70      >300          100       >100                                           71      >300          101       >300                                           72      >300          102       >100                                           73      >300          103       >300                                           74      >300          104       >100                                           75      >300          105       >100                                           76      >300          106       >100                                           77      >300          107       >100                                           78      >300          108       >100                                           79      >300          109       >100                                           80      >100          110       >100                                           81      >300          111       >100                                           82      >300          112       >100                                           83      >300          113       >300                                           84      >100          114       >100                                           85      >100          115       >300                                           86      >300          116       >300                                           87      >300          117       >300                                           88      >100          118       >100                                           89      >300          119       >100                                           90      >100          120       >100                                           91      >300          121       >300                                           92      >100          122       >100                                           93      >100          123       >100                                           ______________________________________                                    

                  TABLE 2-3                                                        ______________________________________                                         Compound                                                                               MLD (mg/kg)   Compound  MLD (mg/kg)                                    ______________________________________                                         124     >100          161       >100                                           125     >300          162       >100                                           126     >300          163       >100                                           127     >100          164       >100                                           128     >100          165       >100                                           129     >300          166       >100                                           130     >100          167       >100                                           131     >300          168       >100                                           132     >100          169       >100                                           133     >300          170       >100                                           134     >100          171       >100                                           135     >300          172       >100                                           136     >100          173       >100                                           137     >300          174       >100                                           138     >100          175       >100                                           139     >100          176       >100                                           140     >100          177       >100                                           141     >100          178       >100                                           142     >100          179       >100                                           143     >100          180       >100                                           144     >100          181       >100                                           145     >100          182       >100                                           146     >100          183       >100                                           147     >100          184       >100                                           148     >100          185       >100                                           149     >100          186       >300                                           150     >100          187       >300                                           151     >100          188       >300                                           152     >100          189       >100                                           153     >100          190       >100                                           154     >100          191       >100                                           155     >100          192       >100                                           156     >100          193       >300                                           157     >100          194       >100                                           158     >100          195       >100                                           159     >100          196       >100                                           160     >100          197       >100                                           ______________________________________                                    

As shown in Table 2, the MLD value of all the compounds are greater than 100 mg/kg or 300 mg/kg, indicating that the toxicity of the compounds is weak. Therefore, these compounds can be safely used in a wide range of doses.

Experimental Example 2 Adenosine Receptor Antagonistic Activity

1) Adenosine A₁ Receptor Binding Test

The test was conducted according to the method of Bruns et al. [Proc. Natl. Acad. Sci., 77, 5547 (1980)] with slight modification.

Cerebrum of a guinea pig was suspended in ice-cooled 50 mM Tris hydroxymethyl aminomethane hydrochloride (Tris HCl) buffer (pH 7.7) by using Polytron homogenizer (manufactured by Kinematicas Co.). The suspension was centrifuged (50,000×g, 10 minutes), and the precipitate was suspended again in the same amount of 50 mM Tris HCl buffer. The suspension was centrifuged under the same conditions, and the final precipitate was suspended once again in 50 mM Tris HCl buffer to give a tissue concentration of 100 mg (wet weight)/ml. The tissue suspension was incubated at 37° C. for 30 minutes in the presence of 0.02 unit/mg tissue of adenosine deaminase (manufactured by Sigma Co.). The tissue suspension was then centrifuged (50,000×g, 10 minutes), and 50 mM Tris HCl buffer was added to the precipitate to adjust the concentration of tissue to 10 mg (wet weight)/ml.

To 1 ml of the tissue suspension thus prepared were added 50 μl of cyclohexyladenosine labeled with tritium (³ H-CHA: 27 Ci/mmol, manufactured by New England Nuclear Co.) (final concentration: 1.1 nM) and 50 μl of a test compound. The mixture solution was allowed to stand at 25° C. for 90 minutes and then rapidly filtered by suction through a glass fiber filter (GF/C manufactured by Whatman Co.). The filter was immediately washed three times with 5 ml each of ice-cooled 50 mM Tris HCl buffer, and transferred to a vial, and a scintillator (EX-H by Wako Pure Chemical Industries, Ltd.) was added thereto. The radioactivity on the filter was determined with a liquid scintillation counter (manufactured by Packard Instrument Co.).

The inhibition rate of the test compound against the binding of A₁ receptor (³ H-CHA binding) was calculated by the following equation: ##EQU1## [Notes]1. "B" means the amount of radioactivity of ³ H-CHA bound in the presence of a test compound at a concentration shown in Table 3.

2. "T" means the amount of radioactivity of ³ H-CHA bound in the absence of a test compound.

3. "N" means the amount of radioactivity of ³ H-CHA bound in the presence of 10 μM N⁶ -(L-2-phenylisopropyl)adenosine (manufactured by Sigma Co.).

The results are shown in Table 3. The inhibition constant (Ki value) shown in the table was calculated by the Cheng-Prusoff's equation.

                  TABLE 3                                                          ______________________________________                                                 A.sub.1 Receptor                                                                  Inhibition (%)                                                                             K.sub.i                                                 Compound  10.sup.-5 M  10.sup.-4 M                                                                            (nM)                                            ______________________________________                                         64        84           86                                                      65        67           62                                                      67        55           70                                                      70        34           49      >10,000                                         71        89           94                                                      72        14           26      >100,000                                        73        57           56                                                      76        59           71                                                      77        84           86                                                      78        25           35      >100,000                                        79        53           72                                                      80        23           31      >100,000                                        81        56           66                                                      82        10           31      >100,000                                        83        11           1       >100,000                                        84        36           40      >100,000                                        85        1            1       >100,000                                        86        32           38      >100,000                                        87        -4           -25     >100,000                                        ______________________________________                                    

2) Adenosine A₂ Receptor Binding test

The test was conducted according to the method of Bruns et al. [Mol. Pharmacol., 29, 331 (1986)] with slight modification.

The similar procedure as in the above-described adenosine A₁ receptor binding test was repeated using rat corpus striatum to obtain the final precipitate of the tissue thereof. The precipitate was suspended in 50 mM Tris HCl buffer containing 10 mM magnesium chloride and 0.02 unit/rag tissue of adenosine deaminase (manufactured by Sigma Co.) to give a tissue concentration of 5 mg (wet weight)/ml.

To 1 ml of the tissue suspension thus prepared were added 50 μl of a mixture of N-ethylcarboxamidoadenosine labeled with tritium (³ H-NECA: 26 Ci/mmol, manufactured by Amersham Co.) (final concentration: 3.8 nM) and cyclopentyladenosine (CPA, manufactured by Sigma Co.) (final concentration: 50 nM), and 50 μl of a test compound. The mixture solution was allowed to stand at 25° C. for 120 minutes and then treated in the same manner as in the adenosine A₁ receptor binding test to determine the radioactivity bound to the A₂ receptors.

The inhibition rate of the test compound against the binding of A₂ receptor (³ H-NECA binding) was calculated by the following equation: ##EQU2## [Notes]1. "B" means the amount of radioactivity of ³ H-NECA bound in the presence of a test compound at a concentration shown in Table 4.

2. "T" means the amount of radioactivity of ³ H-NECA bound in the absence of a test compound.

3. "N" means the amount of radioactivity of ³ H-NECA bound in the presence of 100 μM CPA.

The similar procedure as above was repeated to determine the radioactivity bound to the A₂ receptors using 50 μl of CGS 21680 labeled with tritium [³ H-2-[p-(2-carboxyethyl)-phenethylamino]-5'-(N-ethylcarboxamide)adenosine: 40 Ci/mmol, manufactured by New England Nuclear Co. (J. Pharmacol. Exp. Ther., 251, 888 (1989)] (final concentration: 4.0 nM) in place of 50 μl of the mixture of N-ethylcarboxamidoadenosine labeled with tritium (³ H-NECA: 26 Ci/mmol, manufactured by Amersham Co.) (final concentration: 3.8 nM) and cyclopentyladenosine (CPA, manufactured by Sigma Co.) (final concentration: 50 nM).

The inhibition rate of the test compound against the binding of A₂ receptors (³ H-CGS 21680 binding) was calculated by the following equation: ##EQU3## [Notes]1. "B" means the amount of radioactivity of ³ H-CGS 21680 bound in the presence of a test compound at a concentration shown in Table 4.

2. "T" means the amount of radioactivity of ³ H-CGS 21680 bound in the absence of a test compound.

3. "N" means the amount of radioactivity of ³ H-CGS 21680 bound in the presence of 100 μM CPA.

The results are shown in Table 4. The Ki value (³ H-NECA binding) shown in the table was calculated by the following equation: ##EQU4## [Notes]IC₅₀ : Concentration at which the inhibition rate is 50%

L: Concentration of ³ H-NECA

Kd: Dissociation constant of ³ H-NECA

C: Concentration of CPA

Kc: Inhibition constant of CPA

                  TABLE 4-1                                                        ______________________________________                                         A.sub.2 Receptor                                                               Inhibition (%)         K.sub.i                                                                               Ratio                                            Compd. 10.sup.-7 M                                                                            10.sup.-6 M                                                                            10.sup.-5 M                                                                          10.sup.-4 M                                                                          (nM) (A.sub.1 /A.sub.2)                     ______________________________________                                         64     53      86      98    100   23                                          65     67      79      94    92    12                                          67     57      84      88    90    33                                          70     65      88      75    83    15   >670                                   71     80      99      95    74    3.9                                         72     79      84      73    86    3.1  >32,000                                73     91      94      90    93    2.0                                         76     77      84      88    95    9.5                                         77     85      91      96    98    1.6                                         78     53      64      70    70    15                                          79     80      96      88    93    6.1                                         80     70      69      80    80    6.3  >16,000                                81     84      90      104   98    1.5                                         82     65      87      92    91    310  >320                                   83     51      83      90    88    50   >2,000                                 84     56      68      83    79    22                                          85     78      85      78    81    3.0  >33,000                                86     38      60      90    81                                                87     62      57      75    85    26   >3,800                                 ______________________________________                                    

                  TABLE 4-2                                                        ______________________________________                                                 A.sub.2 Receptor                                                               Inhibition (%)                                                         Compd.    10.sup.-7 M                                                                            10.sup.-6 M                                                                               10.sup.-5 M                                                                          10.sup.-4 M                                 ______________________________________                                         88                           76    70                                          89        27      59         75    79                                          90                           89    90                                          91        46      80         86    99                                          94        74      82         89    79                                          95        83      84         82    98                                          96                           93    92                                          97        86      93         90    94                                          112       73      76         108   112                                         113       88      95         88    93                                          114                          88    91                                          115       78      88         81    83                                          117       63      94         95    96                                          118       56      65         77    81                                          119       74      92         97    99                                          121                          84    78                                          123                          75    84                                          126                          74    79                                          ______________________________________                                    

                  TABLE 4-3                                                        ______________________________________                                         A.sub.2 Receptor            A.sub.2 Receptor                                   Inhibition (%)              Inhibition (%)                                     Compd. 10.sup.-7 M                                                                              10.sup.-6 M                                                                            Compd.   10.sup.-7 M                                                                          10.sup.-6 M                            ______________________________________                                         98     54        71      149      29*   73*                                    99     71        101     150      59*   66*                                    100    56        60      152      59*   78*                                    101    71        94      153      85*   94*                                    102    80*       88*     154      9*    51*                                    103    88*       98*     155      93*   103*                                   104    27*       52*     156      53*   85*                                    105    46*       87*     157      71*   98*                                    106    68*       70*     158      75*   89*                                    107    64*       103*    159      84*   101*                                   110    67*       92*     160      66*   87*                                    111    83*       99*     161      92*   95*                                    127    89*       94*     162      25    64                                     128    64        64      164      36*   76*                                    129    78        93      165      70*   94*                                    130    73        73      166      75*   102*                                   131    81        88      168      76*   96*                                    133    76        84      169      83*   94*                                    137    59*       87*     170      93*   84*                                    139    30        69      171      87*   94*                                    140    54*       54*     172      97*   96*                                    141    68*       89*     173      61*   96*                                    142    53*       79*     175      79*   95*                                    143    72*       86*     176      34*   68*                                    144    78*       95*     177      23*   87*                                    145    86*       98*     178      34*   79*                                    146    75*       70*     183      89    75*                                    147    82*       100*                                                          ______________________________________                                          *; [.sup.3 H] CGS 21680 was used.                                        

As shown in Tables 3 and 4, Compounds (I) and pharmaceutically acceptable salts thereof exhibit an extremely potent affinity especially for adenosine A₂ receptors.

Experimental Example 3 Effect on Locomotor Activity in Parkinson's Disease Model in Mice

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is known to cause an acute Parkinson's syndrome (parkinsonism) when administered to humans. The syndrome resembles spontaneous parkinsonism in terms of cardinal symptoms (muscular rigidity, bradycinesia, and resting tremor) and pathological phenomena (extensive degeneration of the nigrostriatal dopamine system) [Science, 219, 979 (1983)]. MPTP-treated mice also exhibit the syndrome similar to parkinsonism [Science, 224, 1451 (1984)].

Especially, MPTP-treated C57BL/6 mice have been reported to serve as a suitable model for Parkinson's disease. In this strain of mice, striatal dopamine is remarkably decreased and locomotor activity is profoundly depressed [Brain Res., 528, 181 (1990)].

The experiment was performed by using several groups of 7-weeks-old male C57BL/6 mice (weighing 20 to 24 g, Japan SLC), each group consisting of 8 mice. MPTP (Aldrich Chemical Co., Inc.) dissolved in a physiological saline solution (Otsuka Pharmaceutical Co., Ltd.) was intraperitoneally administered to each mouse once a day for five consecutive days at a dose of 30 mg/kg. A test compound was suspended in injectable distilled water (Otsuka Phamaceutical Co., Ltd.) containing Tween 80 [polyoxyethylene (20) sorbitan monooleate]. L-DOPA (Kyowa Hakko Kogyo Co., Ltd.) was suspended in 0.3% CMC (sodium carboxylmethylcellulose) and bromocriptine was suspended in injectable distilled water. Thirty minutes after the final MPTP administration, the test compound suspensions and the control suspension [injectable distilled water (Otsuka Pharmaceutical Co., Ltd.) containing Tween 80] containing no test compound were orally administered to separate groups of the mice (0.1 ml per 10 g of body weight). The amount of active movements (horizontal activity) of each mouse was measured by using Automex-II (Columbus Instruments International Corp.) for the period of 30 minutes starting 30 minutes after the administration of the test compound. Bromocriptine was administerd 3 hours proir to the final MPTP treatment, and the amount of active movements was measured for the period of 30 minutes from 1 hour after the MPTP treatment. The effect of the compounds was evaluated by comparing the average counts of the active movements of the test compound-administered groups with those of the control groups. Statistical comparison of the values was carried out by Student's t-test.

The results are shown in Table 5.

                  TABLE 5-1                                                        ______________________________________                                                               Dose of   Amount of Active                                                     Test      Movements                                                            Compound  (average                                       Group  Administration (mg/kg)   count ± S.E.M)                              ______________________________________                                         Normal MPTP        (-)    --      1875 ± 77.7                               Control                                                                               Test Compound                                                                              (-)                                                         MPTP   MPTP        (+)    --       207 ± 85.5.sup.##                               Test Compound                                                                              (-)                                                         Com-   MPTP        (+)    10       628 ± 174.5*                             pound 1                                                                               Compound 1  (+)                                                         Com-   MPTP        (+)    10      1134 ± 267.0*                             pound 2                                                                               Compound 2  (+)                                                         ______________________________________                                          .sup.##: p < 0.01 (comparison with normal control group)                       *: p < 0.05 (comparison with MPTPtreated group)                          

                  TABLE 5-2                                                        ______________________________________                                                               Dose of   Amount of Active                                                     Test      Movements                                                            Compound  (average                                       Group  Administration (mg/kg)   count ± S.E.M)                              ______________________________________                                         Normal MPTP        (-)    --      2185 ± 156.2                              Control                                                                               Test Compound                                                                              (-)                                                         MPTP   MPTP        (+)    --       38 ± 24.2.sup.##                                Test Compound                                                                              (-)                                                         Com-   MPTP        (+)    40       228 ± 82.6                               pound 3                                                                               Compound 3  (+)                                                         Com-   MPTP        (+)    10       961 ± 164.7*                             pound 4                                                                               Compound 4  (+)                                                         ______________________________________                                          .sup.##: p < 0.01 (comparison with normal control group)                       *: p < 0.05 (comparison with MPTPtreated group)                          

                  TABLE 5-3                                                        ______________________________________                                                               Dose of   Amount of Active                                                     Test      Movements                                                            Compound  (average                                       Group  Administration (mg/kg)   count ± S.E.M)                              ______________________________________                                         Normal MPTP        (-)    --      2255 ± 203.1                              Control                                                                               Test Compound                                                                              (-)                                                         MPTP   MPTP        (+)    --       17 ± 4.9.sup.##                                 Test Compound                                                                              (-)                                                         Com-   MPTP        (+)    10       24 ± 6.5                                 pound 5                                                                               Compound 5  (+)                                                         Com-   MPTP        (+)    10       34 ± 12.1                                pound 6                                                                               Compound 6  (+)                                                         Com-   MPTP        (+)    10       78 ± 48.3                                pound 7                                                                               Compound 7  (+)                                                         ______________________________________                                          .sup.##: p < 0.01 (comparison with normal control group)                 

                  TABLE 5-4                                                        ______________________________________                                                               Dose of   Amount of Active                                                     Test      Movements                                                            Compound  (average                                       Group  Administration (mg/kg)   count ± S.E.M)                              ______________________________________                                         Normal MPTP        (-)    --      2032 ± 167.4                              Control                                                                               Test Compound                                                                              (-)                                                         MPTP   MPTP        (+)    --       55 ± 16.8.sup.##                                Test Compound                                                                              (-)                                                         Com-   MPTP        (+)    40       217 ± 84.2                               pound 5                                                                               Compound 5  (+)                                                         Com-   MPTP        (+)    40       458 ± 153.7*                             pound 6                                                                               Compound 6  (+)                                                         Com-   MPTP        (+)    40       310 ± 119.5                              pound 7                                                                               Compound 7  (+)                                                         ______________________________________                                          .sup.##: p < 0.01 (comparison with normal control group)                       *: p < 0.05 (comparison with MPTPtreated group)                          

                  TABLE 5-5                                                        ______________________________________                                                               Dose of   Amount of Active                                                     Test      Movements                                                            Compound  (average                                       Group  Administration (mg/kg)   count ± S.E.M)                              ______________________________________                                         Normal MPTP        (-)    --      2252 ± 210.1                              Control                                                                               Test Compound                                                                              (-)                                                         MPTP   MPTP        (+)    --       18 ± 8.4.sup.##                                 Test Compound                                                                              (-)                                                         Com-   MPTP        (+)    40       41 ± 18.0                                pound 9                                                                               Compound 9  (+)                                                         Com-   MPTP        (+)    40       32 ± 21.2                                pound 10                                                                              Compound 10 (+)                                                         Com-   MPTP        (+)    40       20 ± 7.1                                 pound 11                                                                              Compound 11 (+)                                                         Com-   MPTP        (+)    40       43 ± 28.3                                pound 8                                                                               Compound 8  (+)                                                         ______________________________________                                          .sup.##: p < 0.01 (comparison with normal control group)                 

                  TABLE 5-6                                                        ______________________________________                                                               Dose of   Amount of Active                                                     Test      Movements                                                            Compound  (average                                       Group  Administration (mg/kg)   count ± S.E.M.)                             ______________________________________                                         Normal MPTP        (-)    --      2210 ± 101.1                              Control                                                                               Test Compound                                                                              (-)                                                         MPTP   MPTP        (+)    --       45 ± 10.7.sup.##                                Test Compound                                                                              (-)                                                         Com-   MPTP        (+)    10       637 ± 160.0*                             pound 65                                                                              Compound 65 (+)                                                         Com-   MPTP        (+)    10       924 ± 219.5**                            pound 71                                                                              Compound 71 (+)                                                         ______________________________________                                          .sup.## : p < 0.01 (comparison with normal control group)                      *: p < 0.05;                                                                   **:p < 0.01 (comparison with MPTPtreated group)                          

                  TABLE 5-7                                                        ______________________________________                                                               Dose of   Amount of Active                                                     Test      Movements                                                            Compound  (average                                       Group  Administration (mg/kg)   count ± S.E.M.)                             ______________________________________                                         Normal MPTP        (-)    --      2205 ± 232.3                              Control                                                                               Test Compound                                                                              (-)                                                         MPTP   MPTP        (+)    --       60 ± 20.8.sup.##                                Test Compound                                                                              (-)                                                         Com-   MPTP        (+)    2.5     1265 ± 316.9**                            pound 65                                                                              Compound 65 (+)                                                         Com-   MPTP        (+)    2.5      800 ± 156.8**                            pound 71                                                                              Compound 71 (+)                                                         ______________________________________                                          .sup.## : p < 0.01 (comparison with normal control group)                      **: p < 0.01 (comparison with MPTPtreated group)                         

                  TABLE 5-8                                                        ______________________________________                                                               Dose of   Amount of Active                                                     Test      Movements                                                            Compound  (average                                       Group  Administration (mg/kg)   count ± S.E.M.)                             ______________________________________                                         Normal MPTP        (-)    --      2078 ± 180.2                              Control                                                                               Test Compound                                                                              (-)                                                         MPTP   MPTP        (+)    --       132 ± 65.3.sup.##                               Test Compound                                                                              (-)                                                         Com-   MPTP        (+)    0.63     610 ± 147.9*                             pound 65                                                                              Compound 65 (+)                                                         ______________________________________                                          .sup.## : p < 0.01 (comparison with normal control group)                      *: p < 0.05 (comparison with MPTPtreated group)                          

                  TABLE 5-9                                                        ______________________________________                                                               Dose of   Amount of Active                                                     Test      Movements                                                            Compound  (average                                       Group  Administration (mg/kg)   count ± S.E.M.)                             ______________________________________                                         Normal MPTP        (-)    --      2326 ± 147.1                              Control                                                                               Test Compound                                                                              (-)                                                         MPTP   MPTP        (+)    --       71 ± 37.2.sup.##                                Test Compound                                                                              (-)                                                         Com-   MPTP        (+)    10       754 ± 174.2**                            pound 73                                                                              Compound 73 (+)                                                         Com-   MPTP        (+)    10       817 ± 163.1**                            pound 77                                                                              Compound 77 (+)                                                         ______________________________________                                          .sup.## : p < 0.01 (comparison with normal control group)                      **: p < 0.01 (comparison with MPTPtreated group)                         

                  TABLE 5-10                                                       ______________________________________                                                               Dose of   Amount of Active                                                     Test      Movements                                                            Compound  (average                                       Group  Administration (mg/kg)   count ± S.E.M.)                             ______________________________________                                         Normal MPTP        (-)    --      2574 ± 165.9                              Control                                                                               Test Compound                                                                              (-)                                                         MPTP   MPTP        (+)    --       21 ± 5.1.sup.##                                 Test Compound                                                                              (-)                                                         Com-   MPTP        (+)    10       157 ± 25.0**                             pound 97                                                                              Compound 97 (+)                                                         ______________________________________                                          .sup.## : p < 0.01 (comparison with normal control group)                      **: p < 0.01 (comparison with MPTPtreated group)                         

                  TABLE 5-11                                                       ______________________________________                                                                Dose of                                                                        Test     Amount of Active                                                      Com-     Movements                                                             pound    (average                                       Group   Administration (mg/kg)  count ± S.E.M.)                             ______________________________________                                         Normal  MPTP        (-)    --     2349 ± 121.7                              Control Test Compound                                                                              (-)                                                        MPTP    MPTP        (+)    --      44 ± 14.4.sup.##                                 Test Compound                                                                              (-)                                                        Com-    MPTP        (+)    2.5     937 ± 189.5**                            pound 83                                                                               Compound 83 (+)                                                        Com-    MPTP        (+)    2.5     604 ± 192.6*                             pound 170                                                                              Compound 170                                                                               (+)                                                        Com-    MPTP        (+)    10      922 ± 208.2**                            pound 195                                                                              Compound 195                                                                               (+)                                                        ______________________________________                                          .sup.## : p < 0.01 (comparison with normal control group)                      *: p < 0.05;                                                                   **:p < 0.01 (comparison with MPTPtreated group)                          

                  TABLE 5-12                                                       ______________________________________                                                               Dose of   Amount of Active                                                     Test      Movements                                                            Compound  (average                                       Group  Administration (mg/kg)   count ± S.E.M.)                             ______________________________________                                         Normal MPTP        (-)    --      1875 ± 77.7                               Control                                                                               Test Compound                                                                              (-)                                                         MPTP   MPTP        (+)    --       207 ± 85.5.sup.##                               Test Compound                                                                              (-)                                                         L-DOPA MPTP        (+)    300      561 ± 271.01.sup.1)                             L-DOPA      (+)                                                         ______________________________________                                          .sup.## : p < 0.01 (comparison with normal control group)                      .sup.1) : no significant difference as compared with MPTPtreated group)  

                  TABLE 5-13                                                       ______________________________________                                                               Dose of   Amount of Active                                                     Test      Movements                                                            Compound  (average                                       Group  Administration (mg/kg)   count ± S.E.M.)                             ______________________________________                                         Normal MPTP        (-)    --      1984 ± 122.3                              Control                                                                               Test Compound                                                                              (-)                                                         MPTP   MPTP        (+)    --       41 ± 14.3.sup.##                                Test Compound                                                                              (-)                                                         Bromo- MPTP        (+)    40      1739 ± 494.9**                            criptine                                                                              Bromocriptine                                                                              (+)                                                         ______________________________________                                          .sup.## : p < 0.01 (comparison with normal control group)                      **: p < 0.01 (comparison with MPTPtreated group)                         

                  TABLE 5-14                                                       ______________________________________                                                               Dose of   Amount of Active                                                     Test      Movements                                                            Compound  (average                                       Group  Administration (mg/kg)   count ± S.E.M.)                             ______________________________________                                         Normal MPTP        (-)    --      2574 ± 165.9                              Control                                                                               Test Compound                                                                              (-)                                                         MPTP   MPTP        (+)    --       21 ± 5.1.sup.##                                 Test Compound                                                                              (-)                                                         Bromo- MPTP        (+)    10       66 ± 35.4.sup.1)                         criptine                                                                              Bromocriptine                                                                              (+)                                                         ______________________________________                                          .sup.## : p < 0.01 (comparison with normal control group)                      .sup.1) : no significant difference as compared with MPTPtreated group)  

Experimental Example 4 Effect on Haloperidol-Induced Catalepsy

Parkinson's disease is a clinical syndrome caused by degeneration of nigrostriatal dopaminergic neurons. Systemic administration of haloperidol (dopamine D₁ /D₂ antagonist) induces catalepsy resulting from the blockade of postsynaptic dopamine D₂ receptors. It is generally accepted that this haloperidol-induced catalepsy is a classical model of parkinsonism in humans [Eur. J. Pharmacol., 182, 327 (1990)].

The experiment was performed by using several groups of 5-weeks-old male ddY mice (weighing 22 to 24 g, Japan SLC), each group consisting of 5 mice. Haloperidol (Janssen Pharmaceutica) suspended in 0.3% CMC was intraperitoneally administered to each mouse at a dose of 1.0 mg/kg. Test compounds were suspended in 0.3% CMC or in injectable distilled water (Otsuka Pharmaceutical Co., Ltd.) containing Tween 80. L-DOPA (Kyowa Hakko Kogyo Co., Ltd.) and benserazide hydrochloride (Kyowa Hakko Kogyo Co., Ltd.) were suspended in 0.3% CMC. One hour after the haloperidol administration, the test compound suspensions and the control suspension [0.3% CMC or injectable distilled water (Otsuka Pharmaceutical Co., Ltd.) containing Tween 80] containing no test compound were orally administered to separate groups of the mice (0.1 ml per 10 g of body weight). One hour after the administration of the test compound, the forelimbs of each mouse and subsequently the hindlimbs of the same mouse were placed on a 4.5 cm-high, 1.0 cm-wide bar and catalepsy was estimated. All of the test compounds were orally administered at a dose of 10 mg/kg, and L-DOPA (100 mg/kg) and benserazide (25 mg/kg) were intraperitoneally administered together as a control experiment. The catalepsy score and the standard of judgment are shown below.

    ______________________________________                                         score               duration of the cataleptic posture                         ______________________________________                                         0:          forelimbs   less than 5 seconds                                                hindlimbs   less than 5 seconds                                    1:          forelimbs   from 5 (inclusive) to 10                                                       (exclusive) seconds                                                hindlimbs   less than 5 seconds                                    2:          forelimbs   10 seconds or more                                                 hindlimbs   less than 5 seconds                                    3:          forelimbs   from 5 (inclusive) to 10                                                       (exclusive) seconds                                                hindlimbs   from 5 (inclusive) to 10                                                       (exclusive) seconds;                                        or     forelimbs   less than 5 seconds                                                hindlimbs   5 seconds or more                                      4:          forelimbs   10 seconds or more                                                 hindlimbs   from 5 (inclusive) to 10                                                       (exclusive) seconds;                                        or     forelimbs   from 5 (inclusive) to 10                                                       (exclusive) seconds                                                hindlimbs   10 seconds or more                                     5:          forelimbs   10 seconds or more                                                 hindlimbs   10 seconds or more                                     ______________________________________                                    

The effect of the compounds was evaluated by the total of the catalepsy scores of five mice in each group (25 points at the full). The groups wherein the total score was not more than 20 points were estimated to be effective. The number of the animals showing remission against catalepsy is the number of the mice for which the catalepsy score was not more than 4 points. The remission rate shows the rate of decrease in total score based on that of the control group.

The ED₅₀ (50% effective dose) values were determined using ten mice at each dose. A test compound was judged to be effective at the dose where the catalepsy score was 3 or less than 3. The ED₅₀ values were calculated by Probit analysis.

The results are shown in Table 6.

                  TABLE 6-1                                                        ______________________________________                                                                        Re-                                                               Number of the                                                                               mission                                                   Total   Animals Showing                                                                             Rate  ED.sub.50                                 Compound  Score   Remission    (%)   (mg/kg)                                   ______________________________________                                         0.3% CMC  25      0            0                                               (Control)                                                                      L-DOPA    20      3            20                                              + benserazide                                                                   1        13      5            48    2.7                                        2        11      5            56    0.13                                       3        20      4            20                                               4        20      4            20                                               5        18      4            28    3.6                                        6        19      3            24                                               7        13      4            48    0.38                                      11        20      3            20                                              L-DOPA    18      4            28    107.5                                     + benserazide                                                                  13        5       5            80    3.0                                       15        19      4            24                                              16        20      4            20                                              18        20      4            20                                              19        19      3            24                                              20        19      3            24                                              23        18      4            28                                              24        19      4            24                                              ______________________________________                                    

                  TABLE 6-2                                                        ______________________________________                                                                        Re-                                                               Number of the                                                                               mission                                                   Total   Animals Showing                                                                             Rate  ED.sub.50                                 Compound  Score   Remission    (%)   (mg/kg)                                   ______________________________________                                         0.3% Tween 80                                                                            25      0            0                                               (Control)                                                                      L-DOPA    18      4            28    107.5                                     + benserazide                                                                   9        15      5            40                                              17        7       5            72    7.0                                       21        2       5            92    1.2                                       25        12      5            52    6.6                                       31        18      4            28                                              33        16      5            36                                              48        6       5            76    1.1                                       50        19      3            24                                              53        20      4            20                                              59        19      5            24                                              ______________________________________                                    

                  TABLE 6-3                                                        ______________________________________                                                           Number of the                                                                  Animals     Remission                                                  Total   Showing     Rate    ED.sub.50                                Compound  Score   Remission   (%)     (mg/kg)                                  ______________________________________                                         0.3% Tween 80                                                                            25      0           0                                                (Control)                                                                      L-DOPA +  18      4           28      107.5                                    benserazide                                                                    65        2       5           80      0.03                                     69        6       5           76      1.7                                      71        2       5           92      0.23                                     73        8       5           68      0.24                                     75        12      5           52      2.7                                      77        1       5           92      0.6                                      79        4       5           84      0.76                                     81        4       5           84      1.9                                      83        7       5           72      0.35                                     84        19      4           24                                               85        20      3           20                                               94        16      4           36                                               95        17      4           32                                               97        8       5           68      2.6                                      99        6       5           76      1.5                                      101       8       4           68      2.5                                      103       3       5           88                                               107       17      3           32                                               113       19      4           24      3.8                                      115       10      5           60      1.7                                      ______________________________________                                    

                  TABLE 6-4                                                        ______________________________________                                                           Number of the                                                                  Animals     Remission                                                  Total   Showing     Rate    ED.sub.50                                Compound  Score   Remission   (%)     (mg/kg)                                  ______________________________________                                         0.3% Tween 80                                                                            25      0           0                                                (Control)                                                                      L-DOPA +  18      4           28      107.5                                    benserazide                                                                    117       18      5           28                                               119       14      5           44                                               126       17      3           32                                               127       16      4           36                                               130       9       5           64                                               131       5       5           80                                               133       14      4           44                                               139       15      4           40                                               141       18      3           28                                               145       9       5           64                                               147       17      4           32                                               149       16      3           36                                               153       14      4           44                                               155       12      4           52                                               166       16      3           36                                               170       3       5           92      0.01                                     172       4       5           84                                               173       20      3           20                                               175       4       5           84                                               176       19      3           24                                               188       19      3           24                                               189       13      3           48                                               191       2       5           92      0.02                                     193       12      4           52                                               ______________________________________                                    

Experimental Example 5 Augmentation of the Contralateral Rotation in Rats with a 6-Hydroxydopamine-Induced Unilateral Lesion of the Nigrostriatal Dopamine Pathway

When a unilateral lesion of the nigrostriatal pathway is induced by 6-hydroxydopamine in rodents, the sensitivity of dopamine receptors in the denervated striatum is enhanced. Administration of a dopamine agonist to the rodents in such a condition induces a rotational behavior to the side contralateral to the lesioned side [Acta Physiol. Scand., 367, 69 (1971)]. This model has been used for a long time as a model for the study of Parkinson's disease and in the screening of drugs for this disease [Neurol. Neurobiol., 33, 1 (1987)].

Male Sprague-Dawley rats (weighing 200 to 240 g, Japan SLC) were pretreated with desipramine hydrochloride (25 mg/kg, i.p., Sigma Co.) 30 minutes before surgery to protect noradrenergic neurons. Then, the animals were anesthetized with sodium pentobarbital (30 mg/kg, i.p., Dainippon Pharm. Co., Ltd.) and the nigrostriatal pathway was lesioned by injection of 6-hydroxydopamine hydrobromide (8 μg, Sigma Co.) into the left medial forebrain bundle. 6-Hydroxydopamine hydrobromide was dissolved in physiological saline containing 0.05% L-ascorbic acid (Wako Pure Chem. Industries, Ltd.) to make 2 μl of solution and injected over 3 minutes.

More than 10 days after surgery, each rat was placed in a plastic bowl (30 cm in diameter). Apomorphine (0.1 mg/kg, Sandoz, AG) was injected subcutaneously and the rats which showed a rotational behavior to the side contralateral to the lesioned side at a frequency of more than 600 counts/60 minutes after apomorphine administration were used for screening. The number of rotations was counted with an automated rotometer, in which each 180° turn was counted as a rotation.

Test compounds were suspended in 0.3% sodium carboxymethylcellulose and administered orally at a dose of 1 mg/kg 30 minutes before the injection of apomorphine (0.1 mg/kg, s.c.). The counts of rotations were summed up every 5 minutes for 150 minutes after apomorphine administration. The total rotation counts induced by apomorphine (0.1 mg/kg, s.c.) with and without a test compound were statistically compared, using the same animals. Rats were allowed to rest more than 5 days between each experiment. Statistical comparison of the values was carried out by Sign-Wilcoxon test.

The results are shown in Table 7.

                  TABLE 7                                                          ______________________________________                                                   total amount of rotations                                                      (average count ± S.E.M.)                                                                 test compound +                                         Compd.      apomorphine                                                                               apomorphine                                             ______________________________________                                         65          1102 ± 94                                                                              1584 ± 196*                                          71          1003 ± 84                                                                              1406 ± 155*                                          73           1097 ± 147                                                                            1637 ± 127*                                          77          1006 ± 81                                                                              1378 ± 216*                                          170         1041 ± 51                                                                              1490 ± 146*                                          ______________________________________                                          *p < 0.05                                                                

As described above, Compounds (I) and pharmaceutically acceptable salts thereof exhibit anti-Parkinson's syndrome effects. Thus, they are effective as therapeutic agents for Parkinson's disease. Compounds (I) and pharmaceutically acceptable salts thereof can be administered as they are, or in the form of various pharmaceutical compositions. The pharmaceutical compositions in accordance with the present invention can be prepared by uniformly mixing an effective amount of Compound (I) or a pharmaceutically acceptable salt thereof, as an active ingredient, with a pharmaceutically acceptable carrier. It is desired that such pharmaceutical compositions are prepared in a unit dose form suitable for oral administration or administration through injection.

For preparing a pharmaceutical composition for oral administration, any useful pharmaceutically acceptable carrier can be used. For example, liquid preparations for oral administration such as suspension and syrup can be prepared using water, sugars such as sucrose, sorbitol and fructose, glycols such as polyethylene glycol and propylene glycol, oils such as sesame oil, olive oil and soybean oil, preservatives such as p-hydroxybenzoates, flavors such as strawberry flavor and peppermint, and the like. Powders, pills, capsules and tablets can be prepared using excipients such as lactose, glucose, sucrose and mannitol, disintegrating agents such as starch and sodium alginate, lubricants such as magnesium stearate and talc, binders such as polyvinyl alcohol, hydroxypropyl cellulose and gelatin, surfactants such as fatty acid esters, plasticizers such as glycerin, and the like. Tablets and capsules are most useful oral unit dose forms because of the readiness of administration. For preparing tablets and capsules, solid pharmaceutical carriers are used.

Injectable preparations can be prepared using a carrier such as distilled water, a salt solution, a glucose solution or a mixture of a salt solution and a glucose solution. The preparations can be prepared in the form of solution, suspension or dispersion according to a conventional method by using a suitable auxiliary.

Compounds (I) and pharmaceutically acceptable salts thereof can be administered orally in the said dosage forms or parenterally as injections. The effective dose and the administration schedule vary depending upon mode of administration, age, body weight and conditions of a patient, etc. However, generally, Compound (I) or a pharmaceutically acceptable salt thereof is administered in a daily dose of 0.01 to 25 mg/kg in 3 to 4 parts.

Certain embodiments of the invention are illustrated in the following examples.

EXAMPLE 1 (E)-8-[2-(1,4-Benzodioxan-6-yl)vinyl]-1,3-dipropylxanthine (Compound 16)

Substantially the same procedure as in Reference Example 1 was repeated using 1.35 g (5.96 mmol) of 5,6-diamino-1,3-dipropyluracil and 1.35 g (6.55 mmol) of 3-(1,4-benzodioxan-6-yl)acrylic acid. Then, the resultant crude crystals were recrystallized from ethanol/water to give 1.54 g (yield 65%) of Compound 16 as white needles.

Melting Point: >275° C.

Elemental Analysis: C₂₁ H₂₄ N₄ O₄ Calcd. (%): C, 63.62; H, 6.10; N, 14.13 Found (%): C, 63.57; H, 6.24; N, 14.36

IR (KBr) ν_(max) (cm⁻¹): 1693, 1636, 1582, 1511

NMR (DMSO-d₆ ; 270 MHz) δ (ppm): 12.52(1H, brs), 7.63 (1H, d, J=16.2 Hz), 7.10-7.06(2H, m), 6.95-6.86(2H, m), 4.29(4H, s), 4.15-4.10(4H, m), 1.90-1.65(4H, m), 1.05-0.95(6H, m)

EXAMPLE 2 (E)-8-[2-(1,4-Benzodioxan-6-yl)vinyl]-7-methyl-1,3-dipropylxanthine (Compound 17)

Substantially the same procedure as in Reference Example 1 was repeated using 1.0 g (2.52 mmol) of Compound 16 obtained in Example 1 in place of Compound B. Then, the resultant crude crystals were recrystallized from ethanol to give 840 mg (yield 81%) of Compound 17 as pale yellow needles.

Melting Point: 181.9°-182.3° C.

Elemental Analysis: C₂₂ H₂₆ N₄ O₄ Calcd. (%): C, 64.37; H, 6.38; N, 13.64 Found (%): C, 64.56; H, 6.63; N, 13.92

IR (KBr) ν_(max) (cm⁻¹): 1693, 1651, 1510, 1288

NMR (CDCl₃ ; 270 MHz) δ (ppm): 7.67 (1H, d, J=15.5 Hz), 7.10(2H, m), 6.88(1H, d, J=8.3 Hz), 6.74(1H, d, J=15.5 Hz), 4.30(4H, m), 4.13-3.95(4H, m), 4.03(3H, s), 1.88-1.65(4H, m), 1.03-0.94(6H, m)

EXAMPLE 3 (E)-8-(3,4-Methylenedioxystyryl)-1,3-dipropylxanthine (Compound 18)

Substantially the same procedure as in Reference Example 1 was repeated using 4.25 g (18.8 mmol) of 5,6-diamino-1,3-dipropyluracil and 4.33 g (22.6 mmol) of 3,4-methylenedioxycinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane to give 4.92 g (yield 69%) of Compound 18 as a pale yellow powder.

Melting Point: >270° C.

Elemental Analysis: C₂₀ H₂₂ N₄ O₄.0.75H₂ O Calcd. (%): C, 60.50; H, 5.72; N, 14.43 Found (%): C, 60.67; H, 5.98; N, 14.15

IR (KBr) ν_(max) (cm⁻¹): 1688, 1648, 1499

NMR (DMSO-d₆ ; 270 MHz) δ (ppm): 13.49(1H, brs), 7.56 (1H, d, J=16.3 Hz), 7.30(1H, s), 7.07(1H, d, J=8.4 Hz), 6.97-6.89(2H, m), 6.07(2H, s), 3.98 (2H, t, J=7.2 Hz), 3.85(2H, t, J=7.3 Hz), 1.75-1.35(4H, m), 0.95-0.80(6H, m)

EXAMPLE 4 (E)-7-Methyl-8-(3,4-methylenedioxystyryl)-1,3-dipropylxanthine (Compound 19)

Substantially the same procedure as in Reference Example 1 was repeated using 3.0 g (7.85 mmol) of Compound 18 obtained in Example 3 in place of Compound B. Then, the resultant crude crystals were recrystallized from toluene/cyclohexane to give 2.33 g (yield 75%) of Compound 19 as a pale green powder.

Melting Point: 151.7°-155.4° C.

Elemental Analysis: C₂₁ H₂₄ N₄ O₄.0.25H₂ O Calcd. (%): C, 62.91; H, 6.16; N, 13.97 Found (%): C, 62.88; H, 6.25; N, 13.72

IR (KBr) ν_(max) (cm⁻¹): 1689, 1650, 1498, 1443

NMR (CDCl₃ ; 270 MHz) δ (ppm): 7.70(1H, d, J=15.6 Hz), 7.10-6.95(2H, m), 6.84(1H, d, J=7.9 Hz), 6.72(1H, d, J=15.6 Hz), 6.02(2H, s), 4.10(2H, t, J=7.3 Hz), 4.04(3H, s), 3.97(2H, t, J=7.3 Hz), 1.90-1.65(4H, m), 1.05-0.90(6H, m)

EXAMPLE 5 (E)-8-[2-(4-Methoxynaphthyl)vinyl]-1,3-dipropylxanthine (Compound 61)

Substantially the same procedure as in Reference Example 1 was repeated using 3.0 g (13.3 mmol) of 5,6-diamino-1,3-dipropyluracil and 3.33 g (14.6 mmol) of 3-(4-methoxynaphthyl)acrylic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 3.12 g (yield 56%) of Compound 61 as yellow needles.

Melting Point: >280° C.

Elemental Analysis: C₂₄ H₂₆ N₄ O₃ Calcd. (%): C, 68.88; H, 6.26; N, 13.39 Found (%): C, 68.90; H, 6.38; N, 13.49

IR (KBr) ν_(max) (cm⁻): 1699, 1649, 1486, 1273

NMR (DMSO-d₆ ; 270 MHz) δ (ppm): 13.58(1H, brs), 8.43 (1H, d, J=16.5 Hz), 8.36(1H, d, J=8.6 Hz), 8.24(1H, d, J=8.6 Hz), 7.98(1H, d, J=7.8 Hz), 7.70-7.54(2H, m), 7.12-7.06(2H, m), 4.03(3H, s), 4.02-3.86(4H, m), 1.79-1.56 (4H, m), 0.92 (3H, s), 0.89 (3H, s)

EXAMPLE 6 (E)-8-[2-(4-Methoxynaphthyl)vinyl]-7-methyl-1,3-dipropylxanthine (Compound 62)

Substantially the same procedure as in Reference Example 1 was repeated using 1.6 g (3.82 mmol) of Compound 61 obtained in Example 5 in place of Compound B. Then, the resultant crude crystals were recrystallized from ethyl acetate to give 1.25 g (yield 76%) of Compound 62 as pale yellow plates.

Melting Point: 212.6°-213.9° C.

Elemental Analysis: C₂₅ H₂₈ N₄ O₃ Calcd. (%): C, 69.43; H, 6.52; N, 12.95 Found (%): C, 69.46; H, 6.68; N, 12.95

IR (KBr) νmax (cm⁻¹): 1701, 1650, 1486, 1439, 1267

NMR (CDCl₃ ; 270 MHz) δ (ppm): 8.52(1H, d, J=15.5 Hz), 8.34(1H, d, J=8.3 Hz), 8.23(1H, d, J=8.6 Hz), 7.77 (1H, d, J=8.3 Hz), 7.66-7.52(2H, m), 6.89(1H, d, J=15.5 Hz), 6.87(1H, d, J=8.3 Hz), 4.18-4.11(2H, m), 4.07 (3H, s), 4.06 (3H, s), 4.02-3.97 (2H, m), 1.95-1.64(4H, m), 1.03(3H, t, J=7.3 Hz), 0.98(3H, t, J=7.3 Hz)

EXAMPLE 7 (E)-8-(3,4-Dimethoxystyryl)-1,3-diethylxanthine (Compound 64)

3,4-Dimethoxycinnamic acid (1.39 g, 6.67 mmol) and 3-(3-diethylaminopropyl)-1-ethylcarbodiimide hydrochloride (1.74 g, 9.09 mmol) were added to a mixture of dioxane (40 ml) and water (20 ml) containing 5,6-diamino-1,3-diethyluracil [J. Am. Chem. Soc., 75, 114 (1953)] (1.20 g, 6.06 mmol). The resultant solution was stirred at room temperature for 2 hours at pH 5.5. After neutralization, the reaction solution was extracted three times with 50 ml of chloroform. The combined extract was washed with a saturated aqueous solution of sodium chloride and dried over anhydrous sodium sulfate, followed by evaporation under reduced pressure.

To the residue were added 10 ml of dioxane and 15 ml of an aqueous 1N sodium hydroxide solution, followed by heating under reflux for 20 minutes. After cooling, the solution was neutralized and 20 ml of chloroform was added thereto. The organic layer was separated and the aqueous layer was extracted twice with 20 ml of chloroform. The combined extract was washed with a saturated aqueous solution of sodium chloride and dried over anhydrous sodium sulfate, followed by evaporation under reduced pressure. The residue was purified by silica gel column chromatography (eluent: 2% methanol/chloroform), followed by recrystallization from toluene to give 1.06 g (yield 47%) of Compound 64 as pale yellow needles.

Melting Point: 268.8°-269.1° C.

Elemental Analysis: C₁₉ H₂₂ N₄ O₄ Calcd. (%): C, 61.61; H, 5.98; N, 15.12 Found (%): C, 61.99; H, 6.00; N, 14.91

IR (KBr) ν_(max) (cm⁻¹): 1694, 1641, 1514, 1492

NMR (270 MHz; DMSO-d₆) δ (ppm): 13.35(1H, brs), 7.59 (1H, d, J=16.2 Hz), 7.27(1H, d, J=1.4 Hz), 7.14(1H, dd, J=1.4, 8.2 Hz), 6.99(1H, d, J=8.2 Hz), 6.96(1H, d, J=16.2 Hz), 4.06(2H, q, J=7.0 Hz), 3.91(2H, q, J=7.0 Hz), 3.83(3H, s), 3.79(3H, s), 1.26(3H, t, J=7.0 Hz), 1.14 (3H, t, J=7.0 Hz)

EXAMPLE 8 (E)-8-(3,4-Dimethoxystyryl)-1,3-diethyl-7-methylxanthine (Compound 65)

Compound 64 (1.20 g, 3.24 mmol) obtained in Example 7 was dissolved in 25 ml of dimethylformamide. To the solution were added 1.12 g (8.10 mmol) of potassium carbonate and subsequently 0.40 ml (6.49 mmol) of methyl iodide, and the resultant mixture was stirred at 50° C. for 30 minutes. After cooling, insoluble matters were filtered off, and 100 ml of water was added to the filtrate. The mixture was extracted three times with 50 ml of chloroform. The extract was washed twice with water and once with a saturated aqueous solution of sodium chloride, and dried over anhydrous sodium sulfate, followed by evaporation under reduced pressure. The obtained crude crystals were purified by silica gel column chromatography (eluent: 40% ethyl acetate/hexane), followed by recrystallization from isopropanol to give 840 mg (yield 68%) of Compound 65 as pale yellow needles.

Melting Point: 190.4°-191.3° C.

Elemental Analysis: C₂₀ H₂₄ N₄ O₄ Calcd. (%): C, 62.48; H, 6.29; N, 14.57 Found (%): C, 62.52; H, 6.53; N, 14.56

IR (KBr) ν_(max) (cm⁻¹): 1697, 1655, 1518

NMR (270 MHz; CDCl₃) δ (ppm): 7.74(1H, d, J=15.5 Hz), 7.18(1H, dd, J=1.9, 8.3 Hz), 7.08(1H, d, J=1.9 Hz), 6.89(1H, d, J=8.3 Hz), 6.77(1H, d, J=15.5 Hz), 4.21 (2H, q, J=6.9 Hz), 4.09(2H, q, J=6.9 Hz), 4.06(3H, s), 3.96(3H, s), 3.93(3H, s), 1.39(3H, t, J=6.9 Hz), 1.27(3H, t, J=6.9 Hz)

EXAMPLE 9 (E)-8-(2,3-Dimethoxystyryl)-1,3-diethylxanthine (Compound 66)

Substantially the same procedure as in Example 7 was repeated using 2.0 g (10.1 mmol) of 5,6-diamino-1,3-diethyluracil and 2.52 g (12.1 mmol) of 2,3-dimethoxycinnamic acid. Then, the resultant crude crystals were recrystallized from dimethylsulfoxide/water to give 1.72 g (yield 46%) of Compound 66 as a white powder.

Melting Point: 287.5°-289.4° C.

Elemental Analysis: C₁₉ H₂₂ N₄ O₄ Calcd. (%): C, 61.61; H, 5.98; N, 15.12 Found (%): C, 61.56; H, 6.11; N, 14.83

IR (KBr) ν_(max) (cm⁻¹): 1697, 1656, 1500

NMR (270 MHz; DMSO-d₆) δ (ppm): 13.64 (1H, brs), 7.84 (1H, d, J=16.8 Hz), 7.29(1H, dd, J=1.7, 7.6 Hz), 7.15-7.00(3H, m), 4.07(2H, q, J=7.0 Hz), 3.94(2H, q, J=7.0 Hz), 3.83 (3H, s), 3.79(3H, s), 1.26(3H, t, J=7.0 Hz), 1.14(3H, t, J=7.0 Hz)

EXAMPLE 10 (E)-8-(2,3-Dimethoxystyryl)-1,3-diethyl-7-methylxanthine (Compound 67)

Substantially the same procedure as in Example 8 was repeated using 1.60 g (4.32 mmol) of Compound 66 obtained in Example 9 in place of Compound 64. Then, the resultant crude crystals were recrystallized from cyclohexane/toluene to give 1.21 g (yield 73%) of Compound as a pale yellow powder.

Melting Point: 194.9°-195.6° C.

Elemental Analysis: C₂₀ H₂₄ N₄ O₄ Calcd. (%): C, 62.48; H, 6.29; N, 14.57 Found (%): C, 62.67; H, 6.48; N, 14.31

IR (KBr) ν_(max) (cm⁻¹): 1694, 1660, 1272

NMR (270 MHz; CDCl₃) δ (ppm): 8.00(1H, d, J=16.8 Hz), 7.19(1H, dd, J=1.3, 7.9 Hz), 7.15-7.00(2H, m), 6.93 (1H, dd, J=1.3, 7.9 Hz), 4.26(2H, q, J=6.9 Hz), 4.09 (2H, q, J=6.9 Hz), 4.05 (3H, s), 3.91 (3H, s), 3.90 (3H, s), 1.39(3H, t, J=6.9 Hz), 1.27(3H, t, J=6.9 Hz)

EXAMPLE 11 (E)-8-(2,4-Dimethoxystyryl)-1,3-diethylxanthine (Compound 68)

Substantially the same procedure as in Example 7 was repeated using 2.50 g (12.6 mmol) of 5,6-diamino-1,3-diethyluracil and 2.89 g (13.9 mmol) of 2,4-dimethoxycinnamic acid. Then, the resultant crude crystals were recrystallized from dimethylformamide/ethanol to give 0.92 g (yield 20%) of Compound 68 as yellow crystals.

Melting Point: 278.7°-279.8° C.

Elemental Analysis: C₁₉ H₂₂ N₄ O₄ Calcd. (%): C, 61.61; H, 5.98; N, 15.12 Found (%): C, 61.65; H, 5.95; N, 14.74

IR (KBr) ν_(max) (cm⁻): 1698, 1640, 1509, 1292

NMR (270 MHz; DMSO-d₆) δ (ppm): 13.43(1H, brs), 7.77 (1H, d, J=16.8 Hz), 7.54(1H, d, J=8.4 Hz), 6.95(1H, d, J=16.8 Hz), 6.63(1H, d, J=2.5 Hz), 6.60(1H, dd, J=2.5, 8.4 Hz), 4.06(2H, q, J=6.9 Hz), 3.93(2H, q, J=6.9 Hz), 3.89(3H, s), 3.82(3H, s), 1.25(3H, t, J=6.9 Hz), 1.13(3H, t, J=6.9 Hz)

EXAMPLE 12 (E)-8-(2,4-Dimethoxystyryl)-1,3-diethyl-7-methylxanthine (Compound 69)

Substantially the same procedure as in Example 8 was repeated using 400 mg (1.08 mmol) of Compound 68 obtained in Example 11 in place of Compound 64. Then, the resultant crude crystals were recrystallized from hexane/ethyl acetate to give 335 mg (yield 81%) of Compound 69 as yellow needles.

Melting Point: 195.9°-196.7° C.

Elemental Analysis: C₂₀ H₂₄ N₄ O₄ Calcd. (%): C, 62.48; H, 6.29; N, 14.57 Found (%): C, 62.29; H, 6.51; N, 14.66

IR (KBr) ν_(max) (cm⁻¹): 1693, 1654, 1603, 1294

NMR (270 MHz; CDCl₃) δ (ppm): 7.93(1H, d, J=15.8 Hz), 7.48(1H, d, J=8.3 Hz), 6.97(1H, d, J=15.8 Hz), 6.53 (1H, dd, J=2.0, 8.3 Hz), 6.49(1H, d, J=2.0 Hz), 4.22 (2H, q, J=6.9 Hz), 4.08(2H, q, J=6.9 Hz), 4.02(3H, s), 3.92(3H, s), 3.86(3H, s), 1.38(3H, t, J=6.9 Hz), 1.26(3H, t, J=6.9 Hz)

EXAMPLE 13 (E)-1,3-Diethyl-8-(2,3,4-trimethoxystyryl)xanthine (Compound 70)

Substantially the same procedure as in Example 7 was repeated using 2.5 g (12.6 mmol) of 5,6-diamino-1,3-diethyluracil and 2.3 g (13.9 mmol) of 2,3,4-trimethoxycinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 2.85 g (yield 57% of Compound 70 as white crystals.

Melting Point: 276.3°-277.0° C.

Elemental Analysis: C₂₀ H₂₄ N₄ O₅ Calcd. (%): C, 59.99; H, 6.04; N, 13.99 Found (%): C, 60.26; H, 6.24; N, 14.28

IR (KBr) ν_(max) (cm⁻¹): 1696, 1655, 1500

NMR (270 MHz; CDCl₃) δ (ppm): 12.39(1H, brs), 7.88(1H, d, J=16.3 Hz), 7.30(1H, d, J=8.4 Hz ), 7.09(1H, d, J=16.3 Hz), 6.73(1H, d, J=8.4 Hz), 4.26(2H, q, J=6.9 Hz), 4.20(2H, q, J=6.9 Hz), 3.96(3H, s), 3.92 (3H, s), 3.91(3H, s), 1.41(3H, t, J=6.9 Hz), 1.29 (3H, t, J=6.9 Hz)

EXAMPLE 14 (E)-1,3-Diethyl-7-methyl-8-(2,3,4-trimethoxystyryl)xanthine (Compound 71)

Substantially the same procedure as in Example 8 was repeated using 1.5 g (3.75 mmol) of Compound 70 obtained in Example 13 in place of Compound 64. Then, the resultant crude crystals were recrystallized from hexane/ethyl acetate to give 1.32 g (yield 85%) of Compound 71 as colorless needles.

Melting Point: 152.9°-154.3° C.

Elemental Analysis: C₂₁ H₂₆ N₄ O₅ Calcd. (%): C, 60.86; H, 6.32; N, 13.52 Found (%): C, 61.04; H, 6.44; N, 13.79

IR (KBr) ν_(max) (cm⁻¹): 1695, 1655, 1498, 1289

NMR (270 MHz; CDCl₃) δ (ppm): 7.88(1H, d, J=15.8 Hz), 7.28(1H, d, J=8.9 Hz), 7.01(1H, d, J=15.8 Hz), 6.72 (1H, d, J=8.9 Hz), 4.22(2H, q, J=6.9 Hz), 4.09(2H, q, J=6.9 Hz), 4.04(3H, s), 3.97(3H, s), 3.91(3H, s), 3.90(3H, s), 1.38(3H, t, J=6.9 Hz), 1.27(3H, t, J=6.9 Hz)

EXAMPLE 15 (E)-1,3-Diethyl-8-(4-methoxy-2,3-dimethylstyryl)xanthine (Compound 72)

Substantially the same procedure as in Example 7 was repeated using 2.5 g (12.6 mmol) of 5,6-diamino-1,3-diethyluracil and 2.9 g (13.9 mmol) of 4-methoxy-2,3-dimethylcinnamic acid. Then, the resultant crude crystals were recrystallized from ethanol/water to give 0.80 g (yield of Compound 72 as white crystals.

Melting Point: >280.0° C.

Elemental Analysis: C₂₀ H₂₄ N₄ O₃ Calcd. (%): C, 65.20; H, 6.56; N, 15.21 Found (%): C, 65.24; H, 6.61; N, 15.29

IR (KBr) ν_(max) (cm⁻¹): 1697, 1642, 1496, 1270

NMR (270 MHz; DMSO-d₆) δ (ppm): 13.52(1H, brs), 7.93 (1H, d, J=15.8 Hz ), 7.56(1H, d, J=8.2 Hz), 6.89(1H, d, J=8.2 Hz), 6.82 (1H, d, J=15.8 Hz), 4.06(2H, q, J=6.9 Hz), 3.94 (2H, q, J=6.9 Hz), 3.81(3H, s), 2.33 (3H, s), 2.13(3H, s), 1.26(3H, t, J=6.9 Hz), 1.14 (3H, t, J=6.9 Hz)

EXAMPLE 16 (E)-1,3-Diethyl-8-(4-methoxy-2,3-dimethylstyryl)-7-methylxanthine (Compound 73)

Substantially the same procedure as in Example 8 was repeated using 500 mg (1.36 mmol) of Compound 72 obtained in Example 15 in place of Compound 64. Then, the resultant crude crystals were recrystallized from hexane/ethyl acetate to give 493 mg (yield 95%) of Compound 73 as pale yellow needles.

Melting Point: 207.7°-208.3° C.

Elemental Analysis: C₂₁ H₂₆ N₄ O₃ Calcd. (%): C, 65.95; H, 6.85; N, 14.65 Found (%): C, 66.24; H, 6.99; N, 14.69

IR (KBr) ν_(max) (cm⁻¹): 1698, 1651, 1267

NMR (270 MHz; CDCl₃) δ (ppm): 8.08(1H, d, J=15.2 Hz), 7.46(1H, d, J=8.9 Hz), 6.77(1H, d, J=8.9 Hz), 6.67 (1H, d, J=15.2 Hz), 4.22(2H, q, J=6.9 Hz), 4.09(2H, q, J=6.9 Hz), 4.03(3H, s), 3.86(3H, s), 2.40(3H, s), 2.21(3H, s), 1.39(3H, t, J=6.9 Hz), 1.26(3H, t, J=6.9 Hz)

EXAMPLE 17 (E)-1,3-Diethyl-8-(4-methoxy-2,5-dimethylstyryl)xanthine (Compound 74)

Substantially the same procedure as in Example 7 was repeated using 2.5 g (12.6 mmol) of 5,6-diamino-1,3-diethyluracil and 2.9 g (13.9 mmol) of 4-methoxy-2,5-dimethylcinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 2.43 g (yield 52% ) of Compound 74 as white crystals.

Melting Point: >280.0° C.

Elemental Analysis: C₂₀ H₂₄ N₄ O₃ Calcd. (%): C, 65.20; H, 6.56; N, 15.21 Found (%): C, 64.83; H, 6.56; N, 15.43

IR (KBr) ν_(max) (cm⁻¹): 1690, 1646, 1510, 1265

NMR (270 MHz; DMSO-d₆) δ (ppm): 13.52(1H, brs), 7.82 (1H, d, J=16.3 Hz), 7.54(1H, s), 6.86(1H, d, J=16.3 Hz), 6.82(1H, s), 4.06(2H, q, J=6.9 Hz), 3.94 (2H, q, J=6.9 Hz), 3.81(3H, s), 2.41(3H, s), 2.14 (3H, s), 1.25(3H, t, J=6.9 Hz), 1.14(3H, t, J=6.9 Hz )

EXAMPLE 18 (E)-1,3-Diethyl-8-(4-methoxy-2,5-dimethylstyryl)-7-methylxanthine (Compound 75)

Substantially the same procedure as in Example 8 was repeated using 1.10 g (2.98 mmol) of Compound 74 obtained in Example 17 in place of Compound 64. Then, the resultant crude crystals were recrystallized from ethyl acetate to give 0.76 g (yield 67%) of Compound 75 as yellow needles.

Melting Point: 235.4°-236.1° C.

Elemental Analysis: C₂₁ H₂₆ N₄ O₃ Calcd. (%): C, 65.95; H, 6.85; N, 14.65 Found (%): C, 65.56; H, 6.93; N, 14.64

IR (KBr) ν_(max) (cm⁻¹): 1689, 1657, 1510, 1263

NMR (270 MHz; CDCl₃) δ (ppm): 7.97 (1H, d, J=15.5 Hz), 7.42(1H, s), 6.71(1H, d, J=15.5 Hz), 6.66(1H, s), 4.22(2H, q, J=6.9 Hz), 4.09(2H, q, J=6.9 Hz), 4.05 (3H, s), 3.86(3H, s), 2.48(3H, s), 2.23(3H, s), 1.38(3H, t, J=6.9 Hz), 1.26(3H, t, J=6.9 Hz)

EXAMPLE 19 (E)-8-(2,4-Dimethoxy-3-methylstyryl)-1,3-diethylxanthine (Compound 76)

Substantially the same procedure as in Example 7 was repeated using 2.0 g (10.1 mmol) of 5,6-diamino-1,3-diethyluracil and 2.04 g (9.19 mmol) of 2,4-dimethoxy-3-methylcinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 1.22 g (yield 32%) of Compound 76 as a yellow powder.

Melting Point: >275.0° C.

Elemental Analysis: C₂₀ H₂₄ N₄ O₄ Calcd. (%): C, 62.48; H, 6.29; N, 14.57 Found (%): C, 62.28; H, 6.42; N, 14.22

IR (KBr) ν_(max) (cm⁻¹): 1696, 1635, 1592, 1499

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.75(1H, d, J=16.5 Hz), 7.58(1H, d, J=8.8 Hz), 6.99(1H, d, J=16.5 Hz), 6.85 (1H, d, J=8.8 Hz), 4.04(2H, q, J=6.9 Hz), 3.95(2H, q, J=6.9 Hz), 3.83(3H, s), 3.70(3H, s), 2.09(3H, s), 1.26(3H, t, J=6.9 Hz), 1.14(3H, t, J=6.9 Hz)

EXAMPLE 20 (E)-8-(2,4-Dimethoxy-3-methylstyryl)-1,3-diethyl-7-methylxanthine (Compound 77)

Substantially the same procedure as in Example 8 was repeated using 700 mg (1.82 mmol) of Compound 76 obtained in Example 19 in place of Compound 64. Then, the resultant crude crystals were recrystallized from cyclohexane/toluene to give 610 mg (yield 84%) of Compound 77 as pale yellow needles.

Melting Point: 196.1°-196.8° C.

Elemental Analysis: C₂₁ H₂₆ N₄ O₄ Calcd. (%): C, 63.30; H, 6.57; N, 14.06 Found (%): C, 63.32; H, 6.74; N, 14.13

IR (KBr) ν_(max) (cm⁻¹): 1695, 1649, 1498

NMR (270 MHz; CDCl₃) δ (ppm): 7.81(1H, d, J=15.8 Hz), 7.78(1H, d, J=8.6 Hz), 7.23(1H, d, J=15.8 Hz), 6.87 (1H, d, J=8.6 Hz), 4.07(2H, q, J=6.9 Hz), 4.01(3H, s), 3.92(2H, q, J=6.9 Hz), 3.85(3H, s), 3.70(3H, s), 2.10(3H, s), 1.27(3H, t, J=6.9 Hz), 1.13(3H, t, J=6.9 Hz)

EXAMPLE 21 (E)-1,3-Diethyl-8-(3,4-methylenedioxystyryl)xanthine (Compound 78)

Substantially the same procedure as in Example 7 was repeated using 2.0 g (10.1 mmol) of 5,6-diamino-1,3-diethyluracil and 2.33 g (12.1 mmol) of 3,4-methylenedioxycinnamic acid. Then, the resultant crude crystals were recrystallized from dimethylformamide/water to give 1.34 g (yield 38%) of Compound 78 as a yellowish green powder.

Melting Point: >275.0° C.

Elemental Analysis: C₁₈ H₁₈ N₄ O₄ Calcd. (%): C, 61.01; H, 5.11; N, 15.81 Found (%): C, 61.16; H, 5.03; N, 15.80

IR (KBr) ν_(max) (cm⁻¹): 1685, 1638, 1499

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.55(1H, d, J=16.3 Hz), 7.30(1H, s), 7.08(1H, d, J=8.9 Hz), 6.96(1H, d, J=8.9 Hz), 6.90(1H, d, J=16.3 Hz), 6.07(2H, s), 4.05 (2H, q, J=6.9 Hz), 3.93(2H, q, J=6.9 Hz), 1.25(3H, t, J=6.9 Hz), 1.10(3H, t, J=6.9 Hz)

EXAMPLE 22 (E)-1,3-Diethyl-7-methyl-8-(3,4-methylenedioxystyryl)xanthine (Compound 79)

Substantially the same procedure as in Example 8 was repeated using 1.35 g (3.81 mmol) of Compound 78 obtained in Example 21 in place of Compound 64. Then, the resultant crude crystals were recrystallized from cyclohexane/toluene to give 940 mg (yield 67%) of Compound 79 as yellow needles.

Melting Point: 219.4°-219.6° C.

Elemental Analysis: C₁₉ H₂₀ N₄ O₄ Calcd. (%): C, 61.94; H, 5.47; N, 15.20 Found (%): C, 62.09; H, 5.41; N, 15.16

IR (KBr) ν_(max) (cm⁻¹): 1687, 1657, 1569, 1498, 1443

NMR (270 MHz; CDCl₃) δ (ppm): 7.70(1H, d, J=15.5 Hz), 7.10(1H, d, J=1.6 Hz), 7.06(1H, dd, J=1.6, 8.0 Hz), 6.84(1H, d, J=8.0 Hz), 6.73(1H, d, J=15.5 Hz), 6.02 (2H, s), 4.21(2H, q, J=6.9 Hz), 4.09(2H, q, J=6.9 Hz), 4.04(3H, s), 1.38(3H, t, J=6.9 Hz), 1.26 (3H, t, J=6.9 Hz)

EXAMPLE 23 (E)-8-[2-(1,4-Benzodioxan-6-yl)vinyl]-1,3-diethylxanthine (Compound 80)

Substantially the same procedure as in Example 7 was repeated using 2.85 g (14.4 mmol) of 5,6-diamino-1,3-diethyluracil and 2.70. g (13.1 mmol) of 3-(1,4-benzodioxan-6-yl)acrylic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 2.45 g (yield 51%) of Compound 80 as a pale yellow powder.

Melting Point: >300° C.

Elemental Analysis: C₁₉ H₂₀ N₄ O₄ Calcd. (%): C, 61.94; H, 5.47; N, 15.20 Found (%): C, 61.97; H, 5.62; N, 15.07

IR (KBr) ν_(max) (cm⁻¹): 1682, 1637, 1511, 1310

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.51(1H, d, J=16.2 Hz), 7.10-7.03(2H, m), 6.89(1H, d, J=7.9 Hz), 6.87(1H, d, J=16.2 Hz), 4.27(4H, s), 4.05(2H, q, J=6.9 Hz), 3.93(2H, q, J=6.9 Hz), 1.22(3H, t, J=6.9 Hz), 1.13 (3H, t, J=6.9 Hz)

EXAMPLE 24 (E)-8-[2-(1,4-Benzodioxan-6-yl)vinyl]-1,3-diethyl-7-methylxanthine (Compound 81)

Substantially the same procedure as in Example 8 was repeated using 2.00 g (5.43 mmol) of Compound 80 obtained in Example 23 in place of Compound 64. Then, the resultant crude crystals were recrystallized from ethanol/isopropanol to give 1.58 g (yield 76%) of Compound 81 as yellow needles.

Melting Point: 233.1°-233.6° C.

Elemental Analysis: C₂₀ H₂₂ N₄ O₄ Calcd. (%): C, 62.81; H, 5.79; N, 14.65 Found (%): C, 62.55; H, 5.80; N, 14.60

IR (KBr) ν_(max) (cm⁻¹): 1689, 1654, 1509

NMR (270 MHz; CDCl₃) δ (ppm): 7.67(1H, d, J=15.8 Hz), 7.15-7.05(2H, m), 6.88(1H, d, J=8.3 Hz), 6.75(1H, d, J=15.8 Hz), 4.30(4H, s), 4.21(2H, q, J=6.9 Hz), 4.08(2H, q, J=6.9 Hz), 4.03(3H, s), 1.39(3H, t, J=6.9 Hz), 1.35(3H, t, J=6.9 Hz)

EXAMPLE 25 (E)-8-(2,3,4-Trimethoxystyryl)theophylline (Compound 82)

Substantially the same procedure as in Example 7 was repeated using 5.00 g (29.4 mmol) of 5,6-diamino-1,3-dimethyluracil and 7.71 g (32.4 mmol) of 2,3,4-trimethoxycinnamic acid. Then, the resultant crude crystals were recrystallized from isopropanol/water to give 3.78 g (yield 35%) of Compound 82 as an ocher powder.

Melting Point: 264.8°-266.1° C.

Elemental Analysis: C₁₈ H₂₀ N₄ O₅ Calcd. (%): C, 58.05; H, 5.41; N, 15.04 Found (%): C, 58.28; H, 5.38; N, 15.20

IR (KBr) ν_(max) (cm⁻¹): 1697, 1651, 1505, 1297

NMR (270 MHz; CDCl₃) δ (ppm): 12.78(1H, s), 7.91(1H, d, J=16.8 Hz), 7.28(1H, d, J=9.4 Hz), 7.13(1H, d, J=16.8 Hz), 6.73(1H, d, J=9.4 Hz), 3.95(3H, s), 3.92 (3H, s), 3.90(3H, s), 3.69(3H, s), 3.54(3H, s)

EXAMPLE 26 (E)-8-(2,3,4-Trimethoxystyryl)caffeine (Compound 83)

Substantially the same procedure as in Example 8 was repeated using 2.00 g (5.38 mmol) of Compound 82 obtained in Example 25 in place of Compound 64. Then, the resultant crude crystals were recrystallized from cyclohexane/toluene to give 1.68 g (yield 81%) of Compound 83 as a pale yellow powder.

Melting Point: 186.7°-187.9° C.

Elemental Analysis: C₁₉ H₂₂ N₄ O₅ Calcd. (%): C, 59.06; H, 5.74; N, 14.50 Found (%): C, 59.27; H, 5.72; N, 14.60

IR (KBr) ν_(max) (cm⁻¹): 1694, 1655, 1596, 1544, 1501, 1295

NMR (270 MHz; CDCl₃) δ (ppm): 7.90(1H, d, J=16.3 Hz), 7.28(1H, d, J=7.9 Hz), 7.01(1H, d, J=16.3 Hz), 6.72 (1H, d, J=7.9 Hz), 4.04(3H, s), 3.97(3H, s), 3.91 (3H, s), 3.90(3H, s), 3.64(3H, s), 3.42(3H, s)

EXAMPLE 27 (E)-8-(4-Methoxy-2,3-dimethylstyryl)theophylline (Compound 84)

Substantially the same procedure as in Example 7 was repeated using 1.74 g (10.2 mmol) of 5,6-diamino-1,3-dimethyluracil and 2.42 g (11.8 mmol) of 4-methoxy-2,3-dimethylcinnamic acid. Then, the resultant crude crystals were recrystallized from acetonitrile to give 750 mg (yield 22%) of Compound 84 as a white powder.

Melting Point: >275° C.

Elemental Analysis: C₁₈ H₂₀ N₄ O₃ Calcd. (%): C, 63.51; H, 5.92; N, 16.46 Found (%): C, 63.56; H, 5.82; N, 16.30

IR (KBr) ν_(max) (cm⁻¹): 1703, 1634, 1593

NMR (270 MHz; DMSO-d₆) δ (ppm): 13.45(1H, s), 7.93(1H, d, J=16.2 Hz), 7.53(1H, d, J=8.9 Hz), 6.88(1H, d, J=8.9 Hz), 6.79(1H, d, J=16.2 Hz), 3.80(3H, s), 3.75 (3H, s), 3.25(3H, s), 2.32(3H, s), 2.12(3H, s)

EXAMPLE 28 (E)-8-(4-Methoxy-2,3-dimethylstyryl)caffeine (Compound 85)

Substantially the same procedure as in Example 8 was repeated using 500 mg (1.47 mmol) of Compound 84 obtained in Example 27 in place of Compound 64. Then, the resultant crude crystals were recrystallized from toluene to give 280 mg (yield 54%) of Compound 85 as a pale yellow powder.

Melting Point: >275° C.

Elemental Analysis: C₁₉ H₂₂ N₄ O₃ Calcd. (%): C, 64.39; H, 6.25; N, 15.80 Found (%): C, 64.44; H, 6.27; N, 16.11

IR (KBr) ν_(max) (cm⁻¹): 1694, 1650, 1544, 1491, 1435

NMR (270 MHz; CDCl₃) δ (ppm): 7.96(1H, d, J=15.5 Hz), 7.73(1H, d, J=8.6 Hz), 7.07(1H, d, J=15.5 Hz), 6.90 (1H, d, J=8.6 Hz), 4.02(3H, s), 3.82(3H, s), 3.48 (3H, s), 3.29(3H, s), 2.32(3H, s), 2.13(3H, s)

EXAMPLE 29 (E)-8-(3,4-Methylenedioxystyryl)theophylline (Compound 86)

Substantially the same procedure as in Example 7 was repeated using 5.0 g (29.4 mmol) of 5,6-diamino-1,3-dimethyluracil and 6.78 g (35.3 mmol) of 3,4-methylenedioxycinnamic acid. Then, the resultant crude crystals were recrystallized from dimethylformamide/water to give 1.20 g (yield 13%) of Compound 86 as a pale yellow powder.

Melting Point: >275° C.

Elemental Analysis: C₁₆ H₁₄ N₄ O₄ Calcd. (%): C, 58.99; H, 4.32; N, 17.16 Found (%): C, 58.84; H, 4.30; N, 16.97

IR (KBr) ν_(max) (cm⁻¹): 1692, 1642, 1499

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.57(1H, d, J=16.1 Hz), 7.09(1H, s), 7.07(1H, d, J=7.9 Hz), 6.92(1H, d, J=7.9 Hz), 6.88(1H, d, J=16.1 Hz), 6.07(2H, s), 3.47 (3H, s), 3.30(3H, s)

EXAMPLE 30 (E)-8-(3,4-Methylenedioxystyryl)caffeine (Compound 87)

Substantially the same procedure as in Example 8 was repeated using 2.32 g (7.13 mmol) of Compound 86 obtained in Example 29 in place of Compound 64. Then, the resultant crude crystals were recrystallized from dioxane to give 1.54 g (yield 64%) of Compound 87 as yellow needles.

Melting Point: >300° C.

Elemental Analysis: C₁₇ H₁₆ N₄ O₄ Calcd. (%): C, 59.99; H, 4.73; N, 16.46 Found (%): C, 59.98; H, 4.66; N, 16.38

IR (KBr) ν_(max) (cm⁻¹): 1702, 1663, 1545, 1506

NMR (270 MHz; CDCl₃) δ (ppm): 7.72(1H, d, J=15.3 Hz), 7.10 (1H, d, J=1.5 Hz), 7.06(1H, dd, J=1.5, 7.9 Hz), 6.84(1H, d, J=7.9 Hz), 6.73(1H, d, J=15.3 Hz), 6.03 (2H, s), 4.05(3H, s), 3.63(3H, s), 3.42(3H, s)

EXAMPLE 31 (E)-8-(2,3-Dimethoxystyryl)theophylline (Compound 88)

Substantially the same procedure as in Example 7 was repeated using 2.50 g (14.7 mmol) of 5,6-diamino-1,3-dimethyluracil and 3.37 g (16.2 mmol) of 2,3-dimethoxycinnamic acid. Then, the resultant crude crystals were recrystallized from ethanol/water to give 1.03 g (yield 41%) of Compound 88 as pale yellow needles.

Melting Point: 289.2°-290.5° C.

Elemental Analysis: C₁₇ H₁₈ N₄ O₄ Calcd. (%): C, 59.64; H, 5.29; N, 16.36 Found (%): C, 59.42; H, 5.12; N, 16.65

IR (KBr) ν_(max) (cm⁻¹): 1700, 1649, 1499, 1476, 1273

NMR (270 MHz; DMSO-d₆) δ (ppm): 13.60(1H, brs), 7.84 (1H, d, J=16.8 Hz), 7.26(1H, d, J=6.9 Hz), 7.15-7.00 (3H, m), 3.83(3H, s), 3.79(3H, s), 3.48(3H, s), 3.26(3H, s)

EXAMPLE 32 (E)-8-(2,3-Dimethoxystyryl)caffeine (Compound 89)

Substantially the same procedure as in Example 8 was repeated using 1.10 g (3.22 mmol) of Compound 88 obtained in Example 31 in place of Compound 64. Then, the resultant crude crystals were recrystallized from toluene to give 570 mg (yield 50%) of Compound 89 as yellow needles.

Melting Point: 233.6°-236.7° C.

Elemental Analysis: C₁₈ H₂₀ N₄ O₄ Calcd. (%): C, 60.66; H, 5.65; N, 15.72 Found (%): C, 60.21; H, 5.74; N, 16.13

IR (KBr) ν_(max) (cm⁻¹): 1688, 1645, 1545, 1480

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.91(1H, d, J=16.0 Hz), 7.52(1H, dd, J=1.7, 7.6 Hz), 7.32(1H, d, J=16.0 Hz), 7.10-7.05(2H, m), 4.03(3H, s), 3.84(3H, s), 3.79 (3H, s), 3.48(3H, s), 3.24(3H, s)

EXAMPLE 33 (E)-8-(2,4-Dimethoxystyryl)theophylline (Compound 90)

Substantially the same procedure as in Example 7 was repeated using 1.0 g (5.88 mmol) of 5,6-diamino-1,3-dimethyluracil and 1.35 g (6.48 mmol) of 2,4-dimethoxycinnamic acid. Then, the resultant crude crystals were recrystallized from dimethylformamide to give 221 mg (yield 11%) of Compound 90 as pale yellow grains.

Melting Point: >280° C.

Elemental Analysis: C₁₇ H₁₈ N₄ O₄ Calcd. (%): C, 59.64; H, 5.29; N, 16.36 Found (%): C, 59.51; H, 5.34; N, 16.58

IR (KBr) ν_(max) (cm⁻¹): 1705, 1650, 1607, 1505

NMR (270 MHz; DMSO-d₆) δ (ppm): 13.40(1H, brs), 7.78 (1H, d, J=16.5 Hz), 7.53(1H, d, J=8.3 Hz), 6.93(1H, d, J=16.5 Hz), 6.63(1H, d, J=2.3 Hz), 6.60(1H, dd, J=2.3, 8.3 Hz), 3.89(3H, s), 3.82(3H, s), 3.47(3H, s), 3.25(3H, s)

EXAMPLE 34 (E)-8-(2,4-Dimethoxystyryl)caffeine (Compound 91)

Substantially the same procedure as in Example 8 was repeated using 700 mg (2.05 mmol) of Compound 90 obtained in Example 33 in place of Compound 64. Then, the resultant crude crystals were recrystallized from dioxane to give 621 mg (yield 85%) of Compound 91 as yellow needles.

Melting Point: 241.5°-242.1° C.

Elemental Analysis: C₁₈ H₂₀ N₄ O₄ Calcd. (%): C, 60.66; H, 5.65; N, 15.72 Found (%): C, 60.49; H, 5.61; N, 15.69

IR (KBr) ν_(max) (cm⁻¹): 1685, 1650, 1602, 1434

NMR (270 MHz; CDCl₃) δ (ppm): 7.95(1H, d, J=15.8 Hz), 7.48(1H, d, J=8.6 Hz), 6.98(1H, d, J=15.8 Hz), 6.54 (1H, dd, J=2.3, 8.6 Hz), 6.49(1H, d, J=2.3 Hz), 4.03 (3H, s), 3.92(3H, s), 3.86(3H, s), 3.64(3H, s), 3.42(3H, s)

EXAMPLE 35 (E)-8-(4-Methoxy-2,5-dimethylstyryl)theophylline (Compound 92)

Substantially the same procedure as in Example 7 was repeated using 1.0 g (5.88 mmol) of 5,6-diamino-1,3-dimethyluracil and 1.33 g (6.45 mmol) of 4-methoxy-2,5-dimethylcinnamic acid. Then, the resultant crude crystals were recrystallized from dimethylformamide to give 393 mg (yield 20%) of Compound 92 as pale yellow grains.

Melting Point: >280° C.

Elemental Analysis: C₁₈ H₂₀ N₄ O₃ Calcd. (%): C, 63.51; H, 5.92; N, 16.46 Found (%): C, 63.59; H, 6.10; N, 16.23

IR (KBr) ν_(max) (cm⁻¹): 1703, 1648, 1509, 1260

NMR (270 MHz; DMSO-d₆) δ (ppm): 13.48(1H, brs), 7.81 (1H, d, J=16.2 Hz), 7.50(1H, s), 6.82(1H, d, J=16.2 Hz), 6.81(1H, s), 3.81(3H, s), 3.46(3H, s), 3.25(3H, s), 2.40(3H, s), 2.14(3H, s)

EXAMPLE 36 (E)-8-(4-Methoxy-2,5-dimethylstyryl)caffeine (Compound 93)

Substantially the same procedure as in Example 8 was repeated using 300 mg (0.88 mmol) of Compound 92 obtained in Example 35 in place of Compound 64. Then, the resultant crude crystals were recrystallized from dioxane to give 211 mg (yield 68%) of Compound 93 as yellow needles.

Melting Point: >280° C. MS-EI m/e: 354(M⁺), 339(M⁺ -CH₃)

IR (KBr) ν_(max) (cm⁻¹): 1692, 1653, 1508

NMR (270 MHz; CDCl₃) δ (ppm): 8.00(1H, d, J=15.3 Hz), 7.42(1H, s), 6.72(1H, d, J=15.3 Hz), 6.66(1H, s), 4.06(3H, s), 3.86(3H, s), 3.64(3H, s), 3.42(3H, s), 2.49(3H, s), 2.23(3H, s)

EXAMPLE 37 (E)-8-(2,4-Dimethoxy-3-methylstyryl)theophylline (Compound 94)

Substantially the same procedure as in Example 7 was repeated using 1.0 g (5.88 mmol) of 5,6-diamino-1,3-dimethyluracil and 1.44 g (6.45 mmol) of 2,4-dimethoxy-3-methylcinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane to give 581 mg (yield 28%) of Compound 94 as pale yellow needles.

Melting Point: >280° C.

Elemental Analysis: C₁₈ H₂₀ N₄ O₄ Calcd. (%): C, 60.67; H, 5.65; N, 15.72 Found (%): C, 60.34; H, 5.77; N, 15.64

IR (KBr) ν_(max) (cm⁻¹): 1695, 1653, 1499, 1270

NMR (270 MHz; DMSO-d₆) δ (ppm): 13.52(1H, brs), 7.75 (1H, d, J=16.2 Hz), 7.55(1H, d, J=8.3 Hz), 6.96(1H, d, J=16.2 Hz), 6.84(1H, d, J=8.3 Hz), 3.83(3H, s), 3.70(3H, s), 3.47(3H, s), 3.25(3H, s), 2.09(3H, s)

EXAMPLE 38 (E)-8-(2,4-Dimethoxy-3-methylstyryl)caffeine (Compound 95)

Substantially the same procedure as in Example 8 was repeated using 300 mg (0.84 mmol) of Compound 94 obtained in Example 37 in place of Compound 64. Then, the resultant crude crystals were recrystallized from methylene chloride/diethyl ether to give 239 mg (yield 77%) of Compound 95 as white needles.

Melting Point: 252.7°-253.5° C.

Elemental Analysis: C₁₉ H₂₂ N₄ O₄ Calcd. (%): C, 61.61; H, 5.98; N, 15.13 Found (%): C, 61.40; H, 6.06; N, 15.17

IR (KBr) ν_(max) (cm⁻¹): 1692, 1651, 1505

NMR (270 MHz; CDCl₃) δ (ppm): 7.92(1H, d, J=15.8 Hz), 7.42(1H, d, J=8.9 Hz), 6.99(1H, d, J=15.8 Hz), 6.70 (1H, d, J=8.9 Hz), 4.04(3H, s), 3.88(3H, s), 3.78 (3H, s), 3.64(3H, s), 3.42(3H, s), 2.19(3H, s)

EXAMPLE 39 (E)-8-(2,5-Dimethylstyryl)-1,3-diethylxanthine (Compound 96)

Substantially the same procedure as in Example 7 was repeated using 3.00 g (15.1 mmol) of 5,6-diamino-1,3-diethyluracil and 3.20 g (18.2 mmol) of 2,5-dimethylcinnamic acid. Then, the resultant crude crystals were recrystallized from ethanol/toluene to give 2.56 g (yield of Compound 96 as white needles.

Melting Point: 281.8°-282.5° C.

Elemental Analysis: C₁₉ H₂₂ N₄ O₂.0.5H₂ O Calcd. (%): C, 66.46; H, 6.97; N, 15.50 Found (%): C, 66.77; H, 6.82; N, 15.72

IR (KBr) ν_(max) (cm⁻¹): 1706, 1639, 1503

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.84(1H, d, J=16.3 Hz), 7.53(1H, s), 7.13(1H, d, J=7.4 Hz), 7.06(1H, d, J=7.4 Hz), 7.00(1H, d, J=16.3 Hz), 4.06(2H, q, J=7.1 Hz), 3.94(2H, q, J=7.1 Hz), 2.37(3H, s), 2.30 (3H, s), 1.26(3H, t, J=7.1 Hz), 1.14(3H, t, J=7.1 Hz)

EXAMPLE 40 (E)-8-(2,5-Dimethylstyryl)-1,3-diethyl-7-methylxanthine (Compound 97)

Substantially the same procedure as in Example 8 was repeated using 2.00 g (5.92 mmol) of Compound 96 obtained in Example 39 in place of Compound 64. Then, the resultant crude crystals were recrystallized from toluene/cyclohexane to give 1.29 g (yield 62%) of Compound 97 as white needles.

Melting Point: 190.3°-190.7° C.

Elemental Analysis: C₂₀ H₂₄ N₄ O₂ Calcd. (%): C, 68.16; H, 6.86; N, 15.89 Found (%): C, 68.15; H, 7.02; N, 15.65

IR (KBr) ν_(max) (cm⁻¹): 1698, 1657

NMR (270 MHz; CDCl₃) δ (ppm): 7.86(1H, d, J=15.8 Hz), 7.71(1H, s), 7.23(1H, d, J=15.8 Hz), 7.15(1H, d, J=7.9 Hz), 7.09(1H, d, J=7.9 Hz), 4.11-4.04(2H, m), 4.04(3H, s), 3.92(2H, q, J=6.9 Hz), 2.37(3H, s), 2.32(3H, s), 1.26(3H, t, J=6.9 Hz), 1.13(3H, t, J=6.9 Hz)

EXAMPLE 41 (E)-8-(4-Ethoxystyryl)-1,3-diethylxanthine (Compound 98)

Substantially the same procedure as in Example 7 was repeated using 3.00 g (15.1 mmol) of 5,6-diamino-1,3-diethyluracil and 3.20 g (16.7 mmol) of 4-ethoxycinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane to give 2.97 g (yield 55%) of Compound 98 as pale yellow needles.

Melting Point: 296.7°-298.6° C.

Elemental Analysis: C₁₉ H₂₂ N₄ O₃ Calcd. (%): C, 64.39; H, 6.25; N, 15.81 Found (%): C, 64.54; H, 6.52; N, 15.80

IR (KBr) ν_(max) (cm⁻¹): 1695, 1647, 1516, 1250

NMR (270 MHz; DMSO-d₆) δ (ppm): 13.36(1H, brs), 7.59 (1H, d, J=16.2 Hz), 7.55(2H, d, J=8.6 Hz), 6.96(2H, d, J=8.6 Hz), 6.88(1H, d, J=16.2 Hz), 4.11-4.04(4H, m), 3.94 (2H, q, J=6.9 Hz), 1.34(3H, t, J=6.9 Hz), 1.26(3H, t, J=6.9 Hz), 1.14(3H, t, J=6.9 Hz)

EXAMPLE 42 (E)-8-(4-Ethoxystyryl)-1,3-diethyl-7-methylxanthine (Compound 99)

Substantially the same procedure as in Example 8 was repeated using 1.60 g (4.52 mmol) of Compound 98 obtained in Example 41 in place of Compound 64. Then, the resultant crude crystals were recrystallized from ethyl acetate to give 1.47 g (yield 88%) of Compound 99 as pale green needles.

Melting Point: 185.3°-185.7° C.

Elemental Analysis: C₂₀ H₂₄ N₄ O₃ Calcd. (%): C, 65.20; H, 6.56; N, 15.21 Found (%): C, 65.28; H, 6.85; N, 15.18

IR (KBr) ν_(max) (cm⁻¹): 1693, 1666, 1515, 1248

NMR (270 MHz; CDCl₃) δ (ppm): 7.74(1H, d, J=15.8 Hz), 7.52(2H, d, J=8.6 Hz), 6.92(2H, d, J=8.6 Hz), 6.77 (1H, d, J=15.8 Hz), 4.21(2H, q, J=6.9 Hz), 4.12-4.01 (4H, m), 4.04(3H, s), 1.44(3H, t, J=6.9 Hz), 1.38 (3H, t, J=7.6 Hz), 1.26(3H, t, J=6.9 Hz)

EXAMPLE 43 (E)-1,3-Diethyl-8-(4-propoxystyryl)xanthine (Compound 100)

Substantially the same procedure as in Example 7 was repeated using 3.00 g (15.1 mmol) of 5,6-diamino-1,3-diethyluracil and 3.43 g (16.6 mmol) of 4-propoxycinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 3.02 g (yield 54%) of Compound 100 as pale yellow needles.

Melting Point: >270° C.

Elemental Analysis: C₂₀ H₂₄ N₄ O₃ Calcd. (%): C, 65.20; H, 6.56; N, 15.21 Found (%): C, 64.91; H, 6.79; N, 15.14

IR (KBr) ν_(max) (cm⁻¹): 1695, 1656, 1515, 1250

NMR (270 MHz; DMSO-d₆) δ (ppm): 13.38(1H, brs), 7.59 (1H, d, J=16.5 Hz), 7.55(2H, d, J=8.6 Hz), 6.97(2H, d, J=8.6 Hz), 6.87(1H, d, J=16.5 Hz), 4.07(2H, q, J=7.3 Hz), 4.00-3.90(4H, m), 1.81-1.67(2H, m), 1.26 (3H, t, J=6.9 Hz), 1.14(3H, t, J=6.9 Hz), 0.98(3H, t, J=7.3 Hz)

EXAMPLE 44 (E)-1,3-Diethyl-7-methyl-8-(4-propoxystyryl)xanthine (Compound 101)

Substantially the same procedure as in Example 8 was repeated using 1.70 g (4.61 mmol) of Compound 100 obtained in Example 43 in place of Compound 64. Then, the resultant crude crystals were recrystallized from hexane/ethyl acetate to give 1.37 g (yield 78%) of Compound as pale yellow needles.

Melting Point: 155.7°-156.5° C.

Elemental Analysis: C₂₁ H₂₆ N₄ O₃ Calcd. (%): C, 65.92; H, 6.85; N, 14.65 Found (%): C, 65.72; H, 7.05; N, 14.59

IR (KBr) ν_(max) (cm⁻¹): 1696, 1665, 1513, 1246

NMR (270 MHz; CDCl₃) δ (ppm): 7.74(1H, d, J=15.8 Hz), 7.52(2H, d, J=8.6 Hz), 6.92(2H, d, J=8.6 Hz), 6.77 (1H, d, J=15.8 Hz), 4.21(2H, q, J=6.9 Hz), 4.09(2H, q, J=6.9 Hz), 4.04(3H, s), 3.97(2H, t, J=6.6 Hz), 1.90-1.77(2H, m), 1.38(3H, t, J=6.9 Hz), 1.26(3H, t, J=6.9 Hz), 1.05(3H, t, J=7.3 Hz)

EXAMPLE 45 (E)-1,3-Diethyl-8-(3-methoxystyryl)xanthine (Compound 102)

Substantially the same procedure as in Example 7 was repeated using 2.50 g (12.6 mmol) of 5,6-diamino-1,3-diethyluracil and 2.48 g (13.9 mmol) of 3-methoxycinnamic acid. Then, the resultant crude crystals were recrystallized from dimethylformamide/water to give 2.10 g (yield 49%) of Compound 102 as a white powder.

Melting Point: 270.6°-272.5° C.

Elemental Analysis: C₁₈ H₂₀ N₄ O₃ Calcd. (%): C, 63.52; H, 5.92; N, 16.46 Found (%): C, 63.20; H, 6.01; N, 16.34

IR (KBr) ν_(max) (cm⁻¹): 1686, 1634, 1500

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.61(1H, d, J=16.4 Hz), 7.34(1H, t, J=7.9 Hz), 7.20-7.18(2H, m), 7.07(1H, d, J=16.4 Hz), 6.92(1H, d, J=8.6 Hz), 4.06(2H, q, J=7.0 Hz), 3.94(2H, q, J=6.8 Hz), 1.26(3H, t, J=7.0 Hz), 1.14(3H, t, J=6.8 Hz)

EXAMPLE 46 (E)-1,3-Diethyl-8-(3-methoxystyryl)-7-methylxanthine (Compound 103)

Substantially the same procedure as in Example 8 was repeated using 1.70 g (5.00 mmol) of Compound 102 obtained in Example 45 in place of Compound 64. Then, the resultant crude crystals were recrystallized from toluene/cyclohexane to give 1.10 g (yield 62%) of Compound 103 as pale yellow needles.

Melting Point: 153.4°-154.8° C.

Elemental Analysis: C₁₉ H₂₂ N₄ O₃ Calcd. (%): C, 64.39; H, 6.26; N, 15.81 Found (%): C, 64.34; H, 6.38; N, 15.82

IR (KBr) ν_(max) (cm⁻¹): 1692, 1656, 1541

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.64(1H, d, J=15.8 Hz), 7.40-7.30(4H, m), 6.97-6.92(1H, m), 4.31-4.05(2H, m), 4.05(3H, s), 3.92(2H, q, J=7.0 Hz), 1.26(3H, t, J=7.1 Hz), 1.13(3H, t, J=7.0 Hz)

EXAMPLE 47 (E)-8-(4-Butoxystyryl)-1,3-diethylxanthine (Compound 104)

Substantially the same procedure as in Example 7 was repeated using 3.00 g (15.1 mmol) of 5,6-diamino-1,3-diethyluracil and 3.67 g (16.7 mmol) of 4-butoxycinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 3.04 g (yield 53%) of Compound 104 as pale yellow needles.

Melting Point: 257.9°-261.3° C.

Elemental Analysis: C₂₁ H₂₆ N₄ O₃ Calcd. (%): C, 65.95; H, 6.85; N, 14.65 Found (%): C, 65.90; H, 7.21; N, 14.60

IR (KBr) ν_(max) (cm⁻¹): 1695, 1645, 1515, 1248

NMR (270 MHz; DMSO-d₆) δ (ppm): 13.32(1H, brs), 7.59 (1H, d, J=16.5 Hz), 7.55(2H, d, J=8.9 Hz), 6.97(2H, d, J=8.9 Hz), 6.87(1H, d, J=16.5 Hz), 4.10-3.90(6H, m), 1.76-1.66(2H, m), 1.51-1.40(2H, m), 1.26(3H, t, J=6.9 Hz), 1.14(3H, t, J=6.9 Hz), 0.94(3H, t, J=7.3 Hz)

EXAMPLE 48 (E)-8-(4-Butoxystyryl)-1,3-diethyl-7-methylxanthine (Compound 105)

Substantially the same procedure as in Example 8 was repeated using 1.50 g (3.92 mmol) of Compound 104 obtained in Example 47 in place of Compound 64. Then, the resultant crude crystals were recrystallized from hexane/ethyl acetate to give 982 mg (yield 63%) of Compound 105 as pale yellow needles.

Melting Point: 123.4°-123.6° C.

Elemental Analysis: C₂₂ H₂₈ N₄ O₃ Calcd. (%): C, 66.65; H, 7.11; N, 14.13 Found (%): C, 66.81; H, 7.31; N, 14.01

IR (KBr) ν_(max) (cm⁻¹): 1693, 1665, 1513, 1251

NMR (270 MHz; CDCl₃) δ (ppm): 7.74(1H, d, J=15.8 Hz), 7.52(2H, d, J=8.9 Hz), 6.92(2H, d, J=8.9 Hz), 6.76 (1H, d, J=15.8 Hz), 4.21(2H, q, J=6.9 Hz), 4.09(2H, q, J=6.9 Hz), 4.04(3H, s), 4.02(2H, q, J=6.6 Hz), 1.84-1.74(2H, m), 1.58-1.44(2H, m), 1.38(3H, t, J=6.9 Hz), 1.26(3H, t, J=6.9 Hz), 0.99(3H, t, J=7.3 Hz)

EXAMPLE 49 (E)-1,3-Diethyl-8-(4-methylstyryl)xanthine (Compound 106)

Substantially the same procedure as in Example 7 was repeated using 3.00 g (15.1 mmol) of 5,6-diamino-1,3-diethyluracil and 2.70 g (16.7 mmol) of 4-methylcinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane to give 2.64 g (yield 54%) of Compound 106 as pale yellow needles.

Melting Point: >280° C.

Elemental Analysis: C₁₈ H₂₀ N₄ O₂ Calcd. (%): C, 66.65; H, 6.21; N, 17.27 Found (%): C, 66.53; H, 6.27; N, 17.14

IR (KBr) ν_(max) (cm⁻¹): 1692, 1644, 1518, 1490

NMR (270 MHz; DMSO-d₆) δ (ppm): 13.53(1H, brs), 7.62 (1H, d, J=16.5 Hz), 7.52(2H, d, J=7.9 Hz), 7.24(2H, d, J=7.9 Hz), 6.98(1H, d, J=16.5 Hz), 4.07(2H, q, J=6.9 Hz), 3.94(2H, q, J=6.9 Hz), 2.33(3H, s), 1.26 (3H, t, J=6.9 Hz), 1.14(3H, t, J=6.9 Hz)

EXAMPLE 50 (E)-1,3-Diethyl-7-methyl-8-(4-methylstyryl)xanthine (Compound 107)

Substantially the same procedure as in Example 8 was repeated using 1.50 g (4.62 mmol) of Compound 106 obtained in Example 49 in place of Compound 64. Then, the resultant crude crystals were recrystallized from dioxane/water to give 1.39 g (yield 89%) of Compound 107 as yellow needles.

Melting Point: 170.8°-171.5° C.

Elemental Analysis: C₁₉ H₂₂ N₄ O₂ Calcd. (%): C, 67.44; H, 6.55; N, 16.56 Found (%): C, 67.58; H, 6.65; N, 16.68

IR (KBr) ν_(max) (cm⁻¹): 1687, 1650, 1542, 1516

NMR (270 MHz; CDCl₃) δ (ppm): 7.77(1H, d, J=15.8 Hz), 7.48(2H, d, J=8.3 Hz), 7.21(2H, d, J=8.3 Hz), 6.87 (1H, d, J=15.8 Hz), 4.22(2H, q, J=6.9 Hz), 4.09(2H, q, J=6.9 Hz), 4.05(3H, s), 2.39(3H, s), 1.38(3H, t, J=6.9 Hz), 1.26(3H, t, J=6.9 Hz)

EXAMPLE 51 (E)-1,3-Diethyl-8-(2-methoxystyryl)xanthine (Compound 108)

Substantially the same procedure as in Example 7 was repeated using 2.5 g (12.6 mmol) of 5,6-diamino-1,3-diethyluracil and 2.48 g (13.9 mmol) of 2-methoxycinnamic acid. Then, the resultant crude crystals were recrystallized from tetrahydrofuran/water to give 990 mg (yield 24%) of Compound 108 as yellow grains.

Melting Point: >270° C.

Elemental Analysis: C₁₈ H₂₀ N₄ O₃ Calcd. (%): C, 63.52; H, 5.92; N, 16.46 Found (%): C, 63.28; H, 5.86; N, 16.43

IR (KBr) ν_(max) (cm⁻¹) 1694, 1640, 1501

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.85(1H, d, J=16.8 Hz), 7.62(1H, d, J=7.6 Hz), 7.34(1H, t, J=7.6 Hz), 7.11-6.98(3H, m), 4.07(2H, q, J=7.0 Hz), 3.97-3.89(2H, m), 3.89(3H, s), 1.26(3H, t, J=7.0 Hz), 1.14(3H, t, J=6.9 Hz)

EXAMPLE 52 (E)-1,3-Diethyl-8-(2-methoxystyryl)-7-methylxanthine (Compound 109)

Substantially the same procedure as in Example 8 was repeated using 1.5 g (4.41 mmol) of Compound 108 obtained in Example 51 in place of Compound 64. Then, the resultant crude crystals were recrystallized from ethanol/water to give 800 mg (yield 51%) of Compound 109 as yellow needles.

Melting Point: 189.6°-190.0° C.

Elemental Analysis: C₁₉ H₂₂ N₄ O₃ Calcd. (%): C, 64.39; H, 6.26; N, 15.81 Found (%): C, 64.18; H, 6 . 25; N, 15.77

IR (KBr) ν_(max) (cm⁻¹): 1697, 1649

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.94(1H, d, J=15.8 Hz), 7.88(1H, dd, J=7.9, 1.5 Hz), 7.41-7.34(1H, m), 7.31 (1H, d, J=15.8 Hz), 7.10(1H, d, J=7.9 Hz), 7.02(1H, t, J=7.4 Hz), 4.11-4.02(2H, m), 4.02(3H, s), 3.96-3.90(2H, m), 3.90(3H, s), 1.29(3H, t, J=7.2 Hz), 1.13(3H, t, J=7.2 Hz)

EXAMPLE 53 (E)-1,3-Diethyl-8-(4-methoxy-3-methylstyryl)xanthine (Compound 110)

Substantially the same procedure as in Example 7 was repeated using 2.50 g (12.6 mmol) of 5,6-diamino-1,3-diethyluracil and 3.00 g (13.9 mmol) of 4-methoxy-3-methylcinnamic acid. Then, the resultant crude crystals were recrystallized from dimethylsulfoxide/water to give 1.70 g (yield 36%) of Compound 110 as white flocculent precipitates.

Melting Point: >270° C.

Elemental Analysis: C₁₉ H₂₂ N₄ O₃ Calcd. (%): C, 64.39; H, 6.23; N, 15.81 Found (%): C, 64.05; H, 6.34; N, 15.74

IR (KBr) ν_(max) (cm⁻¹): 1689, 1644, 1510, 1459

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.56(1H, d, J=16.3 Hz), 7.45(1H, s), 7.44(1H, d, J=8.2 Hz), 6.98(1H, d, J=8.2 Hz), 6.87(1H, d, J=16.3 Hz), 4.06(2H, q, J=7.1 Hz), 3.93(2H, q, J=7.0 Hz), 3.82(3H, s), 2.18 (3H, s), 1.25(3H, t, J=7.1 Hz), 1.13(3H, t, J=7.0 Hz)

EXAMPLE 54 (E)-1,3-Diethyl-8-(4-methoxy-3-methylstyryl)-7-methylxanthine (Compound 111)

Substantially the same procedure as in Example 8 was repeated using 1.27 g (3.36 mmol) of Compound 110 obtained in Example 53 in place of Compound 64. Then, the resultant crude crystals were recrystallized from toluene/cyclohexane to give 1.01 g (yield 82%) of Compound 111 as yellow needles.

Melting Point: 176.5°-177.6° C.

Elemental Analysis: C₂₀ H₂₄ N₄ O₃ Calcd. (%): C, 65.20; H, 6.57; N, 15.21 Found (%): C, 65.22; H, 6.75; N, 15.22

IR (KBr) ν_(max) (cm⁻¹): 1687, 1648, 1542 1505, 1434

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.65(1H, s), 7.58(1H, d, J=15.8 Hz), 7.57-7.53(1H, m), 7.16(1H, d, J=15.8 Hz), 6.97(1H, d, J=8.9 Hz), 4.10-4.01(2H, m), 4.01(3H, s), 3.91(2H, q, J=6.9 Hz), 3.88(3H, s), 2.19(3H, s), 1.25(3H, t, J=6.9 Hz), 1.12(3H, t, J=6.9 Hz)

EXAMPLE 55 (E)-8-(2-Bromo-4,5-methylenedioxystyryl)-1,3-diethylxanthine (Compound 158)

Substantially the same procedure as in Example 7 was repeated using 2.50 g (12.6 mmol) of 5,6-diamino-1,3-diethyluracil and 3.77 g (13.9 mmol) of 2-bromo-4,5-methylenedioxycinnamic acid. Then, the resultant crude crystals were recrystallized from dimethylsulfoxide/water to give 2.01 g (yield 38%) of Compound 158 as a yellow powder.

Melting Point: >270° C.

Elemental Analysis: C₁₈ H₁₇ BrN₄ O₄.0.25H₂ O Calcd. (%): C, 49.39; H, 4.03; N, 12.80 Found (%): C, 49.42; H, 3.75; N, 12.67

IR (KBr) ν_(max) (cm⁻¹): 1691, 1651, 1497

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.78(1H, d, J=8.2 Hz), 7.48(1H, s), 7.30(1H, s), 6.97(1H, d, J=8.2 Hz), 6.13(2H, s), 4.05(2H, q, J=6.9 Hz), 3.93(2H, q, J=6.9 Hz), 1.24(3H, t, J=6.9 Hz), 1.13(3H, t, J=6.9 Hz)

EXAMPLE 56 (E)-8-(2-Bromo-4,5-methylenedioxystyryl)-1,3-diethyl-7-methylxanthine (Compound 159)

Substantially the same procedure as in Example 8 was repeated using 2.20 g (5.08 mmol) of Compound 158 obtained in Example 55 in place of Compound 64. Then, the resultant crude crystals were recrystallized from toluene/cyclohexane to give 1.17 g (yield 52%) of Compound 159 as a pale yellow powder.

Melting Point: 255.1°-256.0° C.

Elemental Analysis: C₁₉ H₁₉ BrN₄ O₄ Calcd. (%): C, 51.02; H, 4.28; N, 12.53 Found (%): C, 50.94; H, 4.15; N, 12.39

IR (KBr) ν_(max) (cm⁻¹): 1693, 1651

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.87(1H, d, J=15.8 Hz), 7.77(1H, s), 7.30(1H, d, J=15.8 Hz), 7.32(1H, s), 6.15(2H, s), 4.10-4.03(2H, m), 4.03(3H, s), 3.92 (2H, q, J=6.8 Hz), 1.26(3H, t, J=7.2 Hz), 1.13(3H, t, J=6.8 Hz)

EXAMPLE 57 (E)-1,3-Diethyl-8-(3-methoxy-4,5-methylenedioxystyryl)xanthine (Compound 169)

Substantially the same procedure as in Example 7 was repeated using 2.50 g (12.6 mmol) of 5,6-diamino-1,3-diethyluracil and 3.31 g (14.9 mmol) of 3-methoxy-4,5-methylenedioxycinnamic acid. Then, the resultant crude crystals were recrystallized from tetrahydrofuran/water to give 600 mg (yield 53%) of Compound 169 as a white powder.

Melting Point: >270° C.

Elemental Analysis: C₁₉ H₂₀ N₄ O₅ Calcd. (%): C, 59.37; H, 5.24; N, 14.58 Found (%): C, 59.41; H, 5.26; N, 14.66

IR (KBr) ν_(max) (cm⁻¹): 1689, 1654, 1640, 1506

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.54(1H, d, J=16.6 Hz), 6.94(2H, s), 6.93(1H, d, J=16.6 Hz), 6.04(2H, s), 4.05(2H, q, J=6.9 Hz), 3.97-3.88(2H, m), 3.88(3H, s), 1.25(3H, t, J=7.2 Hz), 1.13(3H, t, J=7.2 Hz)

EXAMPLE 58 (E)-1,3-Diethyl-8-(3-methoxy-4,5-methylenedioxystyryl)-7-methylxanthine (Compound 170)

Substantially the same procedure as in Example 8 was repeated using 2.00 g (5.20 mmol) of Compound 169 obtained in Example 57 in place of Compound 64. Then, the resultant crude crystals were recrystallized from 2-propanol to give 730 mg (yield 35%) of Compound 170 as a yellow powder.

Melting Point: 201.5°-202.3° C.

Elemental Analysis: C₂₀ H₂₂ N₄ O₅ Calcd. (%): C, 60.29; H, 5.57; N, 14.06 Found (%): C, 60.18; H, 5.72; N, 13.98

IR (KBr) ν_(max) (cm⁻¹): 1694, 1650, 1543, 1512, 1433

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.58(1H, d, J=15.8 Hz), 7.23(1H, d, J=15.8 Hz), 7.20(1H, d, J=1.0 Hz), 7.09 (1H, d, J=1.0 Hz), 6.05(2H, s), 4.09-4.02(2H, m), 4.02(3H, s), 3.94-3.89(2H, m), 3.89(3H, s), 1.25 (3H, t, J=7.2 Hz), 1.13(3H, t, J=6.9 Hz)

EXAMPLE 59 Tablets

Tablets having the following composition were prepared in a conventional manner.

Compound 1 (40 g) was mixed with 286.8 g of lactose and 60 g of potato starch, followed by addition of 120 g of a 10% aqueous solution of hydroxypropylcellulose. The resultant mixture was kneaded, granulated, and then dried by a conventional method. The granules were refined, thus obtaining granules used to make tablets. After mixing the granules with 1.2 g of magnesium stearate, the mixture was formed into tablets each containing 20 mg of the active ingredient by using a tablet maker (Model RT-15, Kikusui) having pestles of 8 mm diameter. The composition of each tablet thus prepared is shown below.

    ______________________________________                                         Composition of One Tablet                                                      ______________________________________                                         Compound 191       20         mg                                               Lactose            143.4      mg                                               Potato Starch      30         mg                                               Hydroxypropylcellulose                                                                            6          mg                                               Magnesium Stearate 0.6        mg                                                                  200        mg                                               ______________________________________                                    

EXAMPLE 60 Fine Granules

Fine granules having the following composition were prepared in a conventional manner.

Compound 2 (20 g) was mixed with 655 g of lactose and 285 g of corn starch, followed by addition of 400 g of a 10% aqueous solution of hydroxypropylcellulose. The resultant mixture was kneaded, granulated, and then dried by a conventional method, thus obtaining fine granules containing 20 g of the active ingredient in 1,000 g. The composition of one pack of the fine granules is shown below.

    ______________________________________                                         Composition of One Pack of Fine Granules                                       ______________________________________                                         Compound 83        20         mg                                               Lactose            655        mg                                               Corn Starch        285        mg                                               Hydroxypropylcellulose                                                                            40         mg                                                                  1,000      mg                                               ______________________________________                                    

EXAMPLE 61 Capsules

Capsules having the following composition were prepared in a conventional manner.

Compound 1 (200 g) was mixed with 995 g of Avicel and 5 g of magnesium stearate. The mixture was put in hard capsules No. 4 each having a capacity of 120 mg by using a capsule filler (Model LZ-64, Zanashi), thus obtaining capsules each containing 20 mg of the active ingredient. The composition of one capsule thus prepared is shown below.

    ______________________________________                                         Composition of One Capsule                                                     ______________________________________                                         Compound 1             20     mg                                               Avicel                 99.5   mg                                               Magnesium Stearate     0.5    mg                                                                      120    mg                                               ______________________________________                                    

EXAMPLE 62 Injections

Injections having the following composition were prepared in a conventional manner.

Compound 2 (1 g) was dissolved in 100 g of purified soybean oil, followed by addition of 12 g of purified egg yolk lecithin and 25 g of glycerine for injection. The resultant mixture was made up to 1,000 ml with distilled water for injection, thoroughly mixed, and emulsified by a conventional method. The resultant dispersion was subjected to aseptic filtration by using 0.2 μm disposable membrane filters, and then aseptically put into glass vials in 2 ml portions, thus obtaining injections containing 2 mg of the active ingredient per vial. The composition of one injection vial is shown below.

    ______________________________________                                         Composition of One Injection Vial                                              ______________________________________                                         Compound 2          2          mg                                              Purified Soybean Oil                                                                               200        mg                                              Purified Egg Yolk Lecithin                                                                         24         mg                                              Glycerine for Injection                                                                            50         mg                                              Distilled Water for Injection                                                                      1.72       ml                                                                  2.00       ml                                              ______________________________________                                    

EXAMPLE 63 Tablets

Tablets having the following composition were prepared in a conventional manner.

    ______________________________________                                         Composition of One Tablet                                                      ______________________________________                                         Compound 65        20         mg                                               Lactose            143.4      mg                                               Potato Starch      30         mg                                               Hydroxypropylcellulose                                                                            6          mg                                               Magnesium Stearate 0.6        mg                                                                  200        mg                                               ______________________________________                                    

EXAMPLE 64 Fine Granules

Fine granules having the following composition were prepared in a conventional manner.

    ______________________________________                                         Composition of One Pack of Fine Granules                                       ______________________________________                                         Compound 170       20         mg                                               Lactose            655        mg                                               Corn Starch        285        mg                                               Hydroxypropylcellulose                                                                            40         mg                                                                  1,000      mg                                               ______________________________________                                    

EXAMPLE 65 Capsules

Capsules having the following composition were prepared in a conventional manner.

    ______________________________________                                         Composition of One Capsule                                                     ______________________________________                                         Compound 71            20     mg                                               Avicel                 99.5   mg                                               Magnesium Stearate     0.5    mg                                                                      120    mg                                               ______________________________________                                    

EXAMPLE 66 Injections

Injections having the following composition were prepared in a conventional manner.

    ______________________________________                                         Composition of One Injection Vial                                              ______________________________________                                         Compound 73             2      mg                                              Purified Soybean Oil    200    mg                                              Purified Egg Yolk Lecithin                                                                             24     mg                                              Glycerine for Injection 50     mg                                              Distilled Water for Injection                                                                          1.72   ml                                                                      2.00   ml                                              ______________________________________                                    

EXAMPLE 67 Syrup Preparations

Syrup Preparations having the following composition were prepared in a conventional manner.

    ______________________________________                                         Composition of One Syrup Preparation                                           ______________________________________                                         Compound 77             20     mg                                              Refined Sugar           30     mg                                              Ethyl p-Hydroxybenzoate 40     mg                                              Propyl p-Hydroxybenzoate                                                                               10     mg                                              Strawberry Flavor       0.1    ml                                              Water                   99.8   ml                                                                      100    ml                                              ______________________________________                                    

Reference Example 1 (E)-8-(3,4-Dimethoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 1)

3,4-Dimethoxycinnamic acid (2.03 g, 9.74 mmol) and 3-(3-diethylaminopropyl)-1-ethylcarbodiimide hydrochloride (2.54 g, 13.3 mmol) were added to a mixture of water (60 ml) and dioxane (30 ml) containing 5,6-diamino-1,3-dipropyluracil (U.S. Pat. No. 2,602,795) (2.00 g, 8.85 mmol). The resultant solution was stirred at room temperature for 2 hours at pH 5.5. After neutralization, the reaction solution was extracted three times with 50 ml of chloroform. The combined extract was washed with a saturated aqueous solution of sodium chloride and dried over anhydrous sodium sulfate, followed by evaporation under reduced pressure. The residue was purified by silica gel column chromatography (eluent: 2% methanol/chloroform) to give 3.47 g (yield 94%) of (E)-6-amino-5-(3,4-dimethoxycinnamoyl)amino-1,3-dipropyluracil (Compound A) as an amorphous substance.

NMR (CDCl₃ ; 90 MHz) δ (ppm): 7.84(1H, brs), 7.50(1H, d, J=15.9 Hz), 7.10-6.65(3H, m), 6.53(1H, d, J=15.9 Hz), 5.75(2H, brs), 4.00-3.50(4H, m), 3.85(6H, brs), 2.00-1.40(4H, m), 1.10-0.80(6H, m)

To 3.38 g (8.13 mmol) of Compound A were added 40 ml of dioxane and 80 ml of an aqueous 1N sodium hydroxide solution, followed by heating under reflux for 10 minutes. After cooling, the solution was neutralized, and deposited crystals were collected by filtration. Then, the collected crystals were recrystallized from dimethylsulfoxide/water to give 2.49 g (yield 77%) of (E)-8-(3,4-dimethoxystyryl)-1,3-dipropylxanthine (Compound B) as white crystals.

Melting Point: 260.0°-263.8° C.

Elemental Analysis: C₁₂ H₂₆ N₄ O₄ Calcd. (%): C, 63.30; H, 6.57; N, 14.06 Found (%): C, 63.29; H, 6.79; N, 14.21

IR (KBr) ν_(max) (cm⁻¹): 1701, 1640

NMR (DMSO-d₆ ; 270 MHz) δ (ppm): 13.39(1H, brs), 7.59 (1H, d, J=16.7 Hz), 7.26(1H, d, J=1.8 Hz), 7.13(1H, dd, J=1.8, 8.6 Hz), 6.98(1H, d, J=8.6 Hz), 6.95(1H, d, J=16.7 Hz), 3.99(2H, t), 4.00-3.85(2H, t), 3.83(3H, s), 3.80(3H, s), 1.80-1.55(4H, m), 1.00-0.85(6H, m)

Compound B (1.20 g, 3.02 mmol) was dissolved in 20 ml of dimethylformamide. To the solution were added 1.04 g (7.55 mmol) of potassium carbonate and subsequently 0.38 ml (6.04 mmol) of methyl iodide, and the resultant mixture was stirred at 50° C. for 30 minutes. After cooling, insoluble matters were filtered off, and 400 ml of water was added to the flit rate. The mixture was extracted three times with 100 ml of chloroform. The extract was washed twice with water and once with a saturated aqueous solution of sodium chloride, and dried over anhydrous sodium sulfate, followed by evaporation under reduced pressure. The residue was purified by silica gel column chromatography (eluent: 1% methanol/chloroform), followed by recrystallization from propanol/water to give 1.22 g (yield 98%) of Compound 1 as white needles.

Melting Point: 164.1°-166.3° C.

Elemental Analysis: C₂₂ H₂₈ N₄ O₄ Calcd. (%): C, 64.06; H, 6.84; N, 13.58 Found (%): C, 64.06; H, 6.82; N, 13.80

IR (KBr) ν_(max) (cm⁻¹): 1692, 1657

NMR (DMSO-d₆ ; 270 MHz) δ (ppm): 7.60(1H, d, J=15.8 Hz), 7.40(1H, d, 2.0 Hz), 7.28(1H, dd, J=2.0, 8.4 Hz), 7.18(1H, d, J=15.8 Hz), 6.99(1H, d, J=8.4 Hz), 4.02(3H, s), 3.99(2H, t), 3.90-3.80(2H, m), 3.85(3H, s), 3.80(3H, s), 1.80-1.55(4H, m), 1.00-0.85(6H, m)

Reference Example 2 (E)-7-Methyl-1,3-dipropyl-8-styrylxanthine (Compound 3)

5,6-Diamino-1,3-dipropyluracil (U.S. Pat. No. 2,602,795) (6.0 g, 26.5 mmol) was slowly added to a mixture of methanol (360 ml) and acetic acid (15 ml) containing cinnamaldehyde (3.34 ml, 26.5 mmol) under ice cooling. The resultant mixture was stirred at room temperature for 30 minutes, followed by evaporation under reduced pressure to give 6.30 g (yield 70%) of (E)-6-amino-5-(3-phenyl-3-propenylidene)-1,3-dipropyluracil (Compound C) as an amorphous substance.

Melting Point: 159.5°-161.0° C.

IR (KBr) ν_(max) (cm⁻¹): 1687, 1593

NMR (CDCl₃ ; 90 MHz) δ (ppm): 9.75-9.60(1H, m), 7.60-7.25(5H, m), 7.00-6.80(2H, m), 5.70(brs, 2H), 4.00-3.70(4H, m), 2.00-1.40(4H, m), 1.10-0.75(6H, m)

MS m/e (relative intensity): 340(100, M⁺), 130(86)

To 6.30 g (18.5 mmol) of Compound C was added 240 ml of ethanol, and the mixture was heated under reflux for 2 hours in the presence of 4.32 g (26.5 mmol) of ferric chloride. After cooling, deposited crystals were collected by filtration to give 3.61 g (yield 61%) of (E)-1,3-dipropyl-8-styrylxanthine (Compound D) as white crystals.

Melting Point: 259.3°-261.0° C. (recrystallized from ethanol)

Elemental Analysis: C₁₉ H₂₂ N₄ O₂ Calcd. (%): C, 67.43; H, 6.55; N, 16.56 Found (%): C, 67.40; H, 6.61; N, 16.71

IR (KBr) ν_(max) (cm⁻¹): 1700, 1650, 1505

NMR (DMSO-d₆) δ (ppm): 13.59(1H, brs), 7.70-7.55 (3H, m), 7.50-7.30(3H, m), 7.06(1H, d, J=16.5 Hz), 3.99(2H, t), 3.86(2H, t), 2.80-2.50(4H, m), 0.95-0.80(6H, m)

Subsequently, the same procedure as in Reference Example 1 was repeated using Compound D in place of Compound B to give 1.75 g (yield 84%) of Compound 3 as white needles.

Melting Point: 162.8°-163.2° C.

Elemental Analysis: C₂₀ H₂₄ N₄ O₂ Calcd. (%): C, 68.16; H, 6.86; N, 15.90 Found (%): C, 67.94; H, 6.96; N, 16.15

IR (KBr) ν_(max) (cm⁻¹): 1690, 1654, 1542, 1450, 1437

NMR (CDCl₃) δ (ppm): 7.79(1H, d, J=15.8 Hz), 7.65-7.55(2H, m), 7.48-7.35(3H, m), 6.92(1H, d, J=15.8 Hz), 4.11(2H, t), 4.06(3H, s), 3.98(2H, t), 2.00-1.60(4H, m), 1.08-0.95(6H, m)

Reference Example 3 (E)-1,3-Dipropyl-8-(3,4,5-trimethoxystyryl)xanthine (Compound 9)

3,4,5-Trimethoxycinnamic acid (5.78 g, 24.3 mmol) and 6.36 g (33.2 mmol) of 3-(3-diethylaminopropyl)-1-ethylcarbodiimide hydrochloride were added to a mixture of dioxane (150 ml) and water (75 ml) containing 5.00 g (22.1 mmol) of 5,6-diamino-1,3-dipropyluracil. The resultant solution was stirred at room temperature at pH 5.5 for one hour. After the reaction, the solution was adjusted to pH 7 and extracted three times with chloroform. The combined extract was washed with a saturated aqueous solution of sodium chloride and dried over anhydrous sodium sulfate, followed by evaporation under reduced pressure. The residue was purified by silica gel column chromatography (eluent: 3% methanol/chloroform) to give 8.06 g (yield 82%) of (E)-6-amino-1,3-dipropyl-5-(3,4,5-trimethoxycinnamoyl)aminouracil (Compound E) as an amorphous substance.

NMR (CDCl₃ ; 90 MHz) δ (ppm): 7.85(1H, brs), 7.48(1H, d, J=15.6 Hz), 6.67(2H, s), 6.56(1H, d, J=15.6 Hz), 5.80(2H, brs), 4.00-3.70(4H, m), 3.89(9H, s), 1.80-1.45(4H, m), 1.15-0.80(6H, m)

To 10.02 g (22.5 mmol) of Compound E were added 100 ml of dioxane and 100 ml of an aqueous 2N sodium hydroxide solution, and the solution was heated under reflux for 10 minutes. After cooling, the solution was neutralized, and deposited crystals were collected by filtration. Then, the collected crystals were recrystallized from dioxane/water to give 6.83 g (yield 91%) of (E)-1,3-dipropyl-8-(3,4,5-trimethoxystyryl)xanthine (Compound 9) as white crystals.

Melting Point: 161.8°-162.6° C.

Elemental Analysis: C₂₂ H₂₈ N₄ O₅ Calcd. (%): C, 61.66; H, 6.58; N, 13.07 Found (%): C, 61.73; H, 6.37; N, 13.08

IR (KBr) ν_(max) (cm⁻¹): 1702, 1643

NMR (CDCl₃ ; 90 MHz) δ (ppm): 12.87(1H, brs), 7.72(1H, d, J=16.3 Hz), 6.96(1H, d, J=16.3 Hz), 6.81(2H, s), 4.30-3.95(4H, m), 3.92(6H, s), 3.90(3H, s), 2.10-1.50(4H, m), 1.02(2H, t), 0.90(2H, t)

Reference Example 4 (E)-7-Methyl-1,3-dipropyl-8-(3,4,5-trimethoxystyryl)xanthine (Compound 5)

The same procedure as in Reference Example 1 was repeated using Compound 9 in place of Compound B to give 1.75 g (yield 84%) of Compound 5 as white needles.

Melting Point: 168.4°-169.1° C. (recrystallized from ethanol/water)

Elemental Analysis: C₂₃ H₃₀ N₄ O₅ Calcd. (%): C, 62.42; H, 6.83; N, 12.66 Found (%): C, 62.48; H, 6.60; N, 12.70

IR (KBr) ν_(max) (cm⁻¹): 1698, 1659

NMR (CDCl₃ ; 90 MHz) δ (ppm): 7.71(1H, d, J=15.8 Hz), 6.86(2H, s), 6.78(1H, d, J=15.8 Hz), 4.30-3.95(4H, m), 4.07(3H, s), 3.93(6H, s), 3.90(3H, s), 2.05-1.50(4H, m), 1.20-0.85(6H, m)

Reference Example 5 (E)-8-(4-Methoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 6)

Substantially the same procedure as in Reference Example 1 was repeated using 2.00 g (8.85 mmol) of 5,6-diamino-1,3-dipropyluracil and 1.73 g (9.74 mmol) of 4-methoxycinnamic acid to give 2.29 g (overall yield 68%) of Compound 6.

Melting Point: 159.8°-161.3° C. (recrystallized from ethanol/water)

Elemental Analysis: C₂₁ H₂₆ N₄ O₃ Calcd. (%): C, 65.94; H, 6.85; N, 14.64 Found (%): C, 65.92; H, 6.90; N, 14.88

IR (KBr) ν_(max) (cm⁻¹): 1695, 1658

NMR (DMSO-d₆) δ (ppm): 7.72(2H, d, J=8.8 Hz), 7.61(1H, d, J=15.8 Hz), 7.16(1H, d, J=15.8 Hz), 4.05-3.95(2H, m), 4.00(3H, s), 3.83(2H, t), 3.80(3H, s), 1.85-1.50(4H, m), 1.00-0.85(6H, m)

Reference Example 6 (E)-1,3-Diallyl-8-(3,4,5-trimethoxystyryl)xanthine (Compound 11)

Substantially the same procedure as in Reference Example 3 was repeated using 3.0 g (13.5 mmol) of 1,3-diallyl-5,6-diaminouracil and 3.55 g (14.9 mmol) of 3,4,5-trimethoxycinnamic acid to give 4.48 g (yield 75%) of (E)-1,3-diallyl-6-amino-5-(3,4,5-trimethoxycinnamoyl)aminouracil (Compound F) as an amorphous substance.

NMR (CDCl₃ ; 90 MHz) δ (ppm): 7.90(1H, brs), 7.56(1H, d, J=16.0 Hz), 6.71(2H, s), 6.57(1H, d, J=16.0 Hz), 6.15-5.60(4H, m), 5.50-5.05(4H, m), 4.75-4.45(4H, m), 3.90(9H, s)

Substantially the same procedure as in Reference Example 3 was repeated using 4.34 g (9.82 mmol) of Compound F in place of Compound E to give 2.81 g (yield 68%) of Compound 11 as a pale yellowish green powder.

Melting Point: 253.1°-255.4° C. (recrystallized from dioxane)

Elemental Analysis: C₂₂ H₂₄ N₄ O₅.1/2H₂ O Calcd. (%): C, 60.96; H, 5.81; N, 12.93 Found (%): C, 61.05; H, 5.60; N, 12.91

IR (KBr) ν_(max) (cm⁻¹): 1704, 1645, 1583, 1510

NMR (CDCl₃) δ (ppm): 12.94(1H, brs), 7.73(1H, d, J=16.3 Hz), 7.05(1H, d, J=16.3 Hz), 6.81(2H, s), 6.12-5.92(2H, m), 5.37-5.22(4H, m), 4.83-4.76(4H, m), 3.91(6H, s), 3.90(3H, s)

Reference Example 7 (E)-1,3-Diallyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthine (Compound 7)

Substantially the same procedure as in Reference Example 1 was repeated using 1.13 g (2.67 mmol) of Compound 11 in place of Compound B to give 620 mg (yield 53%) of Compound 7 as pale yellow needles.

Melting Point: 189.0°-191.1° C. (recrystallized from ethyl acetate)

Elemental Analysis: C₂₃ H₂₆ N₄ O₅ Calcd. (%): C, 63.00; H, 5.97; N, 12.77 Found (%): C, 63.00; H, 6.05; N, 12.85

IR (KBr) ν_(max) (cm⁻¹): 1699, 1660

NMR (CDCl₃ ; 90 MHz) δ (ppm): 7.78(1H, d, J=16.0 Hz), 6.85(2H, s), 6.84(1H, d, J=16.0 Hz), 6.30-5.75(2H, m), 5.45-5.10(4H, m), 4.85-4.55(4H, m), 4.07(3H, s), 3.92(6H, s), 3.90(3H, s)

Reference Example 8 (E)-1,3-Dibutyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthine (Compound 8)

Substantially the same procedure as in Reference Example 1 was repeated using 4.75 g (18.7 mmol) of 5,6-diamino-1,3-dibutyluracil and 4.90 g (20.6 mmol) of 3,4,5-trimethoxycinnamic acid to give 5.49 g (overall yield 63%) of Compound 8 as a pale green powder.

Melting Point: 136.8°-137.3° C. (recrystallized from ethanol/water)

Elemental Analysis: C₂₅ H₃₄ N₄ O₅ Calcd. (%): C, 63.81; H, 7.28; N, 11.91 Found (%): C, 63.63; H, 6.93; N, 11.99

IR (KBr) ν_(max) (cm⁻¹): 1692, 1659

NMR (CDCl₃ ; 90 MHz) δ (ppm): 7.68(1H, d, J=15.8 Hz), 6.80(2H, s), 6.79(1H, d, J=15.8 Hz), 4.30-3.90(4H, m), 4.03(3H, s), 3.95(6H, s), 3.91(3H, s), 1.90-1.10(8H, m), 1.05-0.80(6H, m)

Reference Example 9 (E)-8-(4-Methoxy-2,3-dimethylstyryl)-1,3-dipropylxanthine (Compound 12)

Substantially the same procedure as in Reference Example 1 was repeated using 2.31 g (10.24 mmol) of 5,6-diamino-1,3-dipropyluracil and 2.42 g (15.4 mmol) of 4-methoxy-2,3-dimethylcinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 1.96 g (yield 48%) of Compound 12 as a white powder.

Melting Point: 270.7°-271.3° C.

Elemental Analysis: C₂₂ H₂₈ N₄ O₃ Calcd. (%): C, 66.64; H, 7.11; N, 14.13 Found (%): C, 66.68; H, 7.20; N, 14.04

Ir (KBr) ν_(max) (cm⁻¹): 1704, 1650, 1591, 1269

NMR (DMSO-d₆ ; 270 MHz) δ (ppm): 7.93(1H, d, J=16.3 Hz), 7.57(1H, d, J=8.9 Hz), 6.88(1H, d, J=8.9 Hz), 6.82(1H, d, J=16.3 Hz), 3.98(2H, t, J=7.1 Hz), 3.86(2H, t, J=7.3 Hz), 3.81(3H, s), 2.32(3H, s), 2.09(3H, s), 1.80-1.55(4H, m), 0.95-0.80(6H, m)

Reference Example 10 (E)-8-(4-Methoxy-2,3-dimethylstyryl)-7-methyl-1,3-dipropylxanthine (Compound 13)

Substantially the same procedure as in Reference Example 1 was repeated using 4.00 g (5.10 mmol) of Compound 12 obtained in Reference Example 9 in place of Compound B to give 1.73 g (yield 83%) of Compound 13 as yellow needles.

Melting Point: 171.0°-173.5° C.

Elemental Analysis: C₂₃ H₃₀ N₄ O₃ Calcd. (%): C, 67.29; H, 7.36; N, 13.64 Found (%): C, 66.87; H, 7.67; N, 13.51

IR (KBr) ν_(max) (cm⁻¹): 1697, 1659, 1593, 1493

NMR (CDCl₃ ; 270 MHz) δ (ppm): 8.07(1H, d, J=15.3 Hz), 7.46(1H, d, J=8.4 Hz), 6.77(1H, d, J=8.4 Hz), 6.67(1H, d, J=15.3 Hz), 4.12(2H, t, J=7.3 Hz), 4.03(3H, s), 3.98(2H, t, J=7.3 Hz), 3.86(3H, s), 2.39(3H, s), 2.26(3H, s), 1.85-1.50(4H, m), 1.05-0.90(6H, m)

Reference Example 11 (E)-8-(2,4-Dimethoxy-3-methylstyryl)-1,3-dipropylxanthine (Compound 14)

Substantially the same procedure as in Reference Example 1 was repeated using 1.25 g (5.52 mmol) of 5,6-diamino-1,3-dipropyluracil and 1.35 g (6.08 mmol) of 2,4-dimethoxy-3-methylcinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 1.14 g (yield 50%) of Compound 14 as white needles.

Melting Point: 255.2°-256.0° C.

Elemental Analysis: C₂₂ H₂₈ N₄ O₄ Calcd. (%): C, 64.06; H, 6.84; N, 13.58 Found (%): C, 63.77; H, 7.01; N, 13.42

IR (KBr) ν_(max) (cm⁻¹): 1694, 1650, 1594, 1495

NMR (DMSO-d₆ ; 270 MHz) δ (ppm): 13.54(1H, brs), 7.76 (1H, d, J=16.5 Hz), 7.59(1H, d, J=8.9 Hz), 6.99(1H, d, J=16.5 Hz), 6.84(1H, d, J=8.9 Hz), 3.99(2H, t, J=7.4 Hz), 3.85(2H, t, J=7.3 Hz), 3.83(3H, s), 3.70 (3H, s), 2.09(3H, s), 1.80-1.55(4H, m), 0.95-0.80(6H, m)

Reference Example 12 (E)-8-(2,4-Dimethoxy-3-methylstyryl)-7-methyl-1,3-dipropylxanthine (Compound 15)

Substantially the same procedure as in Reference Example 1 was repeated using 1.10 g (2.67 mmol) of Compound 14 obtained in Reference Example 11 in place of Compound B. Then, the resultant crude crystals were recrystallized from ethanol/2-propanol to give 620 mg (yield 55%) of Compound 15 as pale yellow grains.

Melting Point: 191.4°-191.8° C.

Elemental Analysis: C₂₃ H₃₀ N₄ O₄ Calcd. (%): C, 64.76; H, 7.08; N, 13.13 Found (%): C, 64.84; H, 7.30; N, 12.89

IR (KBr) ν_(max) (cm⁻¹): 1695, 1654, 1274, 1107

NMR (CDCl₃ ; 270 MHz) δ (ppm): 7.91(1H, d, J=15.8 Hz), 7.42(1H, d, J=8.6 Hz), 6.98(1H, d, J=15.8 Hz), 6.69 (1H, d, J=8.6 Hz), 4.11(2H, t, J=7.4 Hz), 4.03 (3H, s), 4.03-3.95(2H, m), 3.87(3H, s), 3.77(3H, s), 2.19(3H, s), 1.85-1.55(4H, m), 1.03-0.94(6H, m)

Reference Example 13 (E)-1,3-Dipropyl-8-(2,3,4-trimethoxystyryl)xanthine (Compound 20)

Substantially the same procedure as in Reference Example 1 was repeated using 2.00 g (8.85 mmol) of 5,6-diamino-1,3-dipropyluracil and 2.32 g (.9.73 mmol) of 2,3,4-trimethoxycinnamic acid. Then, the resultant crude crystals were recrystallized from 2-propanol/water to give 1.84 g (yield 49%) of Compound 20 as pale yellow needles.

Melting Point: 246.5°-246.8° C.

Elemental Analysis: C₂₂ H₂₈ N₄ O₅ Calcd. (%): C, 61.66; H, 6.58; N, 13.07 Found (%): C, 61.50; H, 6.89; N, 13.06

IR (KBr) ν_(max) (cm⁻¹): 1703, 1651, 1504

NMR (CDCl₃ ; 270 MHz) δ (ppm): 12.72(1H, brs ), 7.92 (1H, d, J=16.5 Hz), 7.31(1H, d, J=8.7 Hz), 7.09(1H, d, J=16.5 Hz), 6.71(1H, d, J=8.7 Hz), 4.25-4.10(4H, m), 3.95(3H, s), 3.91(3H, s), 3.90(3H, s), 2.00-1.65(4H, m), 1.10-0.85(6H, m)

Reference Example 14 (E)-7-Methyl-1,3-dipropyl-8-(2,3,4-trimethoxystyryl)xanthine (Compound 21)

Substantially the same procedure as in Reference Example 1 was repeated using 2.50 g (5.84 mmol) of Compound 20 obtained in Reference Example 13 in place of Compound B. Then, the resultant crude crystals were recrystallized from ethanol to give 1.70 g (yield 66%) of Compound 21 as yellow needles.

Melting Point: 153.5°-153.8° C.

Elemental Analysis: C₂₃ H₃₀ N₄ O₅ Calcd. (%): C, 62.42; H, 6.83; N, 12.66 Found (%): C, 62.77; H, 7.25; N, 12.65

IR (KBr) ν_(max) (cm⁻¹): 1699, 1657, 1590, 1497, 1439

NMR (CDCl₃ ; 270 MHz) δ (ppm): 7.88(1H, d, J=15.8 Hz), 7.28(1H, d, J=8.9 Hz), 7.02(1H, d, J=15.8 Hz), 6.71 (1H, d, J=8.9 Hz), 4.25-3.95(4H, m), 4.03(3H, s), 3.97(3H, s), 3.91 (3H, s), 3.90(3H, s), 2.00-1.65 (4H, m), 1.10-0.85(6H, m)

Reference Example 15 (E)-1,3-Dipropyl-8-(2,4,5-trimethoxystyryl)xanthine (Compound 22)

Substantially the same procedure as in Reference Example 1 was repeated using 2.00 g (8.85 mmol) of 5,6-diamino-1,3-dipropyluracil and 2.32 g (9.73 mmol) of 2,4,5-trimethoxycinnamic acid. Then, the resultant crude crystals were recrystallized from 2-propanol/water to give 870 mg (yield 23%) of Compound 22 as a pale yellow powder.

Melting Point: 254.5°-255.7° C.

Elemental Analysis: C₂₂ H₂₈ N₄ O₅ Calcd. (%): C, 61.66; H, 6.58; N, 13.07 Found (%): C, 61.94; H, 6.97; N, 13.06

IR (KBr) ν_(max) (cm⁻¹): 1693, 1650, 1517

NMR (CDCl₃ ; 270 MHz) δ (ppm): 12.53(1H, brs), 7.97 (1H, d, J=16.5 Hz), 7.10(1H, s), 6.99(1H, d, J=16.5 Hz), 6.54(1H, s), 4.25-4.10(4H, m), 3.95(3H, s), 3.90(6H, s), 1.90-1.65(4H, m), 1.01(3H, t, J=7.6 Hz), 0.86(3H, t, J=7.6 Hz)

Reference Example 16 (E)-7-Methyl-1,3-dipropyl-8-(2,4,5-trimethoxystyryl)xanthine (Compound 23)

Substantially the same procedure as in Reference Example 1 was repeated using 0.5 g (1.17 mmol) of Compound 22 obtained in Reference Example 15 in place of Compound B. Then, the resultant crude crystals were recrystallized from toluene/hexane to give 200 mg (yield 39%) of Compound 23 as a pale yellow powder.

Melting Point: 195.5°-196.2° C.

Elemental Analysis: C₂₃ H₃₀ N₄ O₅ Calcd. (%): C, 62.42; H, 6.83; N, 12.66 Found (%): C, 62.14; H, 7.12; N, 12.56

Ir (KBr) ν_(max) (cm⁻¹): 1688, 1653, 1515, 1439, 1214

NMR (CDCl₃ ; 270 MHz) δ (ppm): 7.93(1H, d, J=15.8 Hz), 7.05(1H, s), 6.94(1H, d, J=15.8 Hz), 6.54(1H, s), 4.15-3.90(4H, m), 4.04(3H, s), 3.95(3H, s), 3.93 (3H, s), 3.91(3H, s), 1.90-1.65(4H, m), 1.03-0.94 (6H, m)

Reference Example 17 (E)-8-(2,4-Dimethoxystyryl)-1,3-dipropylxanthine (Compound 24)

Substantially the same procedure as in Reference Example 1 was repeated using 3.0 g (13.3 mmol) of 5,6-diamino-1,3-dipropyluracil and 3.04 g (14.60 mmol) of 2,4-dimethoxycinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 1.26 g (yield of Compound 24 as white crystals.

Melting Point: 273.1°-273.7° C.

Elemental Analysis: C₂₁ H₂₆ N₄ O₄ Calcd. (%): C, 63.30; H, 6.57; N, 14.06 Found (%): C, 62.94; H, 6.78; N, 14.03

IR (KBr) ν_(max) (cm⁻¹): 1693, 1645, 1506

NMR (DMSO-d₆ ; 270 MHz) δ (ppm): 13.39(1H, brs), 7.78 (1H, d, J=16.5 Hz), 7.54(1H, d, J=8.2 Hz), 6.95(1H, d, J=16.5 Hz), 6.63(1H, d, J=2.3 Hz), 6.00(1H, dd, J=8.2, 2.3 Hz), 4.01-3.85(4H, m), 3.89(3H, s), 3.82 (3H, s), 1.79-1.50(4H, m), 0.93-0.87(6H, m)

Reference Example 18 (E)-8-(2,4-Dimethoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 25)

Substantially the same procedure as in Reference Example 1 was repeated using 600 mg (1.51 mmol) of Compound 24 obtained in Reference Example 17 in place of Compound B. Then, the resultant crude crystals were recrystallized from hexane/ethyl acetate to give 556 mg (yield 90%) of Compound 25 as brown needles.

Melting Point: 167.6°-167.9° C.

Elemental Analysis: C₂₂ H₂₈ N₄ O₄ Calcd. (%): C, 64.06; H, 6.84; N, 13.58 Found (%): C, 63.98; H, 6.94; N, 13.61

IR (KBr) ν_(max) (cm⁻¹): 1691, 1653, 1603, 1437

NMR (CDCl₃ ; 270 MHz) δ (ppm): 7.92(1H, d, J=15.8 Hz), 7.48(1H, d, J=8.6 Hz), 6.98(1H, d, J=15.8 Hz), 6.54 (1H, dd, J=8.6, 2.3 Hz), 6.50(1H, d, J=2.3 Hz), 4.14-3.95(4H, m), 4.02(3H, s), 3.93(3H, s), 3.86 (3H, s), 1.91-1.65(4H, m), 1.03-0.94(6H, m)

Reference Example 19 (E)-8-(4-Benzyloxy-3,5-dimethoxystyryl)-1,3-dipropylxanthine (Compound 26)

A mixture of 5.0 g (22.3 mmol) of 4-hydroxy-3,5-dimethoxycinnamic acid, 8.0 ml (66.9 mmol) of benzyl bromide, and potassium carbonate was stirred in 50 ml of dimethylformamide at 70° C. for 2 hours. Insoluble matters were filtered off and the filtrate was poured into 500 ml of water. The mixture was extracted three times with 100 ml of chloroform. The extract was washed twice with water and twice with a saturated aqueous solution of sodium chloride, and dried over anhydrous sodium sulfate, followed by evaporation under reduced pressure. To the residue were added 50 ml of an aqueous 2N sodium hydroxide solution and 50 ml of ethanol, followed by heating under reflux for 15 minutes. After cooling, the solution was adjusted to pH 3 with a concentrated hydrochloric acid solution and extracted three times with 50 ml of chloroform. The extract was washed with a saturated aqueous solution of sodium chloride, and dried over anhydrous sodium sulfate, followed by evaporation under reduced pressure. The residue was recrystallized from hexane to give 5.4 g (yield 77%) of (E)-4-benzyloxy-3,5-dimethoxycinnamic acid (Compound G) as pale yellow needles.

Melting Point: 101.8°-102.3° C.

Elemental Analysis: C₁₈ H₁₈ O₅ Calcd. (%): C, 68.77; H, 5.77 Found (%): C, 68.95; H, 5.79

IR (KBr) ν_(max) (cm⁻¹): 2900(br), 1683, 1630, 1579, 1502, 1281, 1129

NMR (CDCl₃ ; 90 MHz) δ (ppm): 7.80(1H, d, J=16 Hz), 7.55-7.20(5H, m), 6.80(2H, s), 6.30(1H, d, J=16 Hz), 5.08(2H, s)

Substantially the same procedure as in Reference Example 1 was repeated using 3.30 g (14.5 mmol) of 5,6-diamino-1,3-dipropyluracil and 5.0 g (15.9 mmol) of Compound G. Then, the resultant crude crystals were recrystallized from ethanol/2-propanol to give 5.44 g (yield 74%) of Compound 26 as a white powder.

Melting Point: 221.1°-221.4° C.

Elemental Analysis: C₂₈ H₃₂ N₄ O₅ Calcd. (%): C, 66.65; H, 6.39; N, 11.10 Found (%): C, 66.65; H, 6.51; N, 11.01

IR (KBr) ν_(max) (cm⁻¹): 1704, 1637, 1582, 1505

NMR (CDCl₃ ; 90 MHz) δ (ppm): 7.69(1H, d, J=16 Hz), 7.55-7.20(5H, m), 6.96(1H, d, J=16 Hz), 6.80(2H, s), 5.08(2H, s), 4.25-3.95(4H, m), 3.88(6H, s), 2.10-1.65(4H, m), 1.20-0.80(6H, m)

Reference Example 20 (E)-8-(4-Benzyloxy-3,5-dimethoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 27)

Substantially the same procedure as in Reference Example 1 was repeated using 8.20 g (14.5 mmol) of Compound 26 obtained in Reference Example 19 in place of Compound B. Then, the resultant crude crystals were recrystallized from 2-propanol/water acetate to give 4.78 g (yield 64%) of Compound 27 as a white powder.

Melting Point: 164.7°-165.1° C.

Elemental Analysis: C₂₉ H₃₄ N₄ O₅ Calcd. (%): C, 67.16; H, 6.60; N, 10.80 Found (%): C, 67.01; H, 6.61; N, 10.70

IR (KBr) ν_(max) (cm⁻¹): 1695, 1659, 1580, 1542, 1505, 1455, 1335

NMR (CDCl₃ ; 90 MHz) δ (ppm): 7.70(1H, d, J=16 Hz), 7.55-7.20(5H, m), 6.78(2H, s), 6.72(1H, d, J=16 Hz), 5.07(2H, s), 4.25-3.95(4H, m), 4.07(3H, s), 3.89(6H, s), 2.10-1.65(4H, m), 1.20-0.85(6H, m)

Reference Example 21 (E)-8-(2,3-Dimethoxystyryl)-1,3-dipropylxanthine (Compound 28)

Substantially the same procedure as in Reference Example 1 was repeated using 2.0 g (8.85 mmol) of 5,6-diamino-1,3-dipropyluracil and 2.2 g (10.6 mmol) of 2,3-dimethoxycinnamic acid. Then, the resultant crude crystals were recrystallized from chloroform/cyclohexane to give 1.26 g (yield 36%) of Compound 28 as yellow crystals.

Melting Point: 236.0°-236.5° C.

Elemental Analysis: C₂₁ H₂₆ N₄ O₄ Calcd. (%): C, 63.30; H, 6.57; N, 14.06 Found (%): C, 62.99; H, 6.71; N, 13.83

Ir (KBr) ν_(max) (cm⁻¹): 1701, 1652, 1271

NMR (DMSO-d₆ ; 270 MHz) δ (ppm): 13.63 (1H, brs), 7.84 (1H, d, J=16.8 Hz), 7.28(1H, d, J=6.8 Hz), 7.14-7.05 (3H, m), 4.00(2H, t, J=7.3 Hz), 3.88-3.78(2H, m), 3.83(3H, s), 3.79(3H, s), 1.80-1.50(4H, m), 0.93-0.85(6H, m)

Reference Example 22 (E)-8-(2,3-Dimethoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 29)

Substantially the same procedure as in Reference Example 1 was repeated using 1.5 g (3.77 mmol) of Compound 28 obtained in Reference Example 21 in place of Compound B. Then, the resultant crude crystals were recrystallized from toluene/cyclohexane to give 1.22 g (yield 79%) of Compound 29 as pale brown needles.

Melting Point: 163.5°-163.7° C.

Elemental Analysis: C₂₂ H₂₈ N₄ O₄ Calcd. (%): C, 64.06; H, 6.84; N, 13.58 Found (%): C, 64.03; H, 7.12; N, 13.42

IR (KBr) ν_(max) (cm⁻¹): 1695, 1657, 1272

NMR (DMSO-d₆ ; 270 MHz) δ (ppm): 7.88(1H, d, J=15.8 Hz), 7.50(1H, dd, J=1.7, 7.6 Hz), 7.32(1H, d, J=15.8 Hz), 7.17-7.06(2H, m), 4.02(3H, s), 4.02-3.98(2H, m), 3.86-3.81(2H, m), 3.84(3H, s), 3.79(3H, s), 1.80-1.65(2H, m), 1.65-1.50(2H, m), 0.93-0.84(6H, m)

Reference Example 23 (E)-8-(3,4-Dimethylstyryl)-1,3-dipropylxanthine (Compound 30)

Substantially the same procedure as in Reference Example 1 was repeated using 5.90 g (26.0 mmol) of 5,6-diamino-1,3-dipropyluracil and 5.5 g (31.3 mmol) of 3,4-dimethylcinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 7.70 g (yield 81l%) of Compound 30 as a white powder.

Melting Point: 252.7°-254.0° C.

Elemental Analysis: C₂₁ H₂₆ N₄ O₂ Calcd. (%): C, 68.83; H, 7.15; N, 15.29 Found (%): C, 68.43; H, 7.22; N, 15.22

IR (KBr) ν_(max) (cm⁻¹): 1700, 1648, 1490

NMR (DMSO-d₆ ; 270 MHz) δ (ppm): 7.40(1H, d, J=16.2 Hz), 7.37(1H, s), 7.29(1H, d, J=7.2 Hz), 7.14(1H, d, J=7.2 Hz), 6.95(1H, d, J=16.2 Hz), 3.95(2H, t, J=7.2 Hz), 3.83(2H, t, J=7.4 Hz), 2.25(3H, s), 2.23 (3H, s), 1.80-1.55(4H, m), 1.00-0.90(6H, m)

Reference Example 24 (E)-8-(3,4-Dimethylstyryl)-7-methyl-1,3-dipropylxanthine (Compound 31)

Substantially the same procedure as in Reference Example 1 was repeated using 6.50 g (17.8 mmol) of Compound 30 obtained in Reference Example 23 in place of Compound B. Then, the resultant crude crystals were recrystallized from ethanol/water to give 5.62 g (yield 83%) of Compound 31 as white needles.

Melting Point: 169.3°-170.3° C.

Elemental Analysis: C₂₂ H₂₈ N₄ O₂ Calcd. (%): C, 69.45; H, 7.42; N, 14.72 Found (%): C, 69.33; H, 7.42; N, 14.86

IR (KBr) ν_(max) (cm⁻¹): 1693, 1656

NMR (DMSO-d₆ ; 270 MHz) δ (ppm): 7.59(1H, d, J=15.8 Hz), 7.58(1H, s), 7.49(1H, d, J=7.6 Hz), 7.26(1H, d, J=15.8 Hz), 7.19(1H, d, J=7.6 Hz), 4.02(3H, s), 4.05-3.90(2H, m), 3.84(2H, t, J=7.4 Hz), 2.27(3H, s), 2.25(3H, s), 1.85-1.50(4H, m), 1.00-0.85(6H, m)

Reference Example 25 (E)-8-(3,5-Dimethoxystyryl)-1,3-dipropylxanthine (Compound 32)

Substantially the same procedure as in Reference Example 1 was repeated using 3.95 g (17.5 mmol) of 5,6-diamino-1,3-dipropyluracil and 4.0 g (19.2 mmol) of 3,5-dimethoxycinnamic acid. Then, the resultant crude crystals were recrystallized from dimethylformamide/water to give 3.78 g (yield 54%) of Compound 32 as a white powder.

Melting Point: 248.7°-250.3° C.

Elemental Analysis: C₂₁ H₂₆ N₄ O₄ Calcd. (%): C, 63.30; H, 6.58; N, 14.06 Found (%): C, 63.02; H, 6.71; N, 14.06

IR (KBr) ν_(max) (cm⁻¹): 1687, 1631, 1588, 1494

NMR (DMSO-d₆ ; 270 MHz) δ (ppm): 7.56(1H, d, J=16.6 Hz), 7.08(1H, d, J=16.6 Hz), 6.78(2H, d, J=2.0 Hz), 6.50 (1H, t, J=2.0 Hz), 3.98(2H, t, J=7.3 Hz), 3.85(2H, t, J=7.3 Hz), 3.79(6H, s), 1.80-1.50(4H, m), 0.92-0.84(6H, m)

Reference Example 26 (E)-8-(3,5-Dimethoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 33)

Substantially the same procedure as in Reference Example 1 was repeated using 3.23 g (8.27 mmol) of Compound 32 obtained in Reference Example 25 in place of Compound B. Then, the resultant crude crystals were recrystallized from acetonitrile to give 2.96 g (yield 87%) of Compound 33 as white needles.

Melting Point: 178.0°-178.2° C.

Elemental Analysis: C₂₂ H₂₈ N₄ O₄ Calcd. (%): C, 64.06; H, 6.84; N, 13.58 Found (%): C, 63.87; H, 7.11; N, 13.66

Ir (KBr) ν_(max) (cm⁻¹): 1692, 1657, 1592

NMR (DMSO-d₆ ; 270 MHz) δ (ppm): 7.59(1H, d, J=15.9 Hz), 7.35(1H, d, J=15.9 Hz), 6.98(2H, d, J=2.9 Hz), 6.51 (1H, t, J=2.9 Hz), 4.04(3H, s), 4.10-3.95(2H, m), 3.90-3.75(2H, m), 3.80(6H, s), 1.80-1.50(4H, m), 1.00-0.80(6H, m)

Reference Example 27 (E)-8-(3-Nitrostyryl)-1,3-dipropylxanthine (Compound 34)

Substantially the same procedure as in Reference Example 1 was repeated using 4.0 g (17.7 mmol) of 5,6-diamino-1,3-dipropyluracil and 3.8 g (19.5 mmol) of 3-nitrocinnamic acid. Then, the resultant crude crystals were recrystallized from toluene to give 3.86 g (yield 57%) of Compound 34 as pale yellow needles.

Melting Point: 256.5°-256.8° C.

Elemental Analysis: C₁₉ H₂₁ N₅ O₄.0.25C₆ H₅ CH₃ Calcd. (%): C, 61.32; H, 5.70; N, 17.23 Found (%): C, 61.64; H, 5.94; N, 17.29

IR (KBr) ν_(max) (cm⁻¹): 1701, 1649, 1529, 1355

(DMSO-d₆ ; 270 MHz) δ (ppm): 8.42(1H, s), 8.19(1H, d, J=8.0 Hz), 8.12(1H, d, J=7.6 Hz), 7.80-7.65(2H, m), 7.25(1H, d, J=16.5 Hz), 4.00(2H, t, J=7.2 Hz), 3.86(2H, t, J=7.3 Hz), 1.80-1.55(4H, m), 1.00-0.80(6H, m)

Reference Example 28 (E)-7-Methyl-8-(3-nitrostyryl)-1,3-dipropylxanthine (Compound 35)

Substantially the same procedure as in Reference Example 1 was repeated using 3.20 g (8.36 mmol) of Compound 34 obtained in Reference Example 27 in place of Compound B. Then, the resultant crude crystals were recrystallized from toluene/cyclohexane to give 2.41 g (yield 73%) of Compound 35 as yellow needles.

Melting Point: 218.2°-218.4° C.

Elemental Analysis: C₂₀ H₂₃ N₅ O₄ Calcd. (%): C, 60.44; H, 5.83; N, 17.62 Found (%): C, 59.94; H, 5.97; N, 17.43

IR (KBr) ν_(max) (cm⁻¹): 1699, 1662, 1521

NMR (DMSO-d₆ ; 270 MHz) δ (ppm): 8.70(1H, m), 8.24(1H, d, J=7.9 Hz), 8.19(1H, dd, J=1.6, 7.6 Hz), 7.78(1H, d, J=15.9 Hz), 7.71(1H, t, J=7.9 Hz), 7.61(1H, d, J=15.9 Hz), 4.08(3H, s), 4.01(2H, t, J=7.3 Hz), 3.85 (2H, t, J=7.3 Hz), 1.85-1.55(4H, m), 0.91(3H, t, J=7.5 Hz), 0.87(3H, t, J=7.4 Hz)

Reference Example 29 (E)-8-(3-Fluorostyryl)-1,3-dipropylxanthine (Compound 36)

Substantially the same procedure as in Reference Example 1 was repeated using 3.95 g (17.5 mmol) of 5,6-diamino-1,3-dipropyluracil and 3.19 g (19.2 mmol) of 3-fluorocinnamic acid. Then, the resultant crude crystals were recrystallized from dimethylformamide/water to give 4.67 g (yield 75%) of Compound 36 as a pale yellow powder.

Melting Point: 265.0°-265.9° C.

Elemental Analysis: C₁₉ H₂₁ N₄ O₂ F Calcd. (%): C, 64.03; H, 5.94; N, 15.72 Found (%): C, 64.02; H, 5.96; N, 15.46

IR (KBr) ν_(max) (cm⁻¹): 1701, 1646

NMR (DMSO-d₆ ; 270 MHz) δ (ppm): 7.63(1H, d, J=16.3 Hz), 7.53-7.41(3H, m), 7.23-7.15(1H, m), 7.12(1H, d, J=16.3 Hz), 3.99(2H, t, J=7.0 Hz), 3.86(2H, t, J=7.3 Hz), 1.80-1.50(4H, m), 0.93-0.85(6H, m)

Reference Example 30 (E)-8-(3-Fluorostyryl)-7-methyl-1,3-dipropylxanthine (Compound 37)

Substantially the same procedure as in Reference Example 1 was repeated using 2.92 g (8.19 mmol) of Compound 36 obtained in Reference Example 29 in place of Compound B. Then, the resultant crude crystals were recrystallized from toluene/cyclohexane to give 2.67 g (yield 88%) of Compound 37 as pale yellow needles.

Melting Point: 161.9°-162.0° C.

Elemental Analysis: C₂₀ H₂₃ N₄ O₂ F Calcd. (%): C, 64.85; H, 6.26; N, 15.12 Found (%): C, 64.61; H, 6.40; N, 14.86

IR (KBr) ν_(max) (cm⁻¹): 1693, 1656, 1544

NMR (DMSO-d₆ ; 270 MHz) δ (ppm): 7.80-7.60(3H, m), 7.50-7.38(2H, m), 7.19(1H, dt, J=2.3, 8.3 Hz), 4.04(3H, s), 4.00(2H, t, J=7.3 Hz), 3.84(2H, t, J=7.5 Hz), 1.80-1.55(4H, m), 1.00-0.80(6H, m)

Reference Example 31 (E)-8-(3-Chlorostyryl)-1,3-dipropylxanthine (Compound 38)

Substantially the same procedure as in Reference Example 1 was repeated using 3.95 g (17.5 mmol) of 5,6-diamino-1,3-dipropyluracil and 3.51 g (19.2 mmol) of 3-chlorocinnamic acid. Then, the resultant crude crystals were recrystallized from dimethylformamide/water to give 4.44 g (yield 67%) of Compound 38 as pale yellow crystals.

Melting Point: 258.9°-259.4° C.

Elemental Analysis: C₁₉ H₂₁ N₄ O₂ Cl Calcd. (%): C, 61.21; H, 5.68; N, 15.03 Found (%): C, 61.52; H, 5.73; N, 14.79

IR (KBr) ν_(max) (cm⁻¹): 1700, 1644, 1588, 1494

NMR (DMSO-d₆ ; 270 MHz) δ (ppm): 13.7(1H, brs), 7.71-7.52(3H, m), 7.48-7.39(2H, m), 7.12(1H, d, J=16.3 Hz), 3.99(2H, t, J=7.0 Hz), 3.86(2H, t, J=7.0 Hz), 1.80-1.50(4H, m), 0.93-0.84(6H, m)

Reference Example 32 (E)-8-(3-Chlorostyryl)-7-methyl-1,3-dipropylxanthine (Compound 39)

Substantially the same procedure as in Reference Example 1 was repeated using 2.85 g (7.66 mmol) of Compound 38 obtained in Reference Example 31 in place of Compound B. Then, the resultant crude crystals were recrystallized from ethanol to give 2.69 g (yield 91%) of Compound 39 as white needles.

Melting Point: 167.7°-167.9° C.

Elemental Analysis: C₂₀ H₂₃ N₄ O₂ Cl Calcd. (%): C, 62.09; H, 5.99; N, 14.48 Found (%): C, 62.00; H, 6.08; N, 14.27

IR (KBr) ν_(max) (cm⁻¹): 1691, 1657, 1543

NMR (DMSO-d₆ ; 270 MHz) δ (ppm): 7.99(1H, s), 7.72 (1H, d, J=6.6 Hz), 7.63(1H, d, J=15.8 Hz), 7.50-7.30(3H, m), 4.05(3H, s), 4.00(2H, t, J=7.5 Hz), 3.84(2H, t, J=7.4 Hz), 1.80-1.55(4H, m), 1.00-0.80(6H, m)

Reference Example 33 (E)-8-(2-Chlorostyryl)-1,3-dipropylxanthine (Compound 40)

Substantially the same procedure as in Reference Example 1 was repeated using 3.00 g (13.3 mmol) of 5,6-diamino-1,3-dipropyluracil and 2.67 g (14.6 mmol) of 2-chlorocinnamic acid. Then, the resultant crude crystals were recrystallized from toluene to give 3.72 g (yield 82%) of Compound 40 as white needles.

Melting Point: 269.4°-269.9° C.

Elemental Analysis: C₁₉ H₂₁ N₄ O₂ Cl Calcd. (%): C, 61.21; H, 5.68; N, 15.03 Found (%): C, 60.94; H, 5.69; N, 14.68

IR (KBr) ν_(max) (cm⁻¹): 1695, 1645, 1493

NMR (DMSO-d₆ ; 270 MHz) δ (ppm): 8.00-7.80(2H, m), 7.55-7.50(1H, m), 7.45-7.37(2H, m), 7.12(1H, d, J=16.5 Hz), 3.99(2H, t, J=7.3 Hz), 3.86(2H, t, J=7.4 Hz), 1.80-1.55(4H, m), 1.00-0.80(6H, m)

Reference Example 34 (E)-8-(2-Chlorostyryl)-7-methyl-1,3-dipropylxanthine (Compound 41)

Substantially the same procedure as in Reference Example 1 was repeated using 2.37 g (6.37 mmol) of Compound 40 obtained in Reference Example 33 in place of Compound B. Then, the resultant crude crystals were recrystallized from ethanol/water to give 1.88 g (yield 77%) of Compound 41 as yellow needles.

Melting Point: 159.0°-159.9° C.

Elemental Analysis: C₂₀ H₂₃ N₄ O₂ Cl Calcd. (%): C, 62.09; H, 5.99; N, 14.48 Found (%): C, 61.75; H, 6.14; N, 14.45

IR (KBr) ν_(max) (cm⁻¹): 1696, 1650, 1544

NMR (DMSO-d₆ ; 270 MHz) δ (ppm): 8.10(1H, dd, J=2.3, 7.3 Hz), 7.97(1H, d, J=15.5 Hz), 7.55-7.50(1H, m), 7.46-7.35(3H, m), 4.05(3H, s), 4.00(2H, t, J=7.3 Hz), 3.84(2H, t, J=7.3 Hz), 1.80-1.55(4H, m), 1.00-0.80(6H, m)

Reference Example 35 (E)-8-(2-Fluorostyryl)-1,3-dipropylxanthine (Compound 42)

Substantially the same procedure as in Reference Example 1 was repeated using 3.00 g (13.3 mmol) of 5,6-diamino-1,3-dipropyluracil and 2.43 g (14.6 mmol) of 2-fluorocinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 3 23 g (yield 68%) of Compound 42 as white needles.

Melting Point: 258.8°-259.2° C.

Elemental Analysis: C₁₉ H₂₁ N₄ O₂ F Calcd. (%): C, 64.03; H, 5.94; N, 15.72 Found (%): C, 64.01; H, 6.11; N, 15.52

IR (KBr) ν_(max) (cm⁻¹): 1702, 1648

NMR (DMSO-d₆ ; 270 MHz) δ (ppm): 7.85-7.77(2H, m), 7.46-7.32(1H, m), 7.29-7.23(2H, m), 7.16(1H, d, J=16.5 Hz), 3.99(2H, t, J=7.1 Hz), 3.86(2H, t, J=7.3 Hz), 1.80-1.55(4H, m), 1.00-0.80(6H, m)

Reference Example 36 (E)-8-(2-Fluorostyryl)-7-methyl-1,3-dipropylxanthine (Compound 43)

Substantially the same procedure as in Reference Example 1 was repeated using 3.50 g (9.83 mmol) of Compound 42 obtained in Reference Example 35 in place of Compound B. Then, the resultant crude crystals were recrystallized from ethanol/water to give 1.23 g (yield 34%) of Compound 43 as white needles.

Melting Point: 155.5°-155.9° C.

Elemental Analysis: C₂₀ H₂₃ N₄ O₂ F Calcd. (%): C, 64.85; H, 6.26; N, 15.12 Found (%): C, 65.00; H, 6.44; N, 15.34

IR (KBr) ν_(max) (cm⁻¹): 1694, 1660

NMR (DMSO-d₆ ; 270 MHz) δ (ppm): 8.02(1H, t, J=8.3 Hz), 7.75(1H, d, J=15.5 Hz), 7.47-7.40(2H, m), 7.40-7.25(2H, m), 4.03(3H, s), 4.00(2H, t, J=7.4 Hz), 3.84(2H, t, J=7.4 Hz), 1.80-1.55(4H, m), 1.00-0.80(6H, m)

Reference Example 37 (E)-8-(4-Methoxy-2,5-dimethylstyryl)-1,3-dipropylxanthine (Compound 44)

Substantially the same procedure as in Reference Example 1 was repeated using 2.5 g (11.1 mmol) of 5,6-diamino-1,3-dipropyluracil and 2.51 g (12.17 mmol) of 4-methoxy-2,5-dimethylcinnamic acid. Then, the resultant crude crystals were recrystallized from ethanol/water to give 1.98 g (yield 45%) of Compound 44 as white crystals.

Melting Point: 268.0°-269.2° C.

Elemental Analysis: C₂₂ H₂₈ N₄ O₃ Calcd. (%): C, 66.65; H, 7.11; N, 14.13 Found (%): C, 66.82; H, 7.34; N, 14.14

IR (KBr) ν_(max) (c⁻¹): 1694, 1644, 1506, 1261

NMr (DMSO-d₆ ; 270 MHz) δ (ppm): 12.95(1H, brs), 7.95 (1H, d, J=15.8 Hz), 7.42(1H, s), 6.89(1H, d, J=15.8 Hz), 6.66(1H, s), 4.19-4.07(4H, m), 3.86(3H, s), 2.48(3H, s), 2.21(3H, s), 1.91-1.74(4H, m), 1.02(3H, t, J=6.9 Hz), 0.93(3H, t, J=6.9 Hz)

Reference Example 38 (E)-8-(4-Methoxy-2,5-dimethylstyryl)-7-methyl-1,3-dipropylxanthine (Compound 45)

Substantially the same procedure as in Reference Example 1 was repeated using 973 mg (2.45 mmol) of Compound 44 obtained in Reference Example 37 in place of Compound B. Then, the resultant crude crystals were recrystallized from 2-propanol/water to give 966 mg (yield 96%) of Compound 45 as pale yellow needles.

Melting Point: 245.3°-246.3° C.

Elemental Analysis: C₂₃ H₃₀ N₄ O₃ Calcd. (%): C, 67.30; H, 7.36; N, 13.65 Found (%): C, 67.37; H, 7.51; N, 13.69

IR (KBr) ν_(max) (cm⁻¹): 1690, 1655, 1508, 1261

NMR (DMSO-d₆ ; 270 MHz) δ (ppm): 7.96(1H, d, J=15.8 Hz), 7.41(1H, s), 6.70(1H, d, J=15.8 Hz), 6.66(1H, s), 4.14-4.09(2H, m), 4.05(3H, s), 4.01-3.95(2H, m), 2.48(3H, s), 2.22(3H, s), 1.91-1.77(2H, m), 1.74-1.63(2H, m), 1.03-0.94(6H, m)

Reference Example 39 (Z)-8-(3,4-Dimethoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 46) (an about 6:4 mixture of Compound 46 and Compound 1)

Compound 1 (2.00 g, 4.85 mmol) obtained in Reference Example 1 was dissolved in 180 ml of chloroform, and the solution was irradiated with sunlight for 24 hours. After careful concentration of the reaction mixture, methanol was added thereto and deposited crystals were collected by filtration. The crystals were dried under reduced pressure to give 1.72 g (yield 86%) of a mixture of Compound 46 and Compound 1 as a pale yellow powder (The ratio of Compound 46 to Compound 1 was about 6:4 by NMR analysis).

Melting Point: 115.2°-119.4° C.

Elemental Analysis: C₂₂ H₂₈ N₄ O₄ Calcd. (%): C, 64.06; H, 6.84; N, 13.58 Found (%): C, 64.02; H, 6.82; N, 13.46

IR (KBr) ν_(max) (cm⁻¹): 1695, 1656, 1521

NMR (DMSO-d₆ ; 270 MHz) δ (ppm): 7.60(1×4/10H, d, J=15.8 Hz), 7.40(1×4/10H, d, J=2.0 Hz), 7.32-7.17 (2×4/10H+2×6/10H, m), 6.99(1×4/10H, d, J=8.4 Hz), 6.94(1×6/10H, d, J=12.7 Hz), 6.92(1×6/10H, d, J=8.2 Hz), 6.39(1×6/10H, d, J=12.7 Hz), 4.02 (3×4/10H, s), 4.10-3.80(4H, m), 3.85(3×4/10H, s), 3.80(3×4/10H, s), 3.77(6×6/10H, s), 3.64(3×6/10H, s), 1.80-1.55(4H, m), 1.00-0.85(6H, m)

Reference Example 40 (E)-8-(4-Ethoxystyryl)-1,3-dipropylxanthine (Compound 47)

Substantially the same procedure as in Reference Example 1 was repeated using 3.0 g (13.3 mmol) of 5,6-diamino-1,3-dipropyluracil and 2.80 g (14.6 mmol) of 4-ethoxycinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane to give 3.57 g (yield 70%) of Compound 47 as pale yellow needles.

Melting Point: 261.6°-262.0° C.

Elemental Analysis: C₂₁ H₂₆ N₄ O₃ Calcd. (%): C, 65.96; H, 6.85; N, 14.65 Found (%): C, 65.93; H, 7.13; N, 14.65

IR (KBr) ν_(max) (cm⁻¹): 1701, 1635, 1516, 1261

NMR (DMSO-d₆ ; 270 MHz) δ (ppm): 13.37(1H, brs), 7.59 (1H, d, J=16.5 Hz), 7.55(2H, d, J=8.6 Hz), 6.96(2H, d, J=8.6 Hz), 6.88(1H, d, J=16.5 Hz), 4.07(2H, q, J=6.9 Hz), 3.99(2H, t, J=7.3 Hz), 3.86(2H, t, J=7.3 Hz), 1.73(2H, m), 1.58(2H, m), 1.34(3H, t, J=6.9 Hz), 0.90(3H, t, J=7.3 Hz), 0.87(3H, t, J=7.3 Hz)

Reference Example 41 (E)-8-(4-Ethoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 48)

Substantially the same procedure as in Reference Example 1 was repeated using 2.0 g (5.23 mmol) of Compound 47 obtained in Reference Example 40 in place of Compound B. Then, the resultant crude crystals were recrystallized from hexane/ethyl acetate to give 1.72 g (yield 83%) of Compound 48 as pale green needles.

Melting Point: 174.7°-175.0° C.

Elemental Analysis: C₂₂ H₂₈ N₄ O₃ Calcd. (%): C, 66.65; H, 7.11; N, 14.13 Found (%): C, 66.60; H, 7.20; N, 14.27

IR (KBr) ν_(max) (cm⁻¹): 1702, 1660, 1515, 1252

NMR (CDCl₃ ; 270 MHz) δ (ppm): 7.74(1H, d, J=15.8 Hz), 7.52(2H, d, J=8.6 Hz), 6.92(2H, d, J=8.6 Hz), 6.76 (1H, d, J=15.8 Hz), 4.09(2H, t, J=7.6 Hz), 4.08(2H, q, J=6.9 Hz), 4.04(3H, s), 3.99(2H, t, J=7.6 Hz), 1.44(3H, t, J=6.9 Hz), 1.00(3H, t, J=7.6 Hz), 0.97 (3H, t, J=7.6 Hz)

Reference Example 42 (E)-8-(4-Propoxystyryl)-1,3-dipropylxanthine (Compound 49)

Substantially the same procedure as in Reference Example 1 was repeated using 3.0 g (13.3 mmol) of 5,6-diamino-1,3-dipropyluracil and 3.01 g (14.6 mmol) of 4-propoxycinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 1.71 g (yield 33%) of Compound 49 as pale brown needles.

Melting Point: 248.3°-248.7° C.

Elemental Analysis: C₂₂ H₂₈ N₄ O₃ Calcd. (%): C, 66.65; H, 7.11; N, 14.13 Found (%): C, 66.50; H, 7.48; N, 14.25

IR (KBr) ν_(max) (cm⁻¹): 1694, 1649, 1514, 1253

NMR (DMSO-d₆ ; 270 MHz) δ (ppm): 13.34(1H, brs), 7.58 (1H, d, J=16.5 Hz), 7.55(2H, d, J=8.6 Hz), 6.99(2H, d, J=8.6 Hz), 6.88(1H, d, J=16.5 Hz), 4.01-3.95(4H, m), 3.86(2H, t, J=7.3 Hz), 1.78-1.70(4H, m), 1.62-1.54(2H, m), 0.98(3H, t, J=7.3 Hz), 0.90(3H, t, J=7.6 Hz), 0.87(3H, t, J=7.6 Hz)

Reference Example 43 (E)-7-Methyl-8-(4-propoxystyryl)-1,3-dipropylxanthine (Compound 50)

Substantially the same procedure as in Reference Example 1 was repeated using 1.0 g (2.52 mmol) of Compound 49 obtained in Reference Example 42 in place of Compound B. Then, the resultant crude crystals were recrystallized from hexane/ethyl acetate to give 863 mg (yield 83%) of Compound 50 as pale yellow needles.

Melting Point: 172.6°-173.5° C.

Elemental Analysis: C₂₃ H₃₀ N₄ O₃ Calcd. (%): C, 67.30; H, 7.36; N, 13.65 Found (%): C, 67.15; H, 7.65; N, 13.58

IR (KBr) ν_(max) (cm⁻¹): 1699, 1658, 1514, 1252

NMR (CDCl₃ ; 270 MHz) δ (ppm): 7.74(1H, d, J=15.8 Hz), 7.52(2H, d, J=8.9 Hz), 6.92(2H, d, J=8.9 Hz), 6.76 (1H, d, J=15.8 Hz), 4.13-3.94(6H, m), 4.04(3H, s), 1.90-1.62(6H, m), 1.08-0.94(9H, m)

Reference Example 44 (E)-8-(4-Butoxystyryl)-1,3-dipropylxanthine (Compound 51)

Substantially the same procedure as in Reference Example 1 was repeated using 3.0 g (13.3 mmol) of 5,6-diamino-1,3-dipropyluracil and 3.21 g (14.6 mmol) of 4-butoxycinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 3.47 g (yield 64%) of Compound 51 as white needles.

Melting Point: 237.3°-238.9° C.

Elemental Analysis: C₂₃ H₃₀ N₄ O₃ Calcd. (%): C, 67.30; H, 7.36; N, 13.65 Found (%): C, 67.39; H, 7.45; N, 13.59

IR (KBr) ν_(max) (cm⁻¹): 1697, 1644, 1514, 1257

NMR (DMSO-d₆ ; 270 MHz) δ (ppm): 13.37(1H, brs), 7.58 (1H, d, J=16.2 Hz), 7.55(2H, d, J=8.6 Hz), 6.97(2H, d, J=8.6 Hz), 6.88(1H, d, J=16.2 Hz), 4.04-3.96(4H, m), 3.86(2H, t, J=7.3 Hz), 1.80-1.37(8H, m), 0.97-0.84(9H, m)

Reference Example 45 (E)-8-(4-Butoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 52)

Substantially the same procedure as in Reference Example 1 was repeated using 2.0 g (4.87 mmol) of Compound 51 obtained in Reference Example 44 in place of Compound B. Then, the resultant crude crystals were recrystallized from hexane/ethyl acetate to give 1.56 g (yield 75%) of Compound 52 as pale green needles.

Melting Point: 134.8°-135.6° C.

Elemental Analysis: C₂₄ H₃₂ N₄ O₃ Calcd. (%): C, 67.90; H, 7.59; N, 13.20 Found (%): C, 68.22; H, 7.88; N, 13.49

IR (KBr) ν_(max) (cm⁻¹): 1696, 1651, 1513, 1247

NMR (CDCl₃ ; 270 MHz) δ (ppm): 7.74(1H, d, J=15.5 Hz), 7.52(2H, d, J=8.6 Hz), 6.92(2H, d, J=8.6 Hz), 6.76 (1H, d, J=15.5 Hz), 4.13-3.95(6H, m), 4.04(3H, s), 1.88-1.44(8H, m), 1.03-0.94(9H, m)

Reference Example 46 (E)-8-(3,4-Dihydroxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 53)

Compound 1 (770 mg, 1.87 mmol) obtained in Reference Example 1 was dissolved in 15 ml of methylene chloride. To the solution was added 5.6 ml (5.6 mmol) of boron tribromide (1.0M methylene chloride solution) under ice cooling in argon atmosphere, and the mixture was stirred overnight at room temperature. Methanol was added thereto and the mixture was separated with chloroform-an aqueous solution of sodium bicarbonate. The organic layer was washed with a saturated aqueous solution of sodium chloride and dried over anhydrous sodium sulfate, followed by evaporation under reduced pressure. The residue was purified by silica gel column chromatography to give 550 mg (yield 77%) of Compound 53 as a yellow solid, which was then triturated with ether to give a yellow powder.

Melting Point: 250.1°-251.4° C.

Elemental Analysis: C₂₀ H₂₄ N₄ O₄ Calcd. (%): C, 62.49; H, 6.29; N, 14.57 Found (%): C, 62.27; H, 6.48; N, 14.74

IR (KBr) ν_(max) (cm⁻¹): 1680, 1640, 1543, 1306

NMR (DMSO-d₆ ; 270 MHz) δ (ppm): 9.31(1H, brs), 8.95(1H, brs), 7.49(1H, d, J=15.8 Hz), 7.15(1H, d, J=2.0 Hz), 7.04(1H, dd, J=7.9, 2.0 Hz), 6.98(1H, d, J=15.8 Hz), 6.78(1H, d, J=7.9 Hz), 3.99(2H, t, J=7.6 Hz), 3.98 (3H, s), 3.84(2H, t, J=7.4 Hz), 1.73(2H, m), 1.57 (2H, m), 0.90(3H, t, J=7.4 Hz), 0.87(3H, t, J=7.4 Hz)

Reference Example 47 (E)-8-(3,4-Diethoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 54)

Compound 53 (390 mg, 1.01 mmol) obtained in Reference Example 46 was dissolved in 10 ml of dimethylformamide. To the solution were added 0.20 ml (2.50 mmol) of ethyl iodide and 420 mg (3.04 mmol) of potassium carbonate, and the mixture was stirred overnight at room temperature. Water was added thereto to dissolve potassium carbonate and deposited crystals were collected by filtration. The collected crude crystals were recrystallized from hexane/ethyl acetate to give 237 mg (yield 53%) of Compound 54 as pale yellow needles.

Melting Point: 173.8°-174.0° C.

Elemental Analysis: C₂₄ H₃₂ N₄ O₄ Calcd. (%): C, 65.44; H, 7.32; N, 12.72 Found (%): C, 65.42; H, 7.48; N, 12.62

IR (KBr) ν_(max) (cm⁻¹): 1694, 1653, 1508, 1268

NMR (CDCl₃ ; 270 MHz) δ (ppm): 7.71(1H, d, J=15.5 Hz), 7.15(1H, dd, J=8.3, 2.0 Hz), 7.10(1H, d, J=2.0 Hz), 6.89(1H, d, J=8.3 Hz), 6.74(1H, d, J=15.5 Hz), 4.16 (2H, q, J=6.9 Hz), 4.14(2H, q, J=6.9 Hz), 4.08-3.95 (4H, m), 4.05(3H, s), 1.91-1.76(2H, m), 1.76-1.62 (2H, m), 1.49(3H, t, J=6.9 Hz), 1.48(3H, t, J=6.9 Hz), 1.00(3H, t, J=7.6 Hz), 0.97(3H, t, J=7.6 Hz)

Reference Example 48 (E)-8-(3-Bromo-4-methoxystyryl)-1,3-dipropylxanthine (Compound 55)

Substantially the same procedure as in Reference Example 1 was repeated using 3.0 g (13.3 mmol) of 5,6-diamino-1,3-dipropyluracil and 3.75 g (14.6 mmol) of 3-bromo-4-methoxycinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane to give 3.43 g (yield 58%) of Compound 55 as yellow needles.

Melting Point: 279.8°-280.6° C.

Elemental Analysis: C₂₀ H₂₃ N₄ O₃ Br Calcd. (%): C, 53.70; H, 5.18; N, 12.52 Found (%): C, 53.77; H, 5.20; N, 12.49

IR (KBr) ν_(max) (cm⁻¹): 1685, 1633, 1599, 1503, 1279

NMR (DMSO-d₆ ; 270 MHz) δ (ppm): 13.42(1H, brs), 7.85 (1H, d, J=2.0 Hz), 7.61(1H, dd, J=8.4, 2.0 Hz), 7.55 (1H, d, J=16.3 Hz), 7.15(1H, d, J=8.4 Hz), 6.94(1H, d, J=16.3 Hz), 3.98(2H, t, J=7.4 Hz), 3.89(3H, s), 3.86(2H, t, J=7.4 Hz), 1.80-1.52(4H, m), 0.89(6H, q, J=7.4 Hz)

Reference Example 49 (E)-8-(3-Bromo-4-methoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 56)

Substantially the same procedure as in Reference Example 1 was repeated using 750 mg (1.68 mmol) of Compound 55 obtained in Reference Example 48 in place of Compound B. Then, the resultant crude crystals were recrystallized from hexane/ethyl acetate to give 588 mg (yield 76%) of Compound 56 as pale yellow needles.

Melting Point: 209.4°-210.8° C.

Elemental Analysis: C₂₁ H₂₅ N₄ O₃ Br Calcd. (%): C, 54.67; H, 5.46; N, 12.14 Found (%): C, 54.47; H, 5.51; N, 11.91

IR (KBr) ν_(max) (cm⁻¹): 1693, 1656, 1542, 1500, 1264

NMR (CDCl₃ ; 270 MHz) δ (ppm): 7.83(1H, d, J=2.0 Hz), 7.68(1H, d, J=15.8 Hz), 7.48(1H, dd, J=8.4, 2.0 Hz), 6.92(1H, d, J=8.4 Hz), 6.78(1H, d, J=15.8 Hz), 4.13-4.07(2H, m), 4.06(3H, s), 4.01-3.97(2H, m), 3.95 (3H, s), 1.90-1.65(4H, m), 1.00(3H, t, J=7.4 Hz), 0.97(3H, t, J=7.4 Hz)

Reference Example 50 (E)-8-(2-Bromo-4,5-dimethoxystyryl)-1,3-dipropylxanthine (Compound 57)

Substantially the same procedure as in Reference Example 1 was repeated using 2.0 g (8.85 mmol) of 5,6-diamino-1,3-dipropyluracil and 2.80 g (9.75 mmol) of 2-bromo-4,5-dimethoxycinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane to give 2.38 g (yield 56%) of Compound 57 as pale yellow needles.

Melting Point: 248.2°-249.5° C.

Elemental Analysis: C₂₁ H₂₅ N₄ O₄ Br Calcd. (%): C, 52.84; H, 5.28; N, 11.74 Found (%): C, 52.73; H, 5.31; N, 11.45

IR (KBr) ν_(max) (cm⁻¹): 1697, 1643, 1506, 1263

NMR (DMSO-d₆ ; 270 MHz) δ (ppm): 13.75(1H, brs), 7.81 (1H, d, J=16.3 Hz), 7.39(1H, s), 7.20(1H, s), 7.09 (1H, d, J=16.3 Hz), 4.00-3.82(4H, m), 3.86(3H, s), 3.82(3H, s), 1.76-1.54(4H, m), 0.92-0.85(6H, m)

Reference Example 51 (E)-8-(2-Bromo-4,5-dimethoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 58)

Substantially the same procedure as in Reference Example 1 was repeated using 800 mg (1.68 mmol) of Compound 57 obtained in Reference Example 50 in place of Compound B. Then, the resultant crude crystals were recrystallized from dioxane to give 766 mg (yield 93%) of Compound 58 as yellow needles.

Melting Point: 228.8°-229.4° C.

Elemental Analysis: C₂₂ H₂₇ N₄ O₄ Br Calcd. (%): C, 53.78; H, 5.54; N, 11.40 Found (%): C, 53.76; H, 5.67; N, 11.16

IR (KBr) ν_(max) (cm⁻¹): 1688, 1650, 1509, 1266

NMR (CDCl₃ ; 270 MHz) δ (ppm): 8.01(1H, d, J=15.8 Hz), 7.11(1H, s), 7.09(1H, s), 6.75(1H, d, J=15.8 Hz), 4.15-3.92(4H, m), 4.08(3H, s), 3.95(3H, s), 3.92 (3H, s), 1.91-1.77(2H, m), 1.74-1.63(2H, m), 1.03-0.94(6H, m)

Reference Example 52 (E)-8-(3-Bromo-4,5-dimethoxystyryl)-1,3-dipropylxanthine (Compound 59)

Substantially the same procedure as in Reference Example 1 was repeated using 1.5 g (6.64 mmol) of 5,6-diamino-1,3-dipropyluracil and 2.10 g (7.31 mmol) of 3-bromo-4,5-dimethoxycinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 2.11 g (yield 67%) of Compound 59 as white needles.

Melting Point: 276.7°-277.5° C.

Elemental Analysis: C₂₁ H₂₅ N₄ O₄ Br Calcd. (%): C, 52.84; H, 5.28; N, 11.74 Found (%): C, 52.72; H, 5.16; N, 11.56

IR (KBr) ν_(max) (cm⁻¹): 1701, 1650, 1562, 1498

NMR (DMSO-d₆ ; 270 MHz) δ (ppm): 13.44(1H, brs), 7.55 (1H, d, J=16.3 Hz), 7.39(1H, d, J=2.0 Hz), 7.36(1H, d, J=2.0 Hz), 7.07(1H, d, J=16.3 Hz), 3.99(2H, t, J=7.4 Hz), 3.91(3H, s), 3.86(2H, t, J=7.4 Hz), 3.78 (3H, s), 1.77-1.52(4H, m), 0.93-0.85(6H, m)

Reference Example 53 (E)-8-(3-Bromo-4,5-dimethoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 60)

Substantially the same procedure as in Reference Example 1 was repeated using 1.0 g (2.10 mmol) of Compound 59 obtained in Reference Example 52 in place of Compound B. Then, the resultant crude crystals were recrystallized from hexane/ethyl acetate to give 952 mg (yield 93%) of Compound 60 as pale yellow needles.

Melting Point: 180.9°-181.6° C. MS-EI m/e: 490, 492

IR (KBr) ν_(max) (cm⁻¹): 1691, 1648, 1542, 1493

NMR (CDCl₃ ; 270 MHz) δ (ppm): 7.68(1H, d, J=15.8 Hz), 7.42(1H, d, J=2.0 Hz), 7.02(1H, d, J=2.0 Hz), 6.80 (1H, d, J=15.8 Hz), 4.13-3.95(4H, m), 4.08(3H, s), 3.94(3H, s), 3.90(3H, s), 1.90-1.65(4H, m), 1.01 (3H, t, J=7.4 Hz), 0.97(3H, t, J=7.4 Hz)

Reference Example 54 (E)-8-(3-Hydroxy-4-methoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 63)

Compound 53 (500 mg, 1.30 mmol) obtained in Reference Example 46 was dissolved in 10 ml of dimethylformamide. To the solution were added 0.40 ml (6.43 mmol) of methyl iodide and 400 mg (6.50 mmol) of lithium carbonate, and the mixture was stirred at 80° C. for 5 hours. Water was added thereto to dissolve lithium carbonate and deposited crystals were collected by filtration. The collected crude crystals were dissolved in chloroform, washed with a saturated aqueous solution of sodium chloride and dried over anhydrous sodium sulfate, followed by evaporation under reduced pressure. The residue was purified by silica gel column chromatography (eluent:chloroform) to give 162 mg (yield 31%) of Compound 63 as yellow grains.

Melting Point: 200.3°-203.6° C.

IR (KBr) ν_(max) (cm⁻¹): 1683, 1642, 1512, 1278

NMR (DMSO-d₆ ; 270 MHz) δ (ppm): 8.98(1H, brs), 7.52(1H, d, J=15.5 Hz), 7.22(1H, d, J=2.0 Hz), 7.15(1H, dd, J=8.3, 2.0 Hz), 7.06(1H, d, J=15.5 Hz), 6.96(1H, d, J=8.3 Hz), 4.02-3.97(2H, m), 4.00(3H, s), 3.84-3.82 (2H, m), 3.82(3H, s), 1.80-1.50(4H, m), 0.90(3H, t, J=7.3 Hz), 0.87(3H, t, J=7.3 Hz)

Reference Example 55 (E)-8-(2-Chloro-3,4-dimethoxystyryl)-1,3-diethylxanthine (Compound 112)

Substantially the same procedure as in Example 7 was repeated using 2.00 g (10.1 mmol) of 5,6-diamino-1,3-diethyluracil and 2.94 g (12.1 mmol) of 2-chloro-3,4-dimethoxycinnamic acid. Then, the resultant crude crystals were recrystallized from 2-propanol/water to give 2.19 g (yield 54% ) of Compound 112 as pale yellow needles.

Melting Point: 278.0°-280.9° C.

Elemental Analysis: C₁₉ H₂₁ ClN₄ O₄ Calcd. (%): C, 56.36; H, 5.22; N, 13.83 Found (%): C, 56.13; H, 5.21; N, 13.67

IR (KBr) ν_(max) (cm⁻¹): 1705, 1642, 1499

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.88(1H, d, J=16.3 Hz), 7.64(1H, d, J=8.9 Hz), 7.13(1H, d, J=8.9 Hz), 7.00 (1H, d, J=16.3 Hz), 4.06(2H, q, J=7.1 Hz), 3.98-3.88 (2H, m), 3.88(3H, s), 3.77(3H, s), 1.26(3H, t, J=7.1 Hz), 1.14(3H, t, J=6.9 Hz)

Reference Example 56 (E)-8-(2-Chloro-3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine (Compound 113)

Substantially the same procedure as in Example 8 was repeated using 1.80 g (4.45 mmol) of Compound 112 obtained in Reference Example 55 in place of Compound 64. Then, the resultant crude crystals were recrystallized from 2-propanol/water to give 1.20 g (yield 64%) of Compound 113 as yellow needles.

Melting Point: 204.6°-205.4° C.

Elemental Analysis: C₂₀ H₂₃ ClN₄ O₄ Calcd. (%): C, 57.34; H, 5.53; N, 13.37 Found (%): C, 57.46; H, 5.67; N, 13.10

IR (KBr) ν_(max) (cm⁻¹): 1696, 1657, 1496, 1439, 1292

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.92(1H, d, J=15.8 Hz), 7.86(1H, d, J=8.9 Hz), 7.29(1H, d, J=15.8 Hz), 7.16 (1H, d, J=8.9 Hz), 4.11-4.03(2H, m), 4.03(3H, s), 3.96-3.90(2H, m), 3.90(3H, s), 3.77(3H, s), 1.26 (3H, t, J=6.9 Hz), 1.13(3H, t, J=6.9 Hz)

Reference Example 57 (E)-8-(2-Chloro-3,4-dimethoxystyryl)theophylline (Compound 114)

2-Chloro-3,4-dimethoxycinnamic acid (3.93 g, 16.2 mmol) was dissolved in 57 ml of pyridine. To the solution was added 1.26 ml (17.6 mmol) of thionyl chloride under ice cooling, and the mixture was stirred at 60° C. for 1.5 hours. Methylene chloride (58 ml) containing 2.50g (14.7 mmol) of 5,6-diamino-1,3-dimethyluracil was added dropwise to the solution under ice cooling, and the reaction solution was stirred at room temperature for further 40 minutes. The deposited crystals were collected by filtration and the obtained crude crystals were dissolved in a mixture of 68 ml of an aqueous 2N sodium hydroxide solution, 68 ml of dioxane, and 34 ml of water, followed by heating under reflux for 30 minutes. After cooling, the solution was neutralized with a concentrated aqueous solution of hydrochloric acid, and the deposited crystals were collected by filtration. The collected crystals were washed with water, dried, and recrystallized from dimethylformamide/water to give 1.55 g (yield 30%) of Compound 114 as pale yellow needles.

Melting Point: 241.6°-242.6° C.

Elemental Analysis: C₁₇ H₁₇ ClN₄ O₄ Calcd. (%): C, 54.18; H, 4.54; N, 14.86 Found (%): C, 54.31; H, 4.54; N, 14.43

IR (KBr) ν_(max) (cm⁻¹): 1704, 1653, 1496, 1300

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.88(1H, d, J=16.2 Hz), 7.62(1H, d, J=8.9 Hz), 7.13(1H, d, J=8.9 Hz), 6.97 (1H, d, J=16.2 Hz), 3.88(3H, s), 3.77(3H, s), 3.47 (3H, s), 3.25(3H, s)

Reference Example 58 (E)-8-(2-Chloro-3,4-dimethoxystyryl)caffeine (Compound 115)

Substantially the same procedure as in Example 8 was repeated using 1.0 g (2.66 mmol) of Compound 114 obtained in Reference Example 57 in place of Compound 64. Then, the resultant crude crystals were recrystallized from toluene to give 840 mg (yield 81%) of Compound 115 as a yellow powder.

Melting Point: 284.6°-288.0° C.

Elemental Analysis: C₁₈ H₁₉ ClN₄ O₄ Calcd. (%): C, 55.31; H, 4.59; N, 14.33 Found (%): C, 55.40; H, 4 . 83; N, 14.09

IR (KBr) ν_(max) (cm⁻¹): 1688, 1650, 1493, 1290

NMR (270 MHz; CDCl₃) δ (ppm): 8.10(1H, d, J=15.8 Hz), 7.43(1H, d, J=8.8 Hz), 6.88(1H, d, J=8.8 Hz), 6.83 (1H, d, J=15.8 Hz), 4.06(3H, s), 3.93(3H, s), 3.90 (3H, s), 3.64(3H, s), 3.42(3H, s)

Reference Example 59 (E)-8-(3,4-Difluorostyryl)-1,3-diethylxanthine (Compound 116)

Substantially the same procedure as in Example 7 was repeated using 2.50 g (12.6 mmol) of 5,6-diamino-1,3-diethyluracil and 2.79 g (15.2 mmol) of 3,4-difluorocinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 2.12 g (yield 49%) of Compound 116 as gray plates.

Melting Point: >300° C.

Elemental Analysis: C₁₇ H₁₆ F₂ N₄ O₂ Calcd. (%): C, 58.95; H, 4.65; N, 16.17 Found (%): C, 59.25; H, 4.59; N, 16.42

IR (KBr) ν_(max) (cm⁻¹): 1688, 1640, 1519

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.78(1H, dd, J=11.4, 7.1 Hz), 7.60(1H, d, J=16.3 Hz), 7.50-7.45(2H, m), 7.07(1H, d, J=16.3 Hz), 4.06(2H, q, J=7.0 Hz), 3.94 (2H, q, J=7.1 Hz), 1.26(3H, t, J=7.0 Hz), 1.14(3H, t, J=7.1 Hz)

Reference Example 60 (E)-8-(3,4-Difluorostyryl)-1,3-diethyl-7-methylxanthine (Compound 117)

Substantially the same procedure as in Example 8 was repeated using 1.70 g (4.91 mmol) of Compound 116 obtained in Reference Example 59 in place of Compound 64. Then, the resultant crude crystals were recrystallized from toluene/cyclohexane to give 1.29 g (yield 73%) of Compound 117 as yellow needles.

Melting Point: 208.5°-210.8° C.

Elemental Analysis: C₁₈ H₁₈ F₂ N₄ O₂ Calcd. (%): C, 59.99; H, 5.03; N, 15.54 Found (%): C, 60.09; H, 5.04; N, 15.19

IR (KBr) ν_(max) (cm⁻¹): 1688, 1652, 1545, 1520, 1441

NMR (270 MHz; DMSO-d₆) δ (ppm): 8.02(1H, ddd, J=12.4, 7.7, 2.0 Hz), 7.65-7.60(1H, m), 7.61(1H, d, J=15.8 Hz), 7.54-7.43(1H, m), 7.40(1H, d, J=15.8 Hz), 4.08-4.04(2H, m), 4.04(3H, s), 3.92(2H, q, J=6.9 Hz), 1.26(3H, t, J=6.9 Hz), 1.13(3H, t, J=6.9 Hz)

Reference Example 61 (E)-8-(3-Bromo-4-methoxystyryl)-1,3-diethylxanthine (Compound 118)

Substantially the same procedure as in Example 7 was repeated using 2.00 g (10.1 mmol) of 5,6-diamino-1,3-diethyluracil and 2.72 g (10.6 mmol) of 3-bromo-4-methoxycinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane to give 726 mg (yield 17%) of Compound 118 as pale brown needles.

Melting Point: >280° C.

Elemental Analysis: C₁₈ H₁₉ BrN₄ O₃ Calcd. (%): C, 51.57; H, 4.57; N, 13.36 Found (%): C, 51.33; H, 4.56; N, 13.17

IR (KBr) ν_(max) (cm⁻¹): 1694, 1648, 1506, 1281, 1260

NMR (270 MHz; DMSO-d₆) δ (ppm): 13.52(1H, brs), 7.87 (1H, d, J=2.0 Hz), 7.63(1H, dd, J=8.4, 2.0 Hz), 7.56 (1H, d, J=16.3 Hz), 7.16(1H, d, J=8.4 Hz), 6.95(1H, d, J=16.3 Hz), 4.06(2H, q, J=6.9 Hz), 3.93(2H, q, J=6.9 Hz), 3.89(3H, s), 1.26(3H, t, J=6.9 Hz), 1.14 (3H, t, J=6.9 Hz)

Reference Example 62 (E)-8-(3-Bromo-4-methoxystyryl)-1,3-diethyl-7-methylxanthine (Compound 119)

Substantially the same procedure as in Example 8 was repeated using 400 mg (0.95 mmol) of Compound 118 obtained in Reference Example 61 in place of Compound 64. Then, the resultant crude crystals were recrystallized from dioxane/water to give 332 mg (yield 80%) of Compound 119 as pale yellow needles.

Melting Point: 219.1°-223.7° C.

Elemental Analysis: C₁₉ H₂₁ BrN₄ O₃ Calcd. (%): C, 52.67; H, 4.88; N, 12.93 Found (%): C, 52.79; H, 4.97; N, 12.70

IR (KBr) ν_(max) (cm⁻¹): 1686, 1651, 1541, 1501, 1435

NMR (270 MHz; CDCl₃) δ (ppm): 7.83(1H, d, J=2.0 Hz), 7.69(1H, d, J=15.8 Hz), 7.48(1H, dd, J=8.4, 2.0 Hz), 6.92(1H, d, J=8.4 Hz), 6.78(1H, d, J=lS.8 Hz), 4.21 (2H, q, J=6.9 Hz), 4.09(2H, q, J=6.9 Hz), 4.06(3H, s), 3.95(3H, s), 1.38(3H, t, J=6.9 Hz), 1.26(3H, t, J=6.9 Hz)

Reference Example 63 (E)-8-(3-Bromo-4-methoxystyryl)theophylline (Compound 120)

Substantially the same procedure as in Example 7 was repeated using 2.00 g (11.8 mmol) of 5,6-diamino-1,3-dimethyluracil and 3.32 g (12.9 mmol) of 3-bromo-4-methoxycinnamic acid. Then, the resultant crude crystals were recrystallized from dimethylformamide to give 2.00 g (yield 43%) of Compound 120 as a pale yellow powder.

Melting Point: >280° C.

Elemental Analysis: C₁₆ H₁₅ BrN₄ O₃ Calcd. (%): C, 49.12; H, 3.86; N, 14.32 Found (%): C, 49.16; H, 3.80; N, 14.06

IR (KBr) ν_(max) (cm⁻¹): 1691, 1644, 1598, 1499, 1257

NMR (270 MHz; DMSO-d₆) δ (ppm): 13.41(1H, brs), 7.84 (1H, d, J=2.0 Hz), 7.61(1H, dd, J=8.4, 2.0 Hz), 7.56 (1H, d, J=16.3 Hz), 7.15(1H, d, J=8.4 Hz), 6.92(1H, d, J=16.3 Hz), 3.89(3H, s), 3.47(3H, s), 3.26(3H, s)

Reference Example 64 (E)-8-(3-Bromo-4-methoxystyryl)caffeine (Compound 121)

Substantially the same procedure as in Example 8 was repeated using 1.00 g (2.56 mmol) of Compound 120 obtained in Reference Example 63 in place of Compound 64. Then, the resultant crude crystals were recrystallized from dioxane to give 877 mg (yield 85%) of Compound 121 as a yellow powder.

Melting Point: 283.3°-283.4° C.

Elemental Analysis: C₁₇ H₁₇ BrN₄ O₃ Calcd. (%): C, 50.39; H, 4.23; N, 13.83 Found (%): C, 50.04; H, 4.00; N, 13.49

IR (KBr) ν_(max) (cm⁻¹): 1693, 1654, 1500

NMR (270 MHz; CDCl₃) δ (ppm): 7.82(1H, d, J=2.0 Hz), 7.70(1H, d, J=15.8 Hz), 7.47(1H, dd, J=8.4, 2.0 Hz), 6.92(1H, d, J=8.4 Hz), 6.78(1H, d, J=15.8 Hz), 4.07 (3H, s), 3.95(3H, s), 3.62(3H, s), 3.42(3H, s)

Reference Example 65 (E)-8-(2-Bromo-4,5-dimethoxystyryl)-1,3-diethylxanthine (Compound 122)

Substantially the same procedure as in Example 7 was repeated using 3.00 g (15.1 mmol) of 5,6-diamino-1,3-diethyluracil and 4.78 g (17.2 mmol) of 2-bromo-4,5-dimethoxycinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane to give 3.34 g (yield 49%) of Compound 122 as pale yellow needles.

Melting Point: >285° C.

Elemental Analysis: C₁₉ H₂₁ BrN₄ O₄ Calcd. (%): C, 50.79; H, 4.71; N, 12.47 Found (%): C, 50.49; H, 4.64; N, 12.36

IR (KBr) ν_(max) (cm⁻¹): 1693, 1621, 1509, 1260

NMR (270 MHz; DMSO-d₆) δ (ppm): 13.65(1H, brs), 7.81 (1H, d, J=16.3 Hz), 7.37(1H, s), 7.20(1H, s), 7.06 (1H, d, J=16.3 Hz), 4.07(2H, q, J=6.9 Hz), 3.95(2H, q, J=6.9 Hz), 3.86(3H, s), 3.82(3H, s), 1.27(3H, t, J=6.9 Hz), 1.15(3H, t, J=6.9 Hz)

Reference Example 66 (E)-8-(2-Bromo-4,5-dimethoxystyryl)-1,3-diethyl-7-methylxanthine (Compound 123)

Substantially the same procedure as in Example 8 was repeated using 1.50 g (3.34 mmol) of Compound 122 obtained in Reference Example 65 in place of Compound 64. Then, the resultant crude crystals were recrystallized from hexane/ethyl acetate to give 1.43 g (yield 92%) of Compound 123 as yellow needles.

Melting Point: 234.2°-234.9° C.

Elemental Analysis: C₂₀ H₂₃ BrN₄ O₄ Calcd. (%): C, 51.85; H, 5.00; N, 12.09 Found (%): C, 51.96; H, 4.95; N, 11.90

IR (KBr) ν_(max) (cm⁻¹): 1688, 1648, 1504, 1307, 1261

NMR (270 MHz; CDCl₃) δ (ppm): 8.01(1H, d, J=15.8 Hz), 7.11(1H, s), 7.09(1H, s), 6.76(1H, d, J=15.8 Hz), 4.22(2H, q, J=6.9 Hz), 4.09(2H, q, J=6.9 Hz), 4.08 (3H, s), 3.95(3H, s), 3.92(3H, s), 1.39(3H, t, J=6.9 Hz), 1.27(3H, t, J=6.9 Hz)

Reference Example 67 (E)-8-(4,5-Dimethoxy-2-nitrostyryl)-1,3-diethylxanthine (Compound 124)

Substantially the same procedure as in Example 7 was repeated using 1.50 g (7.57 mmol) of 5,6-diamino-1,3-diethyluracil and 2.11 g (8.33 mmol) of 4,5-dimethoxy-2-nitrocinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane to give 1.22 g (yield 39%) of Compound 124 as orange needles.

Melting Point: 283.6°-284.2° C.

Elemental Analysis: C₁₉ H₂₁ N₅ O₆ Calcd. (%): C, 54.94; H, 5.09; N, 16.86 Found (%): C, 54.90; H, 5.07; N, 16.88

IR (KBr) ν_(max) (cm⁻¹): 1692, 1641, 1520

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.99(1H, d, J=16.3 Hz), 7.61(1H, s), 7.38(1H, s), 7.15(1H, d, J=16.3 Hz), 4.06(2H, q, J=6.9 Hz), 3.98(3H, s), 3.95(2H, q, J=6.9 Hz), 3.89(3H, s), 1.26(3H, t, J=6.9 Hz), 1.15 (3H, t, J=6.9 Hz)

Reference Example 68 (E)-8-(4,5-Dimethoxy-2-nitrostyryl)-1,3-diethyl-7-methylxanthine (Compound 125)

Substantially the same procedure as in Example 8 was repeated using 822 mg (1.98 mmol) of Compound 124 obtained in Reference Example 67 in place of Compound 64. Then, the resultant crude crystals were recrystallized from ethyl acetate to give 762 mg (yield 90%) of Compound 125 as orange needles.

Melting Point: 246.3°-246.8° C.

Elemental Analysis: C₂₀ H₂₃ N₅ O₆ Calcd. (%): C, 55.94; H, 5.40; N, 16.31 Found (%): C, 55.98; H, 5.42; N, 16.43

IR (KBr) ν_(max) (cm⁻¹): 1692, 1657, 1519, 1273

NMR (270 MHz; CDCl₃) δ (ppm): 8.27(1H, d, J=15.8 Hz), 7.66(1H, s), 7.03(1H, s), 6.77(1H, d, J=15.8 Hz), 4.21(2H, q, J=6.9 Hz), 4.10(3H, s), 4.09(2H, q, J=6.9 Hz), 4.05(3H, s), 4.00(3H, s), 1.37(3H, t, J=6.9 Hz), 1.27(3H, t, J=6.9 Hz)

Reference Example 69 (E)-1,3-Diethyl-8-(3-methoxy-2-nitrostyryl)xanthine (Compound 126)

Substantially the same procedure as in Example 7 was repeated using 2.50 g (12.6 mmol) of 5,6-diamino-1,3-diethyluracil and 3.10 g (13.9 mmol) of 3-methoxy-2-nitrocinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 2.28 g (yield 47%) of Compound 126 as orange needles.

Melting Point: >285° C.

Elemental Analysis: C₁₈ H₁₉ N₅ O₅ Calcd. (%): C, 56.10; H, 4.97; N, 18.17 Found (%): C, 56.37; H, 4.88; N, 17.85

IR (KBr) ν_(max) (cm⁻¹): 1695, 1640, 1533

NMR (270 MHz; DMSO-d₆) δ (ppm): 13.88(1H, brs), 7.60-7.56(2H, m), 7.39(1H, d, J=16.3 Hz), 7.32(1H, dd, J=6.9, 3.0 Hz), 7.21(1H, d, J=16.3 Hz), 4.05(2H, q, J=6.9 Hz), 3.94(2H, q, J=6.9 Hz), 3.91(3H, s), 1.25 (3H, t, J=6.9 Hz), 1.14(3H, t, J=6.9 Hz)

Reference Example 70 (E)-1,3-Diethyl-8-(3-methoxy-2-nitrostyryl)-7-methylxanthine (Compound 127)

Substantially the same procedure as in Example 8 was repeated using 688 mg (1.79 mmol) of Compound 126 obtained in Reference Example 69 in place of Compound 64. Then, the resultant crude crystals were recrystallized from ethyl acetate to give 623 mg (yield 87%) of Compound 127 as yellow needles.

Melting Point: 258.4°-259.9° C.

Elemental Analysis: C₁₉ H₂₁ N₅ O₅ Calcd. (%): C, 57.14; H, 5.30; N, 17.53 Found (%): C, 57.26; H, 5.34; N, 17.26

IR (KBr) ν_(max) (cm⁻¹): 1697, 1546, 1530

NMr (270 MHz; CDCl₃) δ (ppm): 7.62(1H, d, J=15.3 Hz), 7.46(1H, dd, J=8.4, 7.9 Hz), 7.30(1H, d, J=7.9 Hz), 7.05(1H, d, J=8.4 Hz), 6.95(1H, d, J=15.3 Hz), 4.19 (2H, q, J=6.9 Hz), 4.08(2H, q, J=6.9 Hz), 4.05(3H, s), 3.94(3H, s), 1.36(3H, t, J=6.9 Hz), 1.26(3H, t, J=6.9 Hz)

Reference Example 71 (E)-1,3-Diethyl-8-(3-fluorostyryl)xanthine (Compound 128)

Substantially the same procedure as in Example 7 was repeated using 3.00 g (15.1 mmol) of 5,6-diamino-1,3-diethyluracil and 2.77 g (16.7 mmol) of 3-fluorocinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 1.96 g (yield 40%) of Compound 128 as a pale yellow powder.

Melting Point: >270° C.

Elemental Analysis: C₁₇ H₁₇ FN₄ O₂ Calcd. (%): C, 62.19; H, 5.22; N, 17.06 Found (%): C, 61.90; H, 5.21; N, 17.15

IR (KBr) ν_(max) (cm⁻¹): 1692, 1622, 1501

NMR (270 MHZ; CF₃ COOD) δ (ppm): 11.6(1H, brs), 8.05(1H, d, J=16.5 Hz), 7.56-7.46(2H, m), 7.38(1H, d, J=9.2 Hz), 7.29-7.22(1H, m), 7.19(1H, d, J=16.5 Hz), 4.43-4.03(4H, m), 1.52(3H, t, J=7.3 Hz), 1.41(3H, t, J=6.9 Hz)

Reference Example 72 (E)-1,3-Diethyl-8-(3-fluorostyryl)-7-methylxanthine (Compound 129)

Substantially the same procedure as in Example 8 was repeated using 1.80 g (5.49 mmol) of Compound 128 obtained in Reference Example 71 in place of Compound 64. Then, the resultant crude crystals were recrystallized from toluene/cyclohexane to give 1.04 g (yield 55%) of Compound 129 as white needles.

Melting Point: 178.2°-179.4° C.

Elemental Analysis: C₁₈ H₁₉ FN₄ O₂.0.25H₂ O Calcd. (%): C, 62.33; H, 5.67; N, 16.15 Found (%): C, 62.19; H, 5.63; N, 16.26

IR (KBr) ν_(max) (cm⁻¹): 1694, 1650

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.75(1H, dd, J=10.1, 2.0 Hz), 7.66(1H, d, J=15.8 Hz), 7.63-7.60(1H, m), 7.50-7.42(1H, m), 7.44(1H, d, J=15.8 Hz), 7.19(1H, dt, J=2.0, 8.3 Hz), 4.10-4.05(2H, m), 4.05(3H, s), 3.92(2H, q, J=7.0 Hz), 1.26(3H, t, J=7.1 Hz), 1.13 (3H, t, J=7.0 Hz)

Reference Example 73 (E)-8-(3,5-Dimethoxystyryl)-1,3-diethylxanthine (Compound 130)

Substantially the same procedure as in Example 7 was repeated using 3.00 g (15.1 mmol) of 5,6-diamino-1,3-diethyluracil and 3.48 g (16.7 mmol) of 3,5-dimethoxycinnamic acid. Then, the resultant crude crystals were recrystallized from ethanol/water to give 2.74 g (yield 49%) of Compound 130 as a white powder.

Melting Point: >270° C.

Elemental Analysis: C₁₉ H₂₂ N₄ O₄.0.5H₂ O Calcd. (%): C, 60.15; H, 6.11; N, 14.77 Found (%): C, 60.41; H, 6.15; N, 15.02

IR (KBr) ν_(max) (cm⁻¹) 1686, 1638, 1587

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.57(1H, d, J=16.5 Hz), 7.07(1H, d, J=16.5 Hz), 6.79(2H, d, J=2.0 Hz), 6.50 (1H, t, J=2.0 Hz), 4.06(2H, q, J=7.0 Hz), 3.94(2H, q, J=6.9 Hz), 3.79(6H, s), 1.26(3H, t, J=7.0 Hz), 1.14(3H, t, J=6.9 Hz)

Reference Example 74 (E)-8-(3,5-Dimethoxystyryl)-1,3-diethyl-7-methylxanthine (Compound 131)

Substantially the same procedure as in Example 8 was repeated using 3.00 g (8.11 mmol) of Compound 130 obtained in Reference Example 73 in place of Compound 64. Then, the resultant crude crystals were recrystallized from toluene/cyclohexane to give 2.28 g (yield 73%) of Compound 131 as yellow needles.

Melting Point: 184.2°-185.3° C.

Elemental Analysis: C₂₀ H₂₄ N₄ O₄ Calcd. (%): C, 62.49; H, 6.29; N, 14.57 Found (%): C, 62.66; H, 6.48; N, 14.65

IR (KBr) ν_(max) (cm⁻¹): 1690, 1659, 1595

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.60(1H, d, J=15.7 Hz), 7.35(1H, d, J=15.7 Hz), 6.98(2H, d, J=2.2 Hz), 6.51 (1H, t, J=2.2 Hz), 4.11-4.01(2H, m), 4.05(3H, s), 3.92(2H, q, J=7.0 Hz), 3.80(6H, s), 1.26(3H, t, J=7.1 Hz), 1.13(3H, t, J=7.0 Hz)

Reference Example 75 (E)-8-(3-Chlorostyryl)-1,3-diethylxanthine (Compound 132)

Substantially the same procedure as in Example 7 was repeated using 3.50 g (17.7 mmol) of 5,6-diamino-1,3-diethyluracil and 3.55 g (19.4 mmol) of 3-chlorocinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 2.57 g (yield 42%) of Compound 132 as white plates.

Melting Point: >280° C.

Elemental Analysis: C₁₇ H₁₇ ClN₄ O₂ Calcd. (%): C, 59.22; H, 4.97; N, 16.25 Found (%): C, 59.12; H, 5.01; N, 16.30

IR (KBr) ν_(max) (cm⁻¹): 1689, 1640, 1490

NMR (270 MHz; CF₃ COOD) δ (ppm): 8.35(1H, d, J=16.4 Hz), 8.01(1H, s), 7.52-7.36(3H, m), 7.14(1H, d, J=16.4 Hz), 4.37-4.23(4H, m), 1.45(3H, t, J=6.8 Hz), 1.34(3H, t, J=6.9 Hz)

Reference Example 76 (E)-8-(3-Chlorostyryl)-1,3-diethyl-7-methylxanthine (Compound 133)

Substantially the same procedure as in Example 8 was repeated using 3.00 g (8.72 mmol) of Compound 132 obtained in Reference Example 75 in place of Compound 64. Then, the resultant crude crystals were recrystallized from ethanol/water to give 1.41 g (yield 45%) of Compound 133 as a pale yellow powder.

Melting Point: 134.0°-134.4° C.

Elemental Analysis: C₁₈ H₁₉ ClN₄ O₂.H₂ O Calcd. (%): C, 57.37; H, 5.62; N, 14.87 Found (%): C, 57.67; H, 5.51; N, 14.92

IR (KBr) ν_(max) (cm⁻¹): 1688, 1656, 1545

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.98(1H, s), 7.72(1H, t, J=2.0 Hz), 7.63(1H, d, J=15.8 Hz), 7.49-7.39(3H, m), 4.11-4.03(2H, m), 4.05(3H, s), 3.92(2H, q, J=6.9 Hz), 1.26(3H, t, J=6.9 Hz), 1.13(3H, t, J=6.9 Hz)

Reference Example 77 (E)-1,3-Diethyl-8-(α-methylstyryl)xanthine (Compound 134)

Substantially the same procedure as in Example 7 was repeated using 2.00 g (10.1 mmol) of 5,6-diamino-1,3-diethyluracil and 1.80 g (11.1 mmol) of α-methylcinnamic acid. Then, the resultant crude crystals were recrystallized from ethanol/water to give 1.63 g (yield 50%) of Compound 134 as white needles.

Melting Point: 250.8°-252.0° C.

Elemental Analysis: C₁₈ H₂₀ N₄ O₂ Calcd. (%): C, 66.65; H, 6.21; N, 17.27 Found (%): C, 66.62; H, 6.30; N, 17.31

IR (KBr) ν_(max) (cm⁻¹): 1696, 1657, 1493

NMR (270 MHz; DMSO-d₆) δ (ppm): 13.44(1H, brs), 7.61 (1H, d, J=1.3 Hz), 7.49-7.30(6H, m), 4.07(2H, q, J=7.0 Hz), 3.95(2H, q, J=6.9 Hz), 2.31(3H, d, J=1.3 Hz), 1.26(3H, t, J=7.0 Hz), 1.14(3H, t, J=6.9 Hz)

Reference Example 78 (E)-1,3-Diethyl-7-methyl-8-(α-methylstyryl)xanthine (Compound 135)

Substantially the same procedure as in Example 8 was repeated using 1.00 g (3.09 mmol) of Compound 134 obtained in Reference Example 77 in place of Compound 64. Then, the resultant crude crystals were recrystallized from ethanol/2-propanol to give 800 mg (yield 77%) of Compound 135 as white needles.

Melting Point: 137.2°-139.3° C.

Elemental Analysis: C₁₉ H₂₂ N₄ O₂ Calcd. (%): C, 67.44; H, 6.55; N, 16.56 Found (%): C, 67.01; H, 6.73; N, 16.62

IR (KBr) ν_(max) (cm⁻¹): 1699, 1654, 1537

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.52-7.32(5H, m), 7.00 (1H, d, J=1.3 Hz), 4.04(2H, q, J=7.2 Hz), 4.00(3H, s), 3.94(2H, q, J=6.9 Hz), 2.29(3H, d, J=1.3 Hz), 1.24(3H, t, J=7.2 Hz), 1.13(3H, t, J=6.9 Hz)

Reference Example 79 (E)-1,3-Diethyl-8-(4-trifluoromethylstyryl)xanthine (Compound 136)

Substantially the same procedure as in Example 7 was repeated using 2.20 g (11.2 mmol) of 5,6-diamino-1,3-diethyluracil and 2.66 g (12.3 mmol) of 4-trifluoromethylcinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 2.09 g (yield 49%) of Compound 136 as a white powder.

Melting Point: >280° C.

Elemental Analysis: C₁₈ H₁₇ F₃ N₄ O₂ Calcd. (%): C, 57.14; H, 4.53; N, 14.81 Found (%): C, 57.25; H, 4.51; N, 14.82

IR (KBr) ν_(max) (cm⁻¹): 1696, 1654, 1637, 1324

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.86(2H, d, J=8.1 Hz), 7.76(2H, d, J=8.1 Hz), 7.70(1H, d, J=16.5 Hz), 7.20 (1H, d, J=16.5 Hz), 4.07(2H, q, J=7.1 Hz), 3.94(2H, q, J=7.0 Hz), 1.26(3H, t, J=7.1 Hz), 1.14(3H, t, J=7.0 Hz)

Reference Example 80 (E)-1,3-Diethyl-7-methyl-8-(4-trifluoromethylstyryl)xanthine (Compound 137)

Substantially the same procedure as in Example 8 was repeated using 1.30 g (3.44 mmol) of Compound 136 obtained in Reference Example 79 in place of Compound 64. Then, the resultant crude crystals were recrystallized from toluene/cyclohexane to give 990 mg (yield 73%) of Compound 137 as yellow needles.

Melting Point: 207.8°-209.0° C.

Elemental Analysis: C₁₉ H₁₉ F₃ N₄ O₂ Calcd. (%): C, 58.16; H, 4.88; N, 14.28 Found (%): C, 58.22; H, 4.84; N, 14.32

IR (KBr) ν_(max) (cm⁻¹): 1700, 1667, 1325

NMR (270 MHz; DMSO-d₆) δ (ppm): 8.03(2H, d, J=8.3 Hz), 7.76(2H, d, J=8.3 Hz), 7.73(1H, d, J=15.8 Hz), 7.53 (1H, d, J=15.8 Hz), 4.11-4.03(2H, m), 4.09(3H, s), 3.92(2H, q, J=7.0 Hz), 1.27(3H, t, J=6.9 Hz), 1.13(3H, t, J=7.0 Hz)

Reference Example 81 (E)-1,3-Diethyl-8-(α-fluorostyryl)xanthine (Compound 138)

Substantially the same procedure as in Example 7 was repeated using 1.08 g (5.47 mmol) of 5,6-diamino-1,3-diethyluracil and 1.00 g (6.02 mmol) of α-fluorocinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 1.04 g (yield 58%) of Compound 138 as white plates.

Melting Point: >280° C.

Elemental Analysis: C₁₇ H₁₇ FN₄ O₂ Calcd. (%): C, 62.19; H, 5.22; N, 17.06 Found (%): C, 62.28; H, 5.22; N, 17.07

IR (KBr) ν_(max) (cm⁻¹): 1695, 1644, 1506

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.68(2H, d, J=6.9 Hz), 7.47-7.35(3H, m), 6.93(1H, d, J=36.3 Hz), 4.06(2H, q, J=6.9 Hz), 3.94(2H, q, J=7.0 Hz), 1.26(3H, t, J=6.9 Hz), 1.14(3H, t, J=7.0 Hz)

Reference Example 82 (E)-1,3-Diethyl-8-(α-fluorostyryl)-7-methylxanthine (Compound 139)

Substantially the same procedure as in Example 8 was repeated using 800 mg (2.44 mmol) of Compound 138 obtained in Reference Example 81 in place of Compound 64. Then, the resultant crude crystals were recrystallized from toluene/cyclohexane to give 550 mg (yield 66%) of Compound 139 as a white powder.

Melting Point: 153.5°-155.5° C.

Elemental Analysis: C₁₈ H₁₉ FN₄ O₂ Calcd. (%): C, 63.15; H, 5.59; N, 16.36 Found (%): C, 63.25; H, 5.66; N, 16.44

IR (KBr) ν_(max) (cm⁻¹): 1696, 1662, 1539

NMR (270 MHz; CDCl₃) δ (ppm): 7.68-7.65(2H, m), 7.47-7.31(3H, m), 6.89(1H, d, J=39.3 Hz), 4.13-4.05(2H, m), 4.21(3H, s), 4.09(2H, q, J=7.1 Hz), 1.37(3H, t, J=7.1 Hz), 1.27(3H, t, J=7.1 Hz)

Reference Example 83 (E)-8-(4-Bromostyryl)-1,3-diethylxanthine (Compound 140)

Substantially the same procedure as in Example 7 was repeated using 2.20 g (11.1 mmol) of 5,6-diamino-1,3-diethyluracil and 2.78 g (12.2 mmol) of 4-bromocinnamic acid. Then, the resultant crude crystals were recrystallized from tetrahydrofuran/water to give 930 mg (yield 22%) of Compound 140 as yellow columns.

Melting Point: >270° C.

Elemental Analysis: C₁₇ H₁₇ BrN₄ O₂ Calcd. (%): C, 52.46; H, 4.40; N, 14.39 Found (%): C, 52.41; H, 4.28; N, 14.43

IR (KBr) ν_(max) (cm⁻¹): 1686, 1619, 1496

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.63-7.18(4H, m), 7.60 (1H, d, J=16.2 Hz), 7.07(1H, d, J=16.2 Hz), 4.06(2H, q, J=6.9 Hz), 3.94(2H, q, J=6.8 Hz), 1.26(3H, t, J=6.9 Hz), 1.14(3H, t, J=6.8 Hz)

Reference Example 84 (E)-8-(4-Bromostyryl)-1,3-diethyl-7-methylxanthine (Compound 141)

Substantially the same procedure as in Example 8 was repeated using 1.80 g (4.63 mmol) of Compound 143 obtained in Reference Example 83 in place of Compound 64. Then, the resultant crude crystals were recrystallized from toluene/ethanol to give 660 mg (yield 35%) of Compound 141 as pale yellow needles.

Melting Point: 198.5°-198.9° C.

Elemental Analysis: C₁₈ H₁₉ BrN₄ O₂.0.25H₂ O Calcd. (%): C, 53.02; H, 4.82; N, 13.74 Found (%): C, 53.09; H, 4.62; N, 13.79

IR (KBr) ν_(max) (cm⁻¹): 1691, 1662, 1543

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.78(2H, d, J=7.6 Hz), 7.67-7.61(3H, m), 7.41(1H, d, J=16.2 Hz), 4.11-4.04 (2H, m), 4.04(3H, s), 3.92(2H, q, J=6.7 Hz), 1.26 (3H, t, J=6.8 Hz), 1.13(3H, t, J=6.7 Hz)

Reference Example 85 (E)-1,3-Diethyl-8-(3-trifluoromethoxystyryl)xanthine (Compound 142)

Substantially the same procedure as in Example 7 was repeated using 1.00 g (5.05 mmol) of 5,6-diamino-1,3-diethyluracil and 1.2 9 g (5.56 mmol ) of 3-trifluoromethoxycinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 1.19 g (yield 60%) of Compound 142 as white needles.

Melting Point: 266.4°-267.3° C.

Elemental Analysis: C₁₈ H₁₇ F₃ N₄ O₃ Calcd. (%): C, 54.83; H, 4.34; N, 14.21 Found (%): C, 54.79; H, 4.22; N, 14.20

IR (KBr) ν_(max) (cm⁻¹): 1697, 1658, 1500, 1262

NMR (270 MHz; DMSO-d₆) δ (ppm): 13.57(1H, brs), 7.67 (1H, d, J=16.5 Hz), 7.66(1H, d, J=7.9 Hz), 7.63(1H, s), 7.55(1H, t, J=7.9 Hz), 7.34(1H, d, J=7.9 Hz), 7.14(1H, d, J=16.5 Hz), 4.07(2H, q, J=6.9 Hz), 3.94 (2H, q, J=6.9 Hz), 1.27(3H, t, J=6.9 Hz), 1.14(3H, t, J=6.9 Hz)

Reference Example 86 (E)-1,3-Diethyl-7-methyl-8-(3-trifluoromethoxystyryl)xanthine (Compound 143)

Substantially the same procedure as in Example 8 was repeated using 700 mg (1.78 mmol) of Compound 142 obtained in Reference Example 85 in place of Compound 64. Then, the resultant crude crystals were recrystallized from ethyl acetate to give 329 mg (yield 45%) of Compound 143 as white needles.

Melting Point: 178.7°-179.3° C.

Elemental Analysis: C₁₉ H₁₉ F₃ N₄ O₃ Calcd. (%): C, 55.88; H, 4.69; N, 13.72 Found (%): C, 56.27; H, 4 . 68; N, 13.67

IR (KBr) ν_(max) (cm⁻¹): 1694, 1660, 1265, 1213

NMR (270 MHz; CDCl₃) δ (ppm): 7.77(1H, d, J=15.8 Hz), 7.53-7.20(4H, m), 6.93(1H, d, J=15.8 Hz), 4.21(2H, q, J=6.9 Hz), 4.09(2H, q, J=6.9 Hz), 4.08(3H, s), 1.38(3H, t, J=6.9 Hz), 1.27(3H, t, J=6.9 Hz)

Reference Example 87 (E)-1,3-Diethyl-8-(4-methoxymethoxystyryl)xanthine (Compound 144)

Substantially the same procedure as in Example 7 was repeated using 4.00 g (20.2 mmol) of 5,6-diamino-1,3-diethyluracil and 4.62 g (22.2 mmol) of 4-methoxymethoxycinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 4.80 g (yield 64%) of Compound 144 as pale yellow needles.

Melting Point: 270.2°-271.4° C.

Elemental Analysis: C₁₉ H₂₂ N₄ O₄ Calcd. (%): C, 61.61; H, 5.98; N, 15.13 Found (%): C, 61.97; H, 5.98; N, 15.05

IR (KBr) ν_(max) (cm⁻¹): 1695, 1641, 1510, 1238

NMR (270 MHz; DMSO-d₆) δ (ppm): 13.40(1H, brs), 7.60 (1H, d, J=16.5 Hz), 7.57(2H, d, J=8.6 Hz), 7.06(2H, d, J=8.6 Hz), 6.90(1H, d, J=16.5 Hz), 5.23(2H, s), 4.07 (2H, q, J=6.9 Hz), 3.94(2H, q, J=6.9 Hz), 3.39 (3H, s), 1.26(3H, t, J=6.9 Hz), 1.14(3H, t, J=6.9 Hz)

Reference Example 88 (E)-1,3-Diethyl-8-(4-methoxymethoxystyryl)-7-methylxanthine (Compound 145)

Substantially the same procedure as in Example 8 was repeated using 3.50 g (9.45 mmol) of Compound 144 obtained in Reference Example 87 in place of Compound 64. Then, the resultant crude crystals were recrystallized from hexane/ethyl acetate to give 3.39 g (yield 93%) of Compound 145 as pale yellow plates.

Melting Point: 163.9°-164.7° C.

Elemental Analysis: C₂₀ H₂₄ N₄ O₄ Calcd. (%): C, 62.49; H, 6.29; N, 14.57 Found (%): C, 62.21; H, 6.27; N, 14.58

IR (KBr) ν_(max) (cm⁻¹): 1688, 1651, 1510, 1238

NMR (270 MHz; CDCl₃) δ (ppm): 7.75(1H, d, J=15.8 Hz), 7.53(2H, d, J=8.6 Hz), 7.07(2H, d, J=8.6 Hz), 6.79 (1H, d, J=15.8 Hz), 5.21(2H, s), 4.21(2H, q, J=6.9 Hz), 4.09(2H, q, J=6.9 Hz), 4.05(3H, s), 3.50 (3H, s), 1.38(3H, t, J=6.9 Hz), 1.26(3H, t, J=6.9 Hz)

Reference Example 89 (E)-1,3-Diethyl-8-(4-fluorostyryl)xanthine (Compound 146)

Substantially the same procedure as in Example 7 was repeated using 2.50 g (12.6 mmol) of 5,6-diamino-1,3-diethyluracil and 2.31 g (13.9 mmol) of 4-fluorocinnamic acid. Then, the resultant crude crystals were recrystallized from tetrahydrofuran/water to give 2.00 g (yield 51%) of Compound 146 as colorless columns.

Melting Point: >270° C.

Elemental Analysis: C₁₇ H₁₇ FN₄ O₂ Calcd. (%): C, 62.19; H, 5.22; N, 17.06 Found (%): C, 62.02; H, 5.12; N, 17.02

IR (KBr) ν_(max) (cm⁻¹): 1689, 1560, 1508

NMR (270 MHz; DMSO-d₆) δ (ppm): 8.06(1H, d, J=16.3 Hz), 7.72(2H, dd, J=8.6, 5.2 Hz), 7.21(2H, t, J=8.6 Hz), 7.10(1H, d, J=16.3 Hz), 4.43-4.30(4H, m), 1.53(3H, t, J=7.2 Hz), 1.41(3H, t, J=7.2 Hz)

Reference Example 90 (E)-1,3-Diethyl-8-(4-fluorostyryl)-7-methylxanthine (Compound 147)

Substantially the same procedure as in Example 8 was repeated using 1.80 g (5.18 mmol) of Compound 146 obtained in Reference Example 89 in place of Compound 64. Then, the resultant crude crystals were recrystallized from toluene/cyclohexane to give 510 mg (yield 29%) of Compound 147 as white needles.

Melting Point: 182.0°-182.5° C.

Elemental Analysis: C₁₈ H₁₉ FN₄ O₂ Calcd. (%): C, 63.15; H, 5.59; N, 16.36 Found (%): C, 63.18; H, 5.61; N, 16.40

IR (KBr) ν_(max) (cm⁻¹): 1687, 1654, 1514

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.88(2H, dd, J=8.1, 5.8 Hz), 7.67(1H, d, J=15.8 Hz), 7.41-7.24(3H, m), 4.11-4.03(2H, m), 4.03(3H, s), 3.92(2H, q, J=6.8 Hz), 1.26(3H, t, J=6.9 Hz), 1.13(3H, t, J=6.8 Hz)

Reference Example 91 (E)-8-[3,5-Bis(trifluoromethyl)styryl]-1,3-diethylxanthine (Compound 148)

Substantially the same procedure as in Example 7 was repeated using 3.00 g (15.1 mmol) of 5,6-diamino-1,3-diethyluracil and 4.73 g (16.7 mmol) of 3,5-bis(trifluoromethyl)cinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane to give 4.09 g (yield 61%) of Compound 148 as pale yellow needles.

Melting Point: >280° C.

Elemental Analysis: C₁₉ H₁₆ F₆ N₄ O₂ Calcd. (%): C, 51.13; H, 3.61; N, 12.55 Found (%): C, 50.96; H, 3.40; N, 12.52

IR (KBr) ν_(max) (cm⁻¹): 1694, 1649, 1495, 1287

NMR (270 MHz; DMSO-d₆) δ (ppm): 13.75(1H, brs), 8.35 (2H, s), 8.05(1H, s), 7.80(1H, d, J=16.5 Hz), 7.40 (1H, d, J=16.5 Hz), 4.08(2H, q, J=6.9 Hz), 3.94(2H, q, J=6.9 Hz), 1.27(3H, t, J=6.9 Hz), 1.14(3H, t, J=6.9 Hz)

Reference Example 92 (E)-8-[3,5-Bis(trifluoromethyl)styryl]-1,3-diethyl-7-methylxanthine (Compound 149)

Substantially the same procedure as in Example 8 was repeated using 2.00 g (4.68 mmol) of Compound 148 obtained in Reference Example 91 in place of Compound 64. Then, the resultant crude crystals were recrystallized from dioxane/water to give 1.43 g (yield 69%) of Compound 149 as pale green needles.

Melting Point: 204.9°-205.1° C. MS-EI m/e: 460(M⁺)

IR (KBr) ν_(max) (cm⁻¹): 1699, 1653, 1546, 1282

NMR (270 MHz; CDCl₃) δ (ppm): 8.55(2H, s), 8.01(1H, s), 7.85(1H, d, J=15.8 Hz), 7.72(1H, d, J=15.8 Hz), 4.09 (3H, s), 4.08(2H, q, J=6.9 Hz), 3.93(2H, q, J=6.9 Hz), 1.28(3H, t, J=6.9 Hz), 1.14(3H, t, J=6.9 Hz)

Reference Example 93 (E)-8-(3,5-Difluorostyryl)-1,3-diethylxanthine (Compound 150)

Substantially the same procedure as in Example 7 was repeated using 3.00 g (15.1 mmol) of 5,6-diamino-1,3-diethyluracil and 3.06 g (16.6 mmol) of 3,5-difluorocinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 3.30 g (yield 63%) of Compound 150 as pale yellow plates.

Melting Point: >280° C.

Elemental Analysis: C₁₇ H₁₆ F₂ N₄ O₂ Calcd. (%): C, 58.96; H, 4.65; N, 16.18 Found (%): C, 58.82; H, 4.65; N, 16.07

IR (KBr) ν_(max) (cm⁻¹): 1686, 1634, 1589, 1489

NMR (270 MHz; DMSO-d₆) δ (ppm): 13.66(1H, brs), 7.60 (1H, d, J=16.5 Hz), 7.36(2H, dd, J=8.6, 2.0 Hz), 7.20(1H, dt, J=9.2, 2.0 Hz), 7.16(1H, d, J=16.5 Hz), 4.07(2H, q, J=6.9 Hz), 3.94(2H, q, J=6.9 Hz), 1.26 (3H, t, J=6.9 Hz), 1.14(3H, t, J=6.9 Hz)

Reference Example 94 (E)-8-(3,5-Difluorostyryl)-1,3-diethyl-7-methylxanthine (Compound 151)

Substantially the same procedure as in Example 8 was repeated using 2.00 g (5.78 mmol) of Compound 150 obtained in Reference Example 93 in place of Compound 64. Then, the resultant crude crystals were recrystallized from hexane/ethyl acetate to give 1.80 g (yield 87%) of Compound 151 as pale yellow needles.

Melting Point: 177.0°-178.6° C. MS-EI m/e: 360(M⁺)

IR (KBr) ν_(max) (cm⁻¹): 1683, 1619, 1593, 1543

NMR (270 MHz; CDCl₃) δ (ppm): 7.70(1H, d, J=15.5 Hz), 7.09(2H, dd, J=8.3, 2.0 Hz), 6.91(1H, d, J=15.5 Hz), 6.81(1H, dt, J=8.6, 2.0 Hz), 4.21(2H, q, J=6.9 Hz), 4.09(2H, q, J=6.9 Hz), 4.08(3H, s), 1.38(3H, t, J=6.9 Hz), 1.27(3H, t, J=6.9 Hz)

Reference Example 95 (E)-1,3-Diethyl-8-(3-nitrostyryl)xanthine (Compound 152)

Substantially the same procedure as in Example 7 was repeated using 2.5 g (12.6 mmol) of 5,6-diamino-1,3-diethyluracil and 2.68 g (13.9 mmol) of 3-nitrocinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 2.01 g (yield 30%) of Compound 152 as a yellow powder.

Melting Point: >270° C.

Elemental Analysis: C₁₇ H₁₇ N₅ O₄.0.25C₄ H₈ O₂ Calcd. (%): C, 57.29; H, 5.07; N, 18.56 Found (%): C, 57.38; H, 5.06; N, 18.63

IR (KBr) ν_(max) (cm⁻¹): 1688, 1640, 1530

NMR (270 MHz; DMSO-d₆) δ (ppm): 8.42(1H, d, J=1.7 Hz), 8.18(1H, dd, J=8.3, 1.7 Hz), 8.12(1H, d, J=7.9 Hz), 7.75(1H, d, J=16.5 Hz), 7.71(tH, t, J=7.9 Hz), 7.24 (1H, d, J=16.5 Hz), 4.08(2H, q, J=7.0 Hz), 3.94(2H, q, J=7.0 Hz), 1.27(3H, t, J=7.0 Hz), 1.14(3H, t, J=7.0 Hz)

Reference Example 96 (E)-1,3-Diethyl-7-methyl-8-(3-nitrostyryl)xanthine (Compound 153)

Substantially the same procedure as in Example 8 was repeated using 700 mg (1.97 mmol) of Compound 152 obtained in Reference Example 95 in place of Compound 64. Then, the resultant crude crystals were recrystallized from acetonitrile to give 340 mg (yield 47%) of Compound 153 as a yellow powder.

Melting Point: 250.5°-251.7° C.

Elemental Analysis: C₁₈ H₁₉ N₅ O₄ Calcd. (%): C, 58.53; H, 5.18; N, 18.96 Found (%): C, 58.47; H, 5.13; N, 18.89

IR (KBr) ν_(max) (cm⁻¹): 1699, 1666, 1524

NMR (270 MHz; DMSO-d₆) δ (ppm): 8.72(1H, s), 8.25(1H, d, J=7.9 Hz), 8.19(1H, d, J=7.4 Hz), 7.79(1H, d, J=15.8 Hz), 7.72(1H, t, J=7.9 Hz), 7.63(1H, d, J=15.8 Hz), 4.12-4.05(2H, m), 4.08(3H, s), 3.93(2H, q, J=7.2 Hz), 1.27(3H, t, J=7.2 Hz), 1.13(3H, t, J=7.2 Hz)

Reference Example 97 (E)-8-(3-Bromostyryl)-1,3-diethylxanthine (Compound 154)

Substantially the same procedure as in Example 7 was repeated using 2.0 g (10.1 mmol) of 5,6-diamino-1,3-diethyluracil and 2.52 g (11.1 mmol) of 3-bromocinnamic acid. Then, the resultant crude crystals were recrystallized from tetrahydrofuran/water to give 2.01 g (yield 37%) of Compound 154 as pale green plates.

Melting Point: >270° C.

Elemental Analysis: C₁₇ H₁₇ BrN₄ O₂ Calcd. (%): C, 52.46; H, 4.40; N, 14.39 Found (%): C, 52.54; H, 4.44; N, 14.37

IR (KBr) ν_(max) (cm⁻¹): 1683, 1636, 1492

NMR (270 MHz; CF₃ COOD) δ (ppm): 7.99(1H, d, J=16.6 Hz), 7.84(1H, s), 7.70(1H, d, J=7.9 Hz), 7.62(1H, d, J=7.9 Hz), 7.40(1H, t, J=7.9 Hz), 7.19(1H, d, J=16.6 Hz), 4.40-4.30(4H, m), 1.53(3H, t, J=7.2 Hz), 1.41(3H, t, J=7.2 Hz)

Reference Example 98 (E)-8-(3-Bromostyryl)-1,3-diethyl-7-methylxanthine (Compound 155)

Substantially the same procedure as in Example 8 was repeated using 2.5 g (6.43 mmol) of Compound 154 obtained in Reference Example 97 in place of Compound 64. Then, the resultant crude crystals were recrystallized from toluene/cyclohexane to give 600 mg (yield 69%) of Compound 155 as a yellow powder.

Melting Point: 187.3°-188.2° C.

Elemental Analysis: C₁₈ H₁₉ BrN₄ O₂ Calcd. (%): C, 53.61; H, 4.75; N, 13.89 Found (%): C, 53.83; H, 4.63; N, 13.70

Ir (KBr) ν_(max) (cm⁻¹): 1694, 1654

NMR (270 MHz; DMSO-d₆) δ (ppm): 8.13(1H, s), 7.76(1H, d, J=7.6 Hz), 7.63(1H, d, J=15.8 Hz), 7.54(1H, d, J=8.9 Hz), 7.46(1H, d, J=15.8 Hz), 7.37(1H, t, J=8.2 Hz), 4.11-4.03(2H, m), 4.05(3H, s), 3.92(2H, q, J=6.9 Hz), 1.26(3H, t, J=6.9 Hz), 1.13(3H, t, J=6.9 Hz)

Reference Example 99 (E)-1,3-Diethyl-8-(3-trifluoromethylstyryl)xanthine (Compound 156)

Substantially the same procedure as in Example 7 was repeated using 2.50 g (12.6 mmol) of 5,6-diamino-1,3-diethyluracil and 3.0 g (13.9 mmol) of 3-trifluoromethylcinnamic acid. Then, the resultant crude crystals were recrystallized from acetonitrile/water to give 2.07 g (yield 44%) of Compound 156 as white needles.

Melting Point: >270° C.

Elemental Analysis: C₁₈ H₁₇ F₃ N₄ O₂ Calcd. (%): C, 57.14; H, 4.53; N, 14.81 Found (%): C, 57.15; H, 4.47; N, 14.65

IR (KBr) ν_(max) (cm⁻¹) 1691, 1641, 1495, 1334

NMR (270 MHz; DMSO-d₆) δ (ppm): 13.65(1H, brs), 7.99-7.95(2H, m), 7.76-7.63(3H, m), 7.21(1H, d, J=16.1 Hz), 4.07(2H, q, J=6.9 Hz), 3.94(2H, q, J=6.7 Hz), 1.27(3H, t, J=6.9 Hz), 1.14(3H, t, J=6.7 Hz)

Reference Example 100 (E)-1,3-Diethyl-7-methyl-8-(3-trifluoromethylstyryl)xanthine (Compound 157)

Substantially the same procedure as in Example 8 was repeated using 1.70 g (4.50 mmol) of Compound 156 obtained in Reference Example 99 in place of Compound 64. Then, the resultant crude crystals were recrystallized from toluene/cyclohexane to give 1.14 g (yield 65%) of Compound 157 as a pale yellow powder.

Melting Point: 214.8°-215.3° C.

Elemental Analysis: C₁₉ H₁₉ F₃ N₄ O₂ Calcd. (%): C, 58.16; H, 4.88; N, 14.28 Found (%): C, 58.13; H, 4.90; N, 14.22

IR (KBr) ν_(max) (cm⁻¹): 1697, 1664

NMR (270 MHz; DMSO-d₆) δ (ppm): 8.26(1H, s), 8.09(1H, d, J=7.4 Hz), 7.75(1H, d, J=15.8 Hz), 7.69-7.62(2H, m), 7.56(1H, d, J=15.8 Hz), 4.12-4.00(2H, m), 4.07 (3H, s), 3.92(2H, q, J=6.9 Hz), 1.27(3H, t, J=6.9 Hz), 1.13(3H, t, J=6.9 Hz)

Reference Example 101 (E)-1,3-Diethyl-8-(2-fluorostyryl)xanthine (Compound 160)

Substantially the same procedure as in Example 7 was repeated using 2.70 g (13.6 mmol) of 5,6-diamino-1,3-diethyluracil and 2.49 g (15.0 mmol) of 2-fluorocinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 1.81 g (yield 41%) of Compound 160 as a white powder.

Melting Point: >270° C.

Elemental Analysis: C₁₇ H₁₇ FN₄ O₂ Calcd. (%): C, 62.19; H, 5.22; N, 17.06 Found (%): C, 62.31; H, 5.23; N, 17.09

IR (KBr) ν_(max) (cm⁻¹): 1687, 1650, 1557, 1498, 1451

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.81(1H, t, J=7.9 Hz), 7.72(1H, d, J=16.3 Hz), 7.42-7.25(3H, m), 7.15(1H, d, J=16.3 Hz), 4.07(2H, q, J=6.9 Hz), 3.94(2H, q, J=6.9 Hz), 1.26(3H, t, J=6.9 Hz), 1.14(3H, t, J=6.9 Hz)

Reference Example 102 (E)-1,3-Diethyl-8-(2-fluorostyryl)-7-methylxanthine (Compound 161)

Substantially the same procedure as in Example 8 was repeated using 1.30 g (3.96 mmol) of Compound 160 obtained in Reference Example 101 in place of Compound 64. Then, the resultant crude crystals were recrystallized from toluene/cyclohexane to give 440 mg (yield 32%) of Compound 161 as white needles.

Melting Point: 184.1°-184.6° C.

Elemental Analysis: C₁₈ H₁₉ FN₄ O₂ Calcd. (%): C, 63.15; H, 5.59; N, 16.36 Found (%): C, 63.01; H, 5.61; N, 16.27

IR (KBr) ν_(max) (cm⁻¹): 1697, 1668, 1541

NMR (270 MHz; DMSO-d₆) δ (ppm): 8.04(1H, t, J=8.4 Hz), 7.77(1H, d, J=15.8 Hz), 7.47-7.43(1H, m), 7.45(1H, d, J=15.8 Hz), 7.35-7.27(2H, m), 4.11-4.04(2H, m), 4.04(3H, s), 3.92(2H, q, J=7.0 Hz), 1.26(3H, t, J=6.9 Hz), 1.13(3H, t, J=7.0 Hz)

Reference Example 103 (E)-8-[4-(N,N-Dimethylamino)styryl]-1,3-diethylxanthine (Compound 162)

Substantially the same procedure as in Example 7 was repeated using 3.00 g (15.1 mmol) of 5,6-diamino-1,3-diethyluracil and 3.30 g (17.3 mmol) of 4-(N,N-dimethylamino)cinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane to give 2.78 g (yield 52%) of Compound 162 as yellow needles.

Melting Point: >300° C.

Elemental Analysis: C₁₉ H₂₃ N₅ O₂ Calcd. (%): C, 64.57; H, 6.56; N, 19.82 Found (%): C, 64.78; H, 6.73; N, 19.94

IR (KBr) ν_(max) (cm⁻¹): 1691, 1650, 1606, 1530

NMR (270 MHz; DMSO-d₆) δ (ppm): 13.20(1H, brs), 7.54 (1H, d, J=16.2 Hz), 7.44(2H, d, J=8.6 Hz), 6.75(1H, d, J=16.2 Hz), 6.74(2H, d, J=8.6 Hz), 4.06(2H, q, J=6.9 Hz), 3.94(2H, q, J=6.9 Hz), 2.97(6H, s), 1.26 (3H, t, J=6.9 Hz), 1.14(3H, t, J=6.9 Hz)

Reference Example 104 (E)-1,3-Diethyl-8-(4-phenylstyryl)xanthine (Compound 163)

Substantially the same procedure as in Example 7 was repeated using 2.50 g (12.6 mmol) of 5,6-diamino-1,3-diethyluracil and 3.12 g (13.9 mmol) of 4-phenylcinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 1.90 g (yield 39%) of Compound 163 as yellow flocculent precipitates.

Melting Point: >270° C.

Elemental Analysis: C₂₃ H₂₂ N₄ O₂.0.25H₂ O Calcd. (%): C, 70.66; H, 5.80; N, 14.33 Found (%): C, 70.90; H, 5.75; N, 14.32

IR (KBr) ν_(max) (cm⁻¹): 1689, 1639, 1492

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.80-7.65(7H, m), 7.49 (2H, t, J=7.3 Hz), 7.39(1H, t, J=7.3 Hz), 7.10(1H, d, J=16.3 Hz), 4.07(2H, q, J=7.1 Hz), 3.94(2H, q, J=6.8 Hz), 1.27(3H, t, J=7.1 Hz), 1.14(3H, t, J=6.8 Hz)

Reference Example 105 (E)-1,3-Diethyl-7-methyl-8-(4-phenylstyryl)xanthine (Compound 164)

Compound 163 (1.50 g, 3.89 mmol) obtained in Reference Example 104 was suspended in a mixed solvent of 13 ml of water, 3.9 ml of a 2N aqueous solution of sodium hydroxide, and 7 ml of methanol. To the suspension was dropwise added 0.55 ml (5.83 mmol) of dimethyl sulfate, and the resultant mixture was stirred at 60° C. for 4 hours. Water (10 ml) was added thereto, and the deposited crystals were collected by filtration and dried. The obtained crude crystals were purified by silica gel column chromatography, followed by recrystallization from ethyl acetate to give 480 mg (yield 28%) of Compound 164 as yellow columns.

Melting Point: 200.5°-201.3° C.

Elemental Analysis: C₂₄ H₂₄ N₄ O₂.0.5CH₃ CO₂ C2H₅ Calcd. (%): C, 70.25; H, 6.35; N, 12.72 Found (%): C, 70.36; H, 6.47; N, 12.60

IR (KBr) ν_(max) (cm⁻¹): 1685, 1649, 1541

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.95(1H, d, J=14.8 Hz), 7.76-7.69(6H, m), 7.52-7.45(3H, m), 7.39(1H, t, J=6.4 Hz), 4.12-3.99(2H, m), 4.06(3H, s), 3.92(2H, q, J=6.9 Hz), 1.27(3H, t, J=6.9 Hz), 1.14(3H, t, J=7.0 Hz)

Reference Example 106 (E)-1,3-Diethyl-8-(3-fluoro-4-methoxystyryl)xanthine (Compound 165)

Substantially the same procedure as in Example 7 was repeated using 2.50 g (12.6 mmol) of 5,6-diamino-1,3-diethyluracil and 2.72 g (13.9 mmol) of 3-fluoro-4-methoxycinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 1.97 g (yield 44% of Compound 165 as pale yellow flocculent precipitates.

Melting Point: >270° C.

Elemental Analysis: C₁₈ H₁₉ FN₄ O₃ Calcd. (%): C, 60.33; H, 5.34; N, 15.63 Found (%): C, 59.99; H, 5.34; N, 15.57

IR (KBr) ν_(max) (cm⁻¹): 1694, 1644, 1520, 1491

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.61-7.54(2H, m), 7.40 (1H, d, J=8.8 Hz), 7.21(1H, t, J=8.8 Hz), 6.93(1H, d, J=16.3 Hz), 4.06(2H, q, J=7.1 Hz), 3.97-3.88(2H, m), 3.88(3H, s), 1.25(3H, t, J=7.2 Hz), 1.14(3H, t, J=7.1 Hz)

Reference Example 107 (E)-1,3-Diethyl-8-(3-fluoro-4-methoxystyryl)-7-methylxanthine (Compound 166)

Substantially the same procedure as in Example 8 was repeated using 1.50 g (4.19 mmol) of Compound 165 obtained in Reference Example 106 in place of Compound 64. Then, the resultant crude crystals were recrystallized from toluene/ethanol to give 1.22 g (yield 78%) of Compound 166 as a pale yellow powder.

Melting Point: 211.7°-212.2° C.

Elemental Analysis: C₁₉ H₂₁ FN₄ O₃.0.25H₂ O Calcd. (%): C, 60.55; H, 5.75; N, 14.87 Found (%): C, 60.75; H, 5.81; N, 14.92

IR (KBr) ν_(max) (cm⁻¹): 1694, 1653, 1544, 1520, 1459

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.82(1H, dd, J=12.9, 2.0 Hz), 7.59(1H, d, J=15.8 Hz), 7.56-7.52(1H, m), 7.26(1H, d, J=15.8 Hz), 7.19(1H, t, J=8.9 Hz), 4.10-4.02(2H, m), 4.02(3H, s), 3.94-3.88(2H, m), 3.88 (3H, s), 1.25(3H, t, J=6.9 Hz), 1.13(3H, t, J=6.9 Hz)

Reference Example 108 (E)-8-(3-Chloro-4-fluorostyryl)-1,3-diethylxanthine (Compound 167)

Substantially the same procedure as in Example 7 was repeated using 2.50 g (12.6 mmol) of 5,6-diamino-1,3-diethyluracil and 3.01 g (15.1 mmol) of 3-chloro-4-fluorocinnamic acid. Then, the resultant crude crystals were recrystallized from tetrahydrofuran/water to give 560 mg (yield 32%) of Compound 167 as a white powder.

Melting Point: >270° C.

Elemental Analysis: C₁₇ H₁₆ ClFN₄ O₂ Calcd. (%): C, 56.28; H, 4.45; N, 15.44 Found (%): C, 56.30; H, 4.43; N, 15.53

IR (KBr) ν_(max) (cm⁻¹): 1695, 1649, 1504

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.93-7.91(1H, m), 7.66-7.63(1H, m), 7.58(1H, d, J=16.3 Hz), 7.46(1H, t, J=8.9 Hz), 7.08(1H, d, J=16.3 Hz), 4.05(2H, q, J=7.1 Hz), 3.93(2H, q, J=6.8 Hz), 1.26(3H, t, J=7.1 Hz), 1.14(3H, t, J=6.8 Hz)

Reference Example 109 (E)-8-(3-Chloro-4-fluorostyryl)-1,3-diethyl-7-methylxanthine (Compound 168)

Substantially the same procedure as in Example 8 was repeated using 1.80 g (4.98 mmol) of Compound 167 obtained in Reference Example 108 in place of Compound 64. Then, the resultant crude crystals were recrystallized from ethyl acetate to give 820 mg (yield 44%) of Compound 168 as yellow needles.

Melting Point: 218.4°-219.1° C.

Elemental Analysis: C₁₈ H₁₈ ClFN₄ O₂ Calcd. (%): C, 57.37; H, 4.81; N, 14.87 Found (%): C, 57.23; H, 4.85; N, 14.81

IR (KBr) ν_(max) (cm⁻¹): 1693, 1648, 1541, 1505, 1438

NMR (270 MHz; DMSO-d₆) δ (ppm): 8.18(1H, dd, J=7.2, 2.3 Hz), 7.84-7.79(1H, m), 7.63(1H, d, J=15.8 Hz), 7.51-7.44(2H, m), 4.11-3.99(2H, m), 4.05(3H, s), 3.92(2H, q, J=6.9 Hz), 1.25(3H, t, J=6.9 Hz), 1.13 (3H, t, J=6.9 Hz)

Reference Example 110 (E)-1,3-Diethyl-8-(3-fluoro-2-methylstyryl)xanthine (Compound 171)

Substantially the same procedure as in Example 7 was repeated using 2.50 g (12.6 mmol) of 5,6-diamino-1,3-diethyluracil and 2.50 g (13.9 mmol) of 3-fluoro-2-methylcinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane to give 2.18 g (yield 51%) of Compound 171 as a white powder.

Melting Point: >270° C.

Elemental Analysis: C₁₈ H₁₉ FN₄ O₂ Calcd. (%): C, 63.15; H, 5.59; N, 16.36 Found (%): C, 62.81; H, 5.71; N, 16.09

IR (KBr) ν_(max) (cm⁻¹): 1696, 1658, 1499

NMR (270 MHz; DMSO-d₆) δ (ppm): 13.7(1H, brs), 7.87(1H, d, J=16.6 Hz), 7.59(1H, d, J=7.4 Hz), 7.31-7.23(1H, m), 7.15(1H, t, J=8.7 Hz), 7.05(1H, d, J=16.6 Hz), 4.06(2H, q, J=6.9 Hz), 3.94(2H, q, J=6.9 Hz), 2.33 (3H, d, J=2.0 Hz), 1.26(3H, t, J=7.1 Hz), 1.14(3H, t, J=6.9 Hz)

Reference Example 111 (E)-1,3-Diethyl-8-(3-fluoro-2-methylstyryl)-7-methylxanthine (Compound 172)

Substantially the same procedure as in Example 8 was repeated using 1.30 g (3.80 mmol) of Compound 171 obtained in Reference Example 110 in place of Compound 64. Then, the resultant crude crystals were recrystallized from 2-propanol/water to give 1.12 g (yield 83%) of Compound 172 as white flocculent precipitates.

Melting Point: 198.1°-198.7° C.

Elemental Analysis: C₁₉ H₂₁ FN₄ O₂.0.5H₂ O Calcd. (%): C, 62.45; H, 6.07; N, 15.33 Found (%): C, 62.39; H, 6.26; N, 15.25

IR (KBr) ν_(max) (cm⁻¹): 1695, 1654, 1543

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.85(1H, d, J=15.5 Hz), 7.75(1H, d, J=7.9 Hz), 7.34-7.27(1H, m), 7.29(1H, d, J=15.5 Hz), 7.18(1H, t, J=8.9 Hz), 4.12-4.04(2H, m), 4.04(3H, s), 3.92(2H, q, J=6.9 Hz), 2.32(3H, d, J=1.7 Hz), 1.27(3H, t, J=7.1 Hz), 1.13(3H, t, J=6.9 Hz)

Reference Example 112 (E)-8-(3,4-Dihydroxystyryl)-1,3-diethyl-7-methylxanthine (Compound 173)

Compound 65 (2.00 g, 5.20 mmol) obtained in Example 8 was dissolved in 40 ml of methylene chloride. To the solution was added 26 ml (26 mmol) of boron tribromide (1.0M methylene chloride solution) under ice cooling in argon atmosphere, and the mixture was stirred overnight at room temperature. Methanol was added thereto and the mixture was separated with chloroform-an aqueous solution of sodium bicarbonate. The organic layer was washed with a saturated aqueous solution of sodium chloride and dried over anhydrous sodium sulfate, followed by evaporation under reduced pressure. The residue was recrystallized from ethanol to give 643 mg (yield 35%) of Compound 173 as pale yellow grains.

Melting Point: 247.5°-248.2° C. MS-EI m/e: 356(M⁺)

IR (KBr) ν_(max) (cm⁻¹): 1675, 1642, 1543, 1520, 1298

NMR (270 MHz; DMSO-d₆) δ (ppm): 9.31(1H, brs), 8.95(1H, brs), 7.50(1H, d, J=15.8 Hz), 7.16(1H, s), 7.05(1H, d, J=7.9 Hz), 7.00(1H, d, J=15.8 Hz), 6.77(1H, d, J=7.9 Hz), 4.06(2H, q, J=6.9 Hz), 3.99(3H, s), 3.92 (2H, q, J=6.9 Hz), 1.25(3H, t, J=6.9 Hz), 1.13(3H, t, J=6.9 Hz)

Reference Example 113 (E)-1,3-Diethyl-8-(3-hydroxy-4-methoxystyryl)-7-methylxanthine (Compound 174)

Compound 173 (400 mg, 1.12 mmol) obtained in Reference Example 112 was dissolved in 8 ml of dimethylformamide. To the solution were added 0.35 ml (5.62 mmol) of methyl iodide and 415 mg (5.62 mmol) of lithium carbonate, and the mixture was stirred at 80° C. for 3.5 hours. Water was added thereto to dissolve lithium carbonate, followed by addition of chloroform. The organic layer was washed with a saturated aqueous solution of sodium chloride and dried over anhydrous sodium sulfate, followed by evaporation under reduced pressure. The residue was purified by silica gel column chromatography (eluent:chloroform) to give 127 mg (yield 76%) of Compound 174 as a pale brown powder. The obtained crude crystals were further recrystallized from ethanol.

Melting Point: 204.5°-205.8° C. MS-EI m/e: 370(M⁺)

IR (KBr) ν_(max) (cm⁻¹): 1689, 1653, 1515, 1442

NMR (270 MHz; DMSO-d₆) δ (ppm): 9.06(1H, s), 7.53(1H, d, J=15.5 Hz), 7.23(1H, s), 7.17(1H, d, J=8.3 Hz), 7.08(1H, d, J=15.5 Hz), 6.96(1H, d, J=8.3 Hz), 4.06 (2H, q, J=6.9 Hz), 4.00(3H, s), 3.92(2H, q, J=6.9 Hz), 3.82(3H, s), 1.25(3H, t, J=6.9 Hz), 1.13 (3H, t, J=6.9 Hz)

Reference Example 114 (E)-1,3-Diethyl-8-(4-hydroxystyryl)-7-methylxanthine (Compound 175)

Compound 145 (2.70 g, 7.02 mmol) obtained in Reference Example 88 was dissolved in 50 ml of tetrahydrofuran. To the solution was added 17.6 ml of 2N hydrochloric acid, and the mixture was heated under reflux for 2.5 hours. The reaction solution was neutralized with a 2N aqueous solution of sodium hydroxide under ice cooling, water was added thereto, and the deposited crystals were collected by filtration. The obtained crude crystals were recrystallized from 2-propanol to give 2.33 g (yield 98%) of Compound 175 as yellow grains.

Melting Point: >270° C.

Elemental Analysis: C₁₈ H₂₀ N₄ O₃ Calcd. (%): C, 63.52; H, 5.92; N, 16.46 Found (%): C, 63.17; H, 6.02; N, 16.18

IR (KBr) ν_(max) (cm⁻¹): 1696, 1636, 1607, 1517

NMR (270 MHz; DMSO-d₆) δ (ppm): 9.79(1H, s), 7.62(2H, d, J=8.3 Hz), 7.58(1H, d, J=15.8 Hz), 7.08(1H, d, J=15.8 Hz), 6.81(2H, d, J=8.3 Hz), 4.07(2H, q, J=6.9 Hz), 3.99(3H, s), 3.92(2H, q, J=6.9 Hz), 1.26 (3H, t, J=6.9 Hz), 1.13(3H, t, J=6.9 Hz)

Reference Example 115 (E)-8-(4-Benzyloxystyryl)-1,3-diethyl-7-methylxanthine (Compound 176)

Compound 175 (100 mg, 0.29 mmol) obtained in Reference Example 114 was dissolved in 2 ml of dimethylformamide. To the solution were added 162 mg (1.17 mmol) of potassium carbonate and 0.28 ml (2.35 mmol) of benzyl bromide, and the mixture was stirred at 80° C. for 2.5 hours. Water was added thereto under ice cooling to dissolve potassium carbonate and the deposited crystals were collected by filtration. The collected crude crystals were dissolved in chloroform, washed with a saturated aqueous solution of sodium chloride and dried over anhydrous sodium sulfate, followed by evaporation under reduced pressure. The residue was recrystallized from hexane/ethyl acetate to give 67 mg (yield 53%) of Compound 176 as yellow needles.

Melting Point: 184.7°-185.4° C.

Elemental Analysis: C₂₅ H₂₆ N₄ O₃ Calcd. (%): C, 69.75; H, 6.08; N, 13.01 Found (%): C, 69.70; H, 6.26; N, 12.79

IR (KBr) ν_(max) (cm⁻¹): 1688, 1655, 1513, 1245

NMR (270 MHz; CDCl₃) δ (ppm): 7.74(1H, d, J=15.8 Hz), 7.53(2H, d, J=8.9 Hz), 7.47-7.32(5H, m), 7.01(2H, d, J=8.9 Hz), 6.78(1H, d, J=15.8 Hz), 5.11(2H, s), 4.21(2H, q, J=6.9 Hz), 4.09(2H, q, J=6.9 Hz), 4.04 (3H, s), 1.38(3H, t, J=6.9 Hz), 1.26(3H, t, J=6.9 Hz)

Reference Example 116 (E)-8-[4-(4-Bromobutoxy)styryl]-1,3-diethyl-7-methylxanthine (Compound 177)

Compound 175 (200 mg, 0.59 mmol) obtained in Reference Example 114 was dissolved in 4 ml of dimethylformamide. To the solution were added 163 mg (1.18 mmol) of potassium carbonate and 0.56 ml (1.18 mmol) of 1,4-dibromobutane, and the mixture was stirred at 50° C. for 4 hours. Water was added thereto under ice cooling to dissolve potassium carbonate and the deposited crystals were collected by filtration. The obtained crude crystals were recrystallized from hexane/ethyl acetate to give 170 mg (yield 61%) of Compound 177 as pale yellow grains.

Melting Point: 174.8°-176.4° C.

Elemental Analysis: C₂₂ H₂₇ BrN₄ O₃ Calcd. (%): C, 55.59; H, 5.72; N, 11.79 Found (%): C, 55.68; H, 5.85; N, 11.69

IR (KBr) ν_(max) (cm⁻¹): 1688, 1656, 1515, 1244

NMR (270 MHz; CDCl₃) δ (ppm): 7.74(1H, d, J=15.8 Hz), 7.53(2H, d, J=8.9 Hz), 6.92(2H, d, J=8.9 Hz), 6.77 (1H, d, J=15.8 Hz), 4.21(2H, q, J=6.9 Hz), 4.13-4.02 (4H, m), 4.04(3H, s), 3.50(2H, t, J=6.6 Hz), 2.14-1.93(4H, m), 1.38(3H, t, J=6.9 Hz), 1.26(3H, t, J=6.9 Hz)

Reference Example 117 (E)-8-[4-(4-Azidobutoxy)styryl]-1,3-diethyl-7-methylxanthine (Compound 178)

Compound 177 (235 mg, 0.49 mmol) obtained in Reference Example 116 was dissolved in 10 ml of dimethylformamide. To the solution was added 161 mg (2.48 mmol) of sodium azide, and the mixture was stirred at 80° C. for 3 hours. Water was added thereto under ice cooling and the deposited crystals, were collected by filtration. The collected crude crystals were dissolved in chloroform, washed with a saturated aqueous solution of sodium chloride and dried over anhydrous sodium sulfate, followed by evaporation under reduced pressure. The residue was purified by silica gel column chromatography (eluent:chloroform), followed by recrystallization from hexane/ethyl acetate to give 216 mg (yield quant.) of Compound 178 as pale yellow grains.

Melting Point: 158.5°-158.9° C. MS-EI m/e: 437(M⁺)

Elemental Analysis: C₂₂ H₂₇ N₇ O₃ Calcd. (%): C, 60.40; H, 6.22; N, 22.41 Found (%): C, 60.15; H, 6.31; N, 22.32

IR (KBr) ν_(max) (cm⁻¹): 2094, 1653, 1605, 1543, 1515

NMR (270 MHz; CDCl₃) δ (ppm): 7.75(1H, d, J=15.5 Hz), 7.53(2H, d, J=8.6 Hz), 6.92(2H, d, J=8.6 Hz), 6.77 (1H, d, J=15.5 Hz), 4.21(2H, q, J=6.9 Hz), 4.13-3.69 (4H, m), 4.04(3H, s), 3.39(2H, t, J=6.6 Hz), 1.93-1.79(4H, m), 1.38(3H, t, J=6.9 Hz), 1.26(3H, t, J=6.9 Hz)

Reference Example 118 (E)-8-[4-(4-Aminobutoxy)styryl]-1,3-diethyl-7-methylxanthine (Compound 179)

Compound 178 (75 mg, 0.17 mmol) obtained in Reference Example 117 was dissolved in 7.5 ml of tetrahydrofuran. To the solution was added 90 mg (0.34 mmol) of triphenylphosphine, and the mixture was heated under reflux for 3 hours. Water (5 ml) was added thereto and the mixture was heated under reflux for further one hour. After cooling, a 2N aqueous solution of sodium hydroxide was added thereto, and the mixture was extracted with chloroform and dried over anhydrous sodium sulfate, followed by evaporation under reduced pressure. The residue was purified by silica gel column chromatography (eluent:chloroform/methanol/triethylamine) to give 74 mg (yield quant.) of Compound 179. The obtained crude crystals were further recrystallized from 2-propanol/water.

Melting Point: 212.1°-214.5° C. MS-EI m/e: 411(M⁺)

IR (KBr) ν_(max) (cm⁻¹): 1692, 1649, 1606, 1544, 1515

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.74(2H, d, J=8.6 Hz), 7.62(1H, d, J=16.2 Hz), 7.20(1H, d, J=16.2 Hz), 6.98 (2H, d, J=8.6 Hz), 4.08-3.88(6H, m), 4.02(3H, s), 2.83-2.74(2H, m), 1.82-1.59(4H, m), 1.26(3H, t, J=6.9 Hz), 1.13(3H, t, J=6.9 Hz)

Reference Example 119 (E)-8-(4-Ethoxycarbonylmethoxystyryl)-1,3-diethyl-7-methylxanthine (Compound 180)

Compound 175 (300 mg, 0.88 mmol) obtained in Reference Example 114 was dissolved in 10 ml of dimethyl formamide. To the solution were added 731 mg (5.29 mmol) of potassium carbonate and 0.47 ml (4.41 mmol) of ethyl chloroacetate, and the mixture was stirred at room temperature for 2 hours. Water was added thereto to dissolve potassium carbonate and the deposited crystals were collected by filtration. The collected crude crystals were dissolved in chloroform, washed with a saturated aqueous solution of sodium chloride and dried over anhydrous sodium sulfate, followed by evaporation under reduced pressure. The residue was recrystallized from hexane/ethyl acetate to give 341 mg (yield 91%) of Compound 180 as pale yellow needles.

Melting Point: 191.8°-192.2° C. MS-EI m/e: 426(M⁺)

IR (KBr) ν_(max) (cm⁻¹): 1688, 1658, 1650, 1514, 1440

NMR (270 MHz; CDCl₃) δ (ppm): 7.74(1H, d, J=15.8 Hz), 7.54(2H, d, J=8.6 Hz), 6.94(2H, d, J=8.6 Hz), 6.79 (1H, d, J=15.8 Hz), 4.66(2H, s), 4.29(2H, q, J=6.9 Hz), 4.21(2H, q, J=6.9 Hz), 4.09(2H, q, J=6.9 Hz), 4.04(3H, s), 1.38(3H, t, J=6.9 Hz), 1.31 (3H, t, J=6.9 Hz), 1.26(3H, t, J=6.9 Hz)

Reference Example 120 (E)-8-(4-Carboxymethoxystyryl)-1,3-diethyl-7-methylxanthine (Compound 181)

Compound 180 (200 mg, 0.47 mmol) obtained in Reference Example 119 was dissolved in a mixed solvent of 4 ml of tetrahydrofuran, 4 ml of ethanol, and 2 ml of water. To the solution was added 98 mg (2.34 mmol) of lithium hydroxide monohydrate, and the mixture was stirred at room temperature for one hour. To the reaction solution was added 2N hydrochloric acid, and the mixture was extracted with chloroform and dried over anhydrous sodium sulfate, followed by evaporation under reduced pressure. The residue was purified by silica gel column chromatography (eluent:chloroform/methanol/acetic acid) to give 40 mg (yield 21%) of Compound 181 as a pale yellow solid.

Melting Point: 267.5°-269.0° C. MS-EI m/e: 398(M⁺)

IR (KBr) ν_(max) (cm⁻¹): 1684, 1653, 1647, 1515

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.74(2H, d, J=8.6 Hz), 7.62(1H, d, J=15.8 Hz), 7.20(1H, d, J=15.8 Hz), 6.96 (2H, d, J=8.6 Hz), 4.70(2H, s), 4.07(2H, q, J=6.9 Hz), 4.01(3H, s), 3.92(2H, q, J=6.9 Hz), 1.26 (3H, t, J=6.9 Hz), 1.13(3H, t, J=6.9 Hz)

Reference Example 121 (E)-1,3-Diethyl-8-(3-phenoxystyryl)xanthine (Compound 182)

Substantially the same procedure as in Example 7 was repeated using 3.00 g (15.1 mmol) of 5,6-diamino-1,3-diethyluracil and 4.00 g (16.7 mmol) of 3-phenoxycinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 3.82 g (yield 63%) of Compound 182 as pale yellow needles.

Melting Point: 241.4°-243.4° C.

Elemental Analysis: C₂₃ H₂₂ N₄ O₃ Calcd. (%): C, 68.64; H, 5.51; N, 13.92 Found (%): C, 68.26; H, 5.59; N, 13.79

IR (KBr) ν_(max) (cm⁻¹): 1640, 1579, 1492, 1265

NMR (270 MHz; DMSO-d₆) δ (ppm): 13.52(1H, brs), 7.87 (1H, d, J=2.0 Hz), 7.63(1H, dd, J=8.4, 2.0 Hz), 7.56 (1H, d, J=16.3 Hz), 7.16(1H, d, J=8.4 Hz), 6.95(1H, d, J=16.3 Hz), 4.06(2H, q, J=6.9 Hz), 3.93(2H, q, J=6.9 Hz), 3.89(3H, s), 1.26(3H, t, J=6.9 Hz), 1.14 (3H, t, J=6.9 Hz)

Reference Example 122 (E)-1,3-Diethyl-7-methyl-8-(3-phenoxystyryl)xanthine (Compound 183)

Substantially the same procedure as in Example 8 was repeated using 2.00 g (4.97 mmol) of Compound 182 obtained in Reference Example 121 in place of Compound 64. Then, the resultant crude crystals were recrystallized from hexane/ethyl acetate to give 1.78 g (yield 86%) of Compound 183 as yellow needles.

Melting Point: 205.1°-205.9° C.

Elemental Analysis: C₂₄ H₂₄ N₄ O₃ Calcd. (%): C, 69.22; H, 5.81; N, 13.45 Found (%): C, 69.02; H, 5.80; N, 13.48

IR (KBr) ν_(max) (cm⁻¹): 1692, 1652, 1492, 1241

NMR (270 MHz; CDCl₃) δ (ppm): 7.74(1H, d, J=15.8 Hz), 7.40-6.98(9H, m), 6.88(1H, d, J=15.8 Hz), 4.20(2H, q, J=6.9 Hz), 4.09(2H, q, J=6.9 Hz), 4.04(3H, s), 1.37(3H, t, J=6.9 Hz), 1.26(3H, t, J=6.9 Hz)

Reference Example 123 (E)-1,3-Diethyl-8-(4-hydroxystyryl)xanthine (Compound 184)

Substantially the same procedure as in Reference Example 114 was repeated using 500 mg (7.02 mmol) of Compound 144 obtained in Reference Example 87. Then, the resultant crude crystals were recrystallized from dioxane/water to give 430 mg (yield 98%) of Compound 184 as pale yellow needles.

Melting Point: >270° C.

Elemental Analysis: C₁₇ H₁₈ N₄ O₃ Calcd. (%): C, 62.57; H, 5.56; N, 17.17 Found (%): C, 62 . 60; H, 5.50; N, 17.07

IR (KBr) ν_(max) (cm⁻¹): 1674, 1634, 1520, 1488

NMR (270 MHz; DMSO-d₆) δ (ppm): 13.34(1H, brs), 9.77 (1H, s), 7.56(1H, d, J=16.2 Hz), 7.46(2H, d, J=8.6 Hz), 6.81(2H, d, J=8.6 Hz), 6.80(1H, d, J=16.2 Hz), 4.06(2H, q, J=6.9 Hz), 3.94(2H, q, J=6.9 Hz), 1.26(3H, t, J=6.9 Hz), 1.14(3H, t, J=6.9 Hz)

Reference Example 124 (E)-1, 3-Diethyl-8-(4-hydroxy-2,3-dimethylstyryl)-7-methylxanthine (Compound 185)

Substantially the same procedure as in Reference Example 112 was repeated using 500 mg (1.31 mmol) of Compound 73 obtained in Example 16. Then, the resultant crude crystals were recrystallized from 2-propanol to give 290 mg (yield 60%) of Compound 185 as a pale yellow powder.

Melting Point: 240.2°-242.0° C. MS-EI m/e: 368(M⁺)

IR (KBr) ν_(max) (cm⁻¹): 1683, 1656, 1586, 1460

NMR (270 MHz; DMSO-d₆) δ (ppm): 10.20(1H, brs), 9.64 (1H, brs), 7.92(1H, d, J=15.6 Hz), 7.57(1H, d, J=8.7 Hz), 6.97(1H, d, J=15.6 Hz), 6.74(1H, d, J=8.7 Hz), 4.07(2H, q, J=6.9 Hz), 3.99(3H, s), 3.91 (2H, q, J=6.9 Hz), 2.29(3H, s), 2.10(3H, s), 1.26 (3H, t, J=6.9 Hz), 1.13(3H, t, J=6.9 Hz)

Reference Example 125 (Z)-8-(3,4-Dimethoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 186)

Compound 1 (1.00 g, 2.42 mmol) obtained in Reference Example 1 was dissolved in 1.6 L of methanol, and the solution was irradiated with sunlight for 5 hours. After evaporation under reduced pressure, the residue was purified by high performance liquid chromatography (column: YMC Pack ODS-A, SH-365-10, S-10; 30 mm.O slashed.×500 mm, flow rate: 90 ml/min, detection: UV 246 nm) to give 565 mg (yield 57%) of Compound 186 as white needles.

Melting Point: 126.9°-127.2° C.

Elemental Analysis: C₂₂ H₂₈ N₄ O₄ Calcd. (%): C, 64.06; H, 6.84; N, 13.58 Found (%): C, 64.12; H, 7.09; N, 13.54

IR (KBr) ν_(max) (cm⁻¹): 1696, 1654, 1542, 1521

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.28(1H, d, J=8.4 Hz), 7.20(1H, s), 6.94(1H, d, J=12.7 Hz), 6.92(1H, d, J=8.4 Hz), 6.39(1H, d, J=12.7 Hz), 3.93(2H, t, J=7.4 Hz), 3.84(2H, t, J=6.9 Hz), 3.77(6H, s), 3.64 (3H, s), 1.75-1.50(4H, m), 0.86(3H, t, J=7.4 Hz), 0.85(3H, t, J=7.4 Hz)

Reference Example 126 (E)-8-(3,4-Dimethoxystyryl)-7-ethyl-1,3-dipropylxanthine (Compound 187)

Substantially the same procedure as in Reference Example 1 was repeated using 1.5 g (3.77 mmol) of Compound B obtained in Reference Example 1 and 0.60 ml (7.54 mmol) of ethyl iodide. Then, the resultant crude crystals were recrystallized from ethanol/water to give 1.38 g (yield 87%) of Compound 187 as white needles.

Melting Point: 107.6°-107.9° C.

Elemental Analysis: C₂₃ H₃₀ N₄ O₄ Calcd. (%): C, 64.77; H, 7.09; N, 13.14 Found (%): C, 64.81; H, 7.28; N, 13.21

IR (KBr) ν_(max) (cm⁻¹): 1695, 1655, 1515, 1265

NMR (270 MHz; CDCl₃) δ (ppm): 7.63(1H, d, J=15.8 Hz), 7.42(1H, d, J=1.7 Hz), 7.32(1H, dd, J=1.7, 8.6 Hz), 7.23(1H, d, J=15.8 Hz), 6.99(1H, d, J=8.6 Hz), 4.51 (2H, q, J=6.9 Hz), 3.99(2H, t, J=7.2 Hz), 3.87-3.80 (2H, m), 3.85(3H, s), 3.80(3H, s), 1.80-1.45(4H, m), 1.33(3H, t, J=6.9 Hz), 0.94-0.85(6H, m)

Reference Example 127 (E)-8-(3,4-Dimethoxystyryl)-7-propargyl-1,3-dipropylxanthine (Compound 188)

Substantially the same procedure as in Reference Example 1 was repeated using 1.5 g (3.77 mmol) of Compound B obtained in Reference Example 1 and 0.67 ml (7.54 mmol) of propargyl bromide. Then, the resultant crude crystals were recrystallized from cyclohexane/toluene to give 1.35 g (yield 82%) of Compound 188 as a yellow powder.

Melting Point: 153.4°-154.8° C.

Elemental Analysis: C₂₄ H₂₈ N₄ O₄ Calcd. (%): C, 66.04; H, 6.47; N, 12.84 Found (%): C, 66.18; H, 6.74; N, 12.87

IR (KBr) ν_(max) (cm⁻¹): 1684, 1647, 1510, 1270

NMR (270 MHz; CDCl₃) δ (ppm): 7.66(1H, d, J=15.7 Hz), 7.41(1H, d, J=1.3 Hz), 7.32(1H, dd, J=1.3, 8.5 Hz), 7.26(1H, d, J=15.7 Hz), 7.02(1H, d, J=8.5 Hz), 5.43 (2H, d, J=2.0 Hz), 4.00(2H, t, J=7.3 Hz), 3.87-3.81 (2H, m), 3.85(3H, s), 3.81(3H, s), 3.48(1H, t, J=2.0 Hz), 1.80-1.45(4H, m), 0.94-0.85(6H, m)

Reference Example 128 (E)-8-[3,4-Bis(methoxymethoxy)styryl]-7-methyl-1,3-dipropylxanthine (Compound 189)

Compound 53 (300 mg, 0.78 mmol) obtained in Reference Example 46 was dissolved in 6 ml of tetrahydrofuran. To the solution were added 1.64 ml (9.41 mmol) of diisopropylethylamine and 1.64 ml (7.12 mmol) of chloromethylmethyl ether under ice-cooling in a stream of argon, and the mixture was heated under reflux for 3 hours. Ice was added to the reaction solution and the mixture was separated with chloroform-a saturated aqueous saline solution. The organic layer was dried over anhydrous sodium sulfate, followed by evaporation under reduced pressure. The residue was purified by silica gel column chromatography (eluent:hexane/ethyl acetate) and recrystallized from hexane/ethyl acetate to give 211 mg (yield 57%) of Compound 189 as white needles.

Melting Point: 172.2°-172.6° C.

Elemental Analysis: C₂₄ H₃₂ N₄ O₆ Calcd. (%): C, 61.01; H, 6.82; N, 11.86 Found (%): C, 61.16; H, 7.00; N, 11.88

IR (KBr) ν_(max) (cm⁻¹): 1688, 1658, 1509, 1267

NMR (270 MHz; CDCl₃) δ (ppm): 7.22(1H, d, J=15.8 Hz), 7.39(1H, d, J=1.3 Hz), 7.25-7.16(2H, m), 6.77(1H, d, J=15.8 Hz), 5.30(2H, s), 5.28(2H, s), 4.13-3.95 (4H, m), 4.04(3H, s), 3.56(3H, s), 3.54(3H, s), 1.91-1.61(4H, m), 1.00(3H, t, J=7.6 Hz), 0.97(3H, t, J=7.6 Hz)

Reference Example 129 (E)-1,3-Diallyl-8-(3,4-dimethoxystyryl)xanthine (Compound 190)

Substantially the same procedure as in Reference Example 1 was repeated using 2.9 g (13.1 mmol) of 1,3-diallyl-5,6-diaminouracil and 2.99 g (14.4 mmol) of 3,4-dimethoxycinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 2.80 g (yield 54%) of Compound 190 as pale yellow flocculent precipitates.

Melting Point: 251.6°-252.4° C.

Elemental Analysis: C₂₁ H₂₂ N₄ O₃ Calcd. (%): C, 63.95; H, 5.62; N, 14.20 Found (%): C, 63.67; H, 5.61; N, 14.14

IR (KBr) ν_(max) (cm⁻¹): 1698, 1644, 1516

NMR (270 MHz; DMSO-d₆) δ (ppm): 13.50(1H, brs), 7.58 (1H, d, J=16.3 Hz), 7.27(1H, d, J=2.0 Hz), 7.13(1H, dd, J=2.0, 8.4 Hz), 6.99(1H, d, J=8.4 Hz), 6.96(1H, d, J=16.3 Hz), 6.07-5.82(2H, m), 5.20-5.01(4H, m), 4.68-4.45(4H, m), 3.82(3H, s), 3.79(3H, s)

Reference Example 130 (E)-1,3-Diallyl-8-(3,4-dimethoxystyryl)-7-methylxanthine (Compound 191)

Substantially the same procedure as in Reference Example 1 was repeated using 2.30 g (5.84 mmol) of Compound 190 obtained in Reference Example 129 in place of Compound B. Then, the resultant crude crystals were recrystallized from ethanol to give 1.85 g (yield 78%) of Compound 191 as pale yellow flocculent precipitates.

Melting Point: 159.5°-160.0° C.

Elemental Analysis: C₂₂ H₂₄ N₄ O₃ Calcd. (%): C, 64.69; H, 5.92; N, 13.72 Found (%): C, 64.50; H, 6.03; N, 13.71

IR (KBr) ν_(max) (cm⁻¹): 1698, 1658, 1515, 1265

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.60(1H, d, J=15.3 Hz), 7.42(1H, d, J=1.5 Hz), 7.29(1H, dd, J=1.5, 8.4 Hz), 7.21(1H, d, J=15.3 Hz), 6.99(1H, d, J=8.4 Hz), 6.05-5.78(2H, m), 5.20-5.01(4H, m), 4.68-4.45(4H, m), 4.03(3H, s), 3.84(3H, s), 3.80(3H, s)

Reference Example 131 (E)-8-(3,4-Dimethoxystyryl)-1,3-dipropyl-2-thioxanthine (Compound 192)

Substantially the same procedure as in Reference Example 1 was repeated using 4.00 g (16.5 mmol) of 5,6-diamino-1,3-dipropyl-2-thiouracil and 3.79 g (18.2 mmol) of 3,4-dimethoxycinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 3.16 g (yield 46%) of Compound 192 as yellow needles.

Melting Point: 273.2°-272.4° C.

Elemental Analysis: C₂₁ H₂₆ N₄ O₃ S Calcd. (%): C, 60.85; H, 6.32; N, 13.52 Found (%): C, 60.85; H, 6.49; N, 13.64

IR (KBr) ν_(max) (cm⁻¹): 1675, 1515

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.64(1H, d, J=16.5 Hz), 7.30(1H, s), 7.15(1H, d, J=8.2 Hz), 7.02(1H, d, J=16.5 Hz), 6.99(1H, d, J=8.2 Hz), 4.56(2H, t, J=7.6 Hz), 4.45(2H, t, J=7.6 Hz), 3.83(3H, s), 3.80 (3H, s), 1.85-1.60(4H, m), 0.98-0.82(6H, m)

Reference Example 132 (E)-8-(3,4-Dimethoxystyryl)-7-methyl-1,3-dipropyl-2-thioxanthine (Compound 193)

Substantially the same procedure as in Reference Example 1 was repeated using 3.00 g (7.25 mmol) of Compound 192 obtained in Reference Example 131 in place of Compound B. Then, the resultant crude crystals were recrystallized from toluene/ethanol to give 1.79 g (yield 58%) of Compound 193 as a pale yellow powder.

Melting Point: 137.3°-139.2° C.

Elemental Analysis: C₂₂ H₂₈ N₄ O₃ S Calcd. (%): C, 61.66; H, 6.59; N, 13.07 Found (%): C, 61.44; H, 6.71; N, 13.05

IR (KBr) ν_(max) (cm⁻¹): 1684, 1515, 1438

NMR (270 MHz; DMSO-d₆) δ (ppm): 7.67(1H, d, J=15.7 Hz), 7.44(1H, d, J=1.3 Hz), 7.33(1H, dd, J=1.3, 8.3 Hz), 7.24(1H, d, J=15.7 Hz), 7.00(1H, d, J=8.3 Hz), 4.56 (2H, t, J=7.6 Hz), 4.42(2H, t, J=7.6 Hz), 4.06(3H, s), 3.85(3H, s), 3.81(3H, s), 1.85-1.60(4H, m), 0.98-0.82(6H, m)

Reference Example 133 (E)-8-(3-Methoxy-4-methoxymethoxystyryl)-1,3-dipropylxanthine (Compound 194)

Substantially the same procedure as in Reference Example 1 was repeated using 4.0 g (17.7 mmol) of 5,6-diamino-1,3-dipropyluracil and 4.63 g (19.4 mmol) of 3-methoxy-4-methoxymethoxycinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 5.06 g (yield 67%) of Compound 194 as pale yellow flocculent precipitates.

Melting Point: 226.7°-227.4° C.

Elemental Analysis: C₂₂ H₂₈ N₄ O₅ Calcd. (%): C, 61.67; H, 6.58; N, 13.08 Found (%): C, 61.56; H, 6.68; N, 13.09

IR (KBr) ν_(max) (cm⁻¹): 1697, 1655, 1650, 1516, 1255

NMR (270 MHz; DMSO-d₆) δ (ppm): 13.47(1H, brs), 7.60 (1H, d, J=16.5 Hz), 7.31(1H, s), 7.10(2H, m), 7.00 (1H, d, J=16.5 Hz), 5.19(2H, s), 3.98(2H, t, J=6.9 Hz), 3.88-3.83(5H, m), 3.40(3H, s), 1.79-1.66 (2H, m), 1.62-1.51(2H, m), 0.90(3H, t, J=7.6 Hz), 0.88(3H, t, J=7.6 Hz)

Reference Example 134 (E)-8-(3-Methoxy-4-methoxymethoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 195)

Substantially the same procedure as in Reference Example 1 was repeated using 4.5 g (10.5 mmol) of Compound 194 obtained in Reference Example 133 in place of Compound B. Then, the resultant crude crystals were recrystallized from hexane/ethyl acetate to give 3.66 g (yield 79%) of Compound 195 as pale yellow flocculent precipitates.

Melting Point: 153.2°-154.9° C.

Elemental Analysis: C₂₃ H₃₀ N₄ O₅.0.3H₂ O Calcd. (%): C, 61.67; H, 6.89; N, 12.51 Found (%): C, 61.76; H, 6.89; N, 12.47

IR (KBr) ν_(max) (cm⁻¹): 1697, 1656, 1544, 1254

NMR (270 MHz; CDCl₃) δ (ppm): 7.73(1H, d, J=15.8 Hz), 7.20-7.13(2H, m), 7.10(1H, m), 6.78(1H, d, J=15.8 Hz), 5.28(2H, s), 4.14-4.08(2H, m), 4.06(3H, s), 4.01-3.97(2H, m), 3.96(3H, s), 3.53(3H, s), 1.91-1.77(2H, m), 1.76-1.63(2H, m), 1.01(3H, t, J=7.6 Hz) 0.97(3H, t, J=7.6 Hz)

Reference Example 135 (E)-8-(4-Hydroxy-3-methoxystyryl)-1,3-dipropylxanthine (Compound 196)

Compound 194 (1.00 g, 2.33 mmol) obtained in Reference Example 133 was dissolved in 10 ml of tetrahydrofuran. To the solution was added 6 ml of 2N hydrochloric acid, and the mixture was heated under reflux for one hour. The reaction solution was neutralized with a 2N aqueous solution of sodium hydroxide under ice cooling. Water was added thereto, and the deposited crystals were collected by filtration. The obtained crude crystals were recrystallized from methanol/water to give 291 mg (yield 32%) of Compound 196 as a yellow powder.

Melting Point: 243.4°-245.2° C.

Elemental Analysis: C₂₀ H₂₄ N₄ O₄.0.4C₄ H₈ O₂ Calcd. (%): C, 61.82; H, 6.53; N, 13.35 Found (%): C, 61.58; H, 6.66; N, 13.55

IR (KBr) ν_(max) (cm⁻¹): 1699, 1635, 1516

NMR (270 MHz; DMSO-d₆) δ (ppm): 13.39(1H, brs), 9.43 (1H, brs), 7.56(1H, d, J=16.5 Hz), 7.24(1H, d, J=1.7 Hz), 7.01(1H, dd, J=1.7, 8.3 Hz), 6.90(1H, d, J=16.5 Hz), 6.81(1H, d, J=8.3 Hz), 3.98(2H, t, J=7.3 Hz), 3.88-3.84(2H, m), 3.84(3H, s), 1.79-1.65 (2H, m), 1.61-1.50(2H, m), 0.90(3H, t, J=7.3 Hz), 0.87(3H, t, J=7.3 Hz)

Reference Example 136 (E)-8-(4-Hydroxy-3-methoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 197)

Substantially the same procedure as in Reference Example 135 was repeated using 3.00 g (6.78 mmol) of Compound 195 obtained in Reference Example 134 in place of Compound 194. Then, the resultant crude crystals were recrystallized from hexane/ethyl acetate to give 1.93 g (yield 72%) of Compound 197 as pale yellow grains.

Melting Point: 186.8°-187.9° C.

Elemental Analysis: C₂₁ H₂₆ N₄ O₄ Calcd. (%): C, 63.30; H, 6.57; N, 14.06 Found (%): C, 63.19; H, 6.69; N, 14.25

IR (KBr) ν_(max) (cm⁻¹): 1693, 1650, 1540, 1520, 1284

NMR (270 MHz; DMSO-d₆) δ (ppm): 9.44(1H, brs), 7.57(1H, d, J=15.5 Hz), 7.39(1H, s), 7.19(1H, d, J=8.3 Hz), 7.13(1H, d, J=15.5 Hz), 6.81(1H, d, J=8.3 Hz), 4.01 (3H, s), 3.99(2H, t, J=7.6 Hz), 3.86(3H, s), 3.84 (2H, t, J=7.6 Hz), 1.77-1.66(2H, m), 1.63-1.50(2H, m), 0.90(3H, t, J=7.6 Hz) 0.87(3H, t, J=7.6 Hz) 

What is claimed is:
 1. A method of treating Parkinson's disease which comprises administering to a patient suffering from Parkinson's disease an effective amount of a xanthine derivative of the following formula (I): ##STR127## in which R¹, R², and R³ are independently hydrogen, lower alkyl, or allyl; and R⁴ is cycloalkyl, --(CH₂)_(n) --R⁵, in which R⁵ is unsubstituted or substituted phenyl or naphthyl, having 1 to 3 independently-selected substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, halogen, nitro and amino, or a substituted or unsubstituted heterocyclic group, wherein the heterocyclic group is selected from the group consisting of furyl, thienyl, pyrrolyl, pyranyl, thiopyranyl, pyridyl, thioazolyl, imidazolyl, pyrimidyl, triazinyl, indolyl, quinolyl, purinyl, and benzothiazolyl; and n is an integer of 0 to 4, or ##STR128## wherein Y¹ and Y² is independently hydrogen or methyl; and Z is unsubstituted or substituted phenyl or naphthyl having 1 to 3 independently-selected substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, halogen, nitro and amino, ##STR129## wherein R⁶ is hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, or amino; and m represents an integer of 1 to 4, or a substituted or unsubstituted heterocyclic group wherein the heterocyclic group is furyl, thienyl, pyrrolyl, pyranyl, thiopyranyl, pyridyl, thioazolyl, imidazolyl, pyrimidyl, triazinyl, indolyl, quinolyl, purinyl, or benzothiazolyl; and X¹ and X² are independently O or S, or a pharmaceutical acceptable salt thereof.
 2. A method of treating Parkinson's disease according to claim 1, in which X¹ and X² are O;and Y¹ and Y² are hydrogen.
 3. A method of treating Parkinson's disease according to claim 2, in which Z is substituted or unsubstituted phenyl.
 4. A method of treating Parkinson's disease according to claim 3, in which R³ is lower alkyl.
 5. A method of treating Parkinson's disease according to claim 4, in which R¹ and R² represent independently lower alkyl or allyl.
 6. A method of treating Parkinson's disease according to claim 5, in which R³ is methyl.
 7. A method of treating Parkinson's disease according to claim 6, in which the benzene ring is substituted by 1 to 4 substituents which are independently selected from the group consisting of lower alkyl and lower alkoxy.
 8. A method of treating Parkinson's disease according to claim 7, in which the configuration at the position 8 of the xanthine ring is (E) form.
 9. A method of treating Parkinson's disease according to claim 8, in which the substituents on the benzene ring are methoxy or methyl.
 10. A method of treating Parkinson's disease according to claim 9, in which R¹ and R² are ethyl;and the substituents on the benzene ring are 3,4-dimethoxy.
 11. A method of treating Parkinson's disease according to claim 8, in which the substituents on the benzene ring are ethoxy or propoxy.
 12. A method of treating Parkinson's disease according to claim 6, in which the configuration at the position 8 of the xanthine ring is (Z) form;R¹ and R² are propyl; and the substituents on the benzene ring are methoxy.
 13. A method of treating Parkinson's disease according to claim 2, in which Z is ##STR130## R³ is methyl; R⁶ is hydrogen or methoxy;and m is 1 or
 2. 14. A method of treating Parkinson's disease according to claim 13, in which R¹ and R² are ethyl;R⁶ is 3-methoxy; and m is
 1. 